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The data based on research of ALA in lead-poisoned and tumor bearing 
animals is divided into three major sections. 
ii 
The first section concerns data obtained from the modification of the 
dual piggyback unit for urinary ALA to a one-column unit for screening a ped-
iatric population for early detection of exposure to lead. The data from the 
present experiments indicate that recovery of ALA from the one-column unit 
averaged 94 percent. In parallel with the modification studies, methods and 
data is presented for the isolation and quantitation of human urinary porphobil-
inogen (PBG) anrl urinary urea utilizing a color chromophore formed with 
modified Ehrlich's reagent. Data is presented indicating that a triad of 
quantitative tests could be rapidly obtained from one 0. 50 ml. aliquot of 
urine--namely ALA, PBG, and urea. 
The second section concerns the effect of lead poisoning on rabbits 
especially in regard to accumulation of ALA in the tissues. The data of the 
present experiments indicates that one gram of tissue is sufficient for the 
analysis of tissue ALA levels. Recovery of ALA from normal tissue averaged 
92 percent and of the 21 tissues isolated and studied the greatest accumulation 
of ALA occurred in the bone marrow and kidney approximately a 100 and 27 fold 
increase over control, respectively. Studies were completed showing ALA 
accumulation in the bone marrow and kidney were dose-nependent on the lead 
acetate injected. It is concluded that the methods described would be most 
useful in determining ALA levels in the post-mortem diagnosis of lead poisoning 
The third section presents data on a tumor-host interaction. This 
involves greatly elevated levels of delta-aminolevulinic acid dehydrase (ALAD) 
with a concomitant increase in reticulocyte formation. The tumor studied was 
the Walker 256 Carcinosarcoma and the host species was the Sprague-Dawley 
iii 
rat. A study of basic hematology parameters was also initiated-- to determine 
red and white cell counts, hemoglobin, hematocrit, body weight, tumor volume, 
and percent reticulocytes. The most significant factor determined was the 
reticulocyte count. The data indicates that immediately after transplantation 
and 4 days before the transplanted tumor becomes palpable, ALAD activity 
increases over control values in conjunction with the increased reticulocyte 
count. ALAD activity increased ll7 percent over control within 24 hours after 
transplantation. The count rose to 619 percent by day 4, the first day of palp-
able tumor growth. The reticulocytes increased to l, 440 percent by day 16, 
the last day of accurate tumor measurement, and rose to 2, 000 percent over 
control on day 20, the final day of the experiment. 
After transplantation the reticulocyte count increased over control was as 
follows: 70 percent at 24 hours, 387 percent at 4 days, l, 822 percent at day 
16, and 2, 300 percent at day 20. 
Two significant results are noted from these data about the growth of 
the Walker tumor in vivo: 1) the similarity and parallelism of ALAD activity 
with the percent reticulocyte formation and 2) the immediate and rapid elevation 
of these two parameters before any growth of the tumor could be detected as 
well as their persistence throughout the time of the growth of the tumor. 
These data indicate that the Walker tumor stimulates reticulocytosis 
with a concomitant increase in ALAD activity suggesting a unique early 
tumor-host interaction. 
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CHAPTER I 
INTRODUCTION 
CHAPTER I 
INTRODUCTION 
A. UNIFYING THEME OF THE DISSERTATION 
The main theme, or unifying concept, of studies based on delta-
aminolevulinic acid (ALA) in lead poisoned and tumor bearing animals should 
2 
be briefly explained at the beginning of this dissertation, later to be developed 
in more detail. 
The heme precursor delta-aminolevulinic acid (ALA), the first product 
in heme synthesis is excreted in significant amounts in the urine of a child 
or an adult having a blood lead concentration over 50 µgrams/100 ml 
(Selander and Cramer, 1970). This excreted precursor is quantitatively 
determined to indicate how severe the exposure to lead was and how severe 
the toxicity is that is borne by the hematopoietic system. The inhibition by 
inorganic lead (Gibson et al, 19 55, Lichtman and Feldman, 19 63, de Bruin 
and Hoolboom, 19 67 and de Bruin, 19 65) of one of the enzymes in the heme 
biosynthetic pathway, namely ALA dehydrase (Chisolm, 1964), is thought to 
be responsible for the spilling over of ALA into the urine. This enzyme is 
dependent on the presence of free sulfhydryl (SH) groups for its activity 
(Chisolm, 19 64). The SH - groups of the active center of ALA dehydrase are 
part of the protein structure of the enzyme molecule. The interaction of lead 
with ALA dehydrase is complex because of the presence of many factors in-
cluding reactive ligands which have not been studied to date. 
3 
The enzyme ALA dehydrase catalyzes the condensation of two molecules 
of the substrate ALA by a Knorr type of reaction to form one molecule of 
porphobilinogen (PBG), the second product in the heme biosynthetic pathway.' 
The enzyme is found in the mature red blood cell and is measured by taking a 
peripheral blood sample. As previously described, lead binds to the free SH 
groups of the dehydrase molecule P.reventing the formation of PBG. The ALA 
dehydrase enzyme which is inhibited in lead poisoning is elevated in the 
animal bearing a Walker 256 carcinosarcoma tumor. This unique finding will 
be thoroughly discussed in this dissertation. 
Therefore, the substrate delta-aminolevulinic acid and its enzyme delta-
aminolevulinic acid dehydrase, which is inhibited in the lead poisoned animal 
and elevated in the animal bearing a Walker tumor, is the unifying concept of 
this dissertation. 
B. HISTORY OF LEAD POISONING 
It has been known. since antiquity that lead poisoning may occur when 
the metal gains access to the body tissues by inhalation, ingestion, or skin 
contact. The first descriptions of the clinical picture of such intoxication 
date back to the middle of the seventeenth century (Stockhausen, 1656). Its 
toxic properties were first recognized by Hippocrates (Hunter, 19 62) and over 
the centuries more has been written about the causation and symptomatology 
-----------------·-~--q·~ .. ---·~"---· ___ , ____ 4.,_., 
of poisoning by lead than by any other toxic agent (Johnstone, 19 66). 
Tanquerel des Planches in 1839 published an epoch-making treatise 
containing an accurate clinical description of lead poisoning and since 
Tanquerel' s time, little has been added to our clinical knowledge of lead 
poisoning. This treatise was responsible for the initiation of a period of 
intensive clinical and experimental investigation of lead poisoning and this 
research is presently continuing. 
Lead is a normal and ubiquitous constituent of the earth's crust being 
present in an average concentration of about 16 parts per million (Swaine, 1955) 
Because of its ubiquitous nature, lead is absorbed along with other trace 
elements by plants and animals v..1hich in turn form the diet of man. Since this 
has been true for many millions of years, it seems reasonable to conclude 
that man has always had a level of lead within his body which has derived 
largely from the diet and was not the result of man's industrial activities. This 
level of lead constitutes a "background" body burden which is always present, 
although varying in amount from place to place on the earth's surface, de-
pending upon the local concentration of lead in the soil and water. 
There is much evidence that lead wastes have been accumulating 
during the past century, particularly in congested urban areas. Increased 
exposure to lead has been shown in populations exposed to lead as an air 
pollutant. Postmortem examinations show a higher lead content in the organs 
of individuals in highly industrialized societies than in organs of most 
---------------------"··-· ~ ... -----~~----------·s~-
individuals in primitive populations. Although no population group is apparent-
ly yet being subjected to levels of exposure associated with the symptoms of 
lead poisoning, it is clear that a continued rise in the pollution of the human 
environment with lead could eventually produce levels of exposure that could 
have adverse effects on human health. 
C. CHILDHOOD LEAD POISONING 
The immediate and urgent problem is to control the exposure to lead 
of well-defined groups that are known to be directly at risk - especially young 
children who live in dilapidated housing where they can nibble chips of 
leaded paint. 
There is a large group of children between one and five years of age 
who live in deteriorating buildings who have the habit of eating nonfood sub-
stances including peeling paint, plaster and putty containing lead (Bradley 
et al, 1956 and Griggs et al, 1964). (This behavior is termed pica, after the 
la tin word for magpie). The epidemiological data are still incomplete but 
large scale screening programs now in progress in Chicago and Ne'I!'! York City 
indicate that between 5 and 10 percent of the children tested show evidence of 
asymptomatic increased lead absorption and that between 1 and 2 percent have 
unsuspected plumbism (Davis, 19 68 ) . 
The causative factors for childhood lead poisoning are commonly a 
triad: a dilapidated old house, a toddler with pica aad parents with inadequate 
resources (emotional, intellectual, informational and/or economic) to cope 
b 
with the family's needs (Chisolm, 197 O). The three factors interact to increase 
the liklihood that the child will eat chips of leaded paint. A chip of paint 
about the size of an adult's thumbnail can contain between 50 and 100 milli-
grams of lead (Chisolm and Harrison, 195 6), so a child eating a few small 
chips a day easily ingests 100 or more times the tolerable adult intake of the 
metal. Pica for leaded paint results in genuinely massive exposures and when 
the abnormal intake ceases it may be several months or years before blood-
lead levels return to normal (Kehoe, 19 61). Kehoe (19 61) measured the rate at 
which the excessive burden of lead is excreted after experimental ingestion 
is terminated. The data indicates that it takes twice as long for the adult to -4-
excrete a given burden of lead as it does for him to accumulate it. Kehoe (19 61) 
has shown that bone is the chief storage depot for lead. The rate of bone turn-
over has considerable influence on lead turnover in man. Since the rate of bonE 
turnover differs between children and adults, these adult data cannot be 
strickly applied to the lead-turnover rates in the growing child. The data 
indicated as presented by Kehoe, does establish the validity of blood lead and 
urinary AI.A as indices of the body burden of lead. 
Whole blood-lead measurements require careful interpretation, and 
serial measurements are necessary to ascertain trends. The following factors 
must be considered in accessing the significance of a given value: hematocrit, 
intercurrent infection, coincident bone disease, current or recent administra-
tion of chelating agents, current or recent excessive absorption of lead and 
the time interval since excessive absorption ceased. About 90 percent of the 
lead in whole blood is transported attached to the red-cell surface (Clarkson 
and Kerch, 1958). Chelating agents have only a transient effect on the dis-
tribution of lead between plasma and red cells (Hammond and Aronson, 1960). 
Thus, the quantity of circulating red cells largely determines the blood's 
carrying capacity for lead. 
Chelating agents temporarily disturb the equilibrium between bone and 
soft tissues because they remove lead from the soft tissues only. Thereafter, 
several weeks may be required for bone and soft tissue lead to be equilibrated 
once again. During this time, the blood lead will rise to a new plateau from 
the temporarily depressed val':1e seen at the end of treatment with chelating 
agents. When chelating agents and intensive absorption cause such fluctu-
ations in blood lead concentrations other parameters of lead' s metabolic 
toxicity such as urinary excretion of delta-aminolevulinic acid (ALA) (Haeger-
Aronson, 19 60) _g_~ a more accurate index of the biologic effects~ead. 
It is apparent from recently published data that previous concepts of 
"normal" blood-lead concentrations should be revised downward (Jacobziner, 
19 66 H. and Rennert, O. M. et al, 1970). Beyond infancy there is general 
agreement that the median value in unexposed subjects is approximately 27 
µgrams and that the upper limit is 40 µgrams lead per 100 ml of whole blood. 
In the past, 50 to 60 µ grams has been cited as the upper limit of "normal". 
In part, this old higher limit was based on the observation that clinically -
overt acute plumbism is virtually always associated with values greater than 
60 µ grams. The higher value was based on the use of 
11 normal 11 samples 
containing a large proportion of young children drawn from old urban housing 
areas (Kaplan and McDonald, 194 2). T\111enty or thirty years ago the extent of 
lead exposure in such an environment was not fully appreciated. More recently, 
a random sample of 333 children drawn from a low-income area of Baltimore, 
Maryland gave a mean value for whole blood lead of 4 3 ± 14 µ grams (Bradley 
et al, 19 56). 
-
Therefore, in a child with pica, the rep·eated ingestion of leaded-paint 
chips for about 3 months or longer can lead to clinical symptoms and eventually 
to the absorption of potentially lethal body burden of lead. During the first 
four to six weeks of abnormal ingestion there are no symptoms. After a few 
weeks minor symptoms such as decreased appetites, irritability, clumsiness, 
unwillingness to play, fatigue, headache, abdominal pain and vomiting begin 
to appear, These, of course, are all quite nonspecific symptoms, easily 
ignored as behavior problems or blamed on various childhood diseases. In a 
few weeks the lassitude may progress to intermittent drowsiness and stupor; 
the vomiting may become persistent and forceful; brief convulsions may occur. 
If exposure to lead continues, the course of the disease can culminate abruptly 
in coma, intractable convulsions and sometimes death. 
This picture of fulminating encephalopathy is commonest in children 
between 15 and 30 months of age; older children tend to suffer recurrent but 
less severe acute episodes and are usually brought to the hospital 'l/ltith a 
history of sporadic convulsions, behavior problems, hyperactivity or mental 
retardation. The symptoms tend to wax and wane usually becoming more 
severe in summer. Some 85 percent of all lead-poisoned cases are reported 
from May through October. 
It is certain that acute lead encephalopathy in early childhood produces 
irreversible injury to the brain (Blockman, 1937). Byers and Lord (1943) were 
the first to suggest that lead might produce mental deficiency, and clinical 
and experimental evidence has since supported this idea. Moncrieff et al, 
(1964) showed that the frequency of blood lead levels greater than 36 µgram 
per 100 ml in 122 mentally retarded children was 45 percent, and Gibson (19 67) 
noted an increased incidence of blood lead levels greater than 40 µgrams 
per 100 ml in a group of children who were mentally retarded but in v.•hom no 
etiological factor for their mental deficiency was known, compared with normal 
children or mentally retarded children of known etiology. 
Today public attention is finally being focused on childhood lead 
poisoning, although the difficult task of eradicating it has just begun. I 
believe it is impermissible for ~ humane society to fail to do Vl.·ha t is so 
necessary to eliminate a wholly preventable disease. 
D. LABORATORY METHODS USED TO DETECT INCREASED LEAD EXPOSURE 
1. Number of basophilic stippled cells in perpheral blood 
Behrend in 1899 was the first to report that lead causes stippling of the 
erythrocyte. Today, we recognize that two different types of granulations may 
be present in the erythrocytes of lead-intoxicated patients and animals (Griggs, 
19 64). The first type of granulation is due to an accumulation of excessive 
iron unusable for hemoglobin formation and the second type represents damaged 
mitochondria that do not contain iron. 
Stippling, however, is generally considered an unreliable criterion of 
lead intoxication because it also occurs in a large number of blood diseases 
such as various types of hemolytic anemia, post hemorrhogic anemia, leukemia, 
and after exposure to benzene, aniline, carbon monoxide, arsenic, copper, 
and bismuth (Haeger-Arons en, 19 60). The upper limit of normal is approximate 
and the values cited vary considerably, ranging from 1 per 10, 000 RBC 
(Schmidt, 1919) to 90 per 10, 000 (Sanders, 1943). Therefore, the method can 
hardly be more than an "adjunct to other more specific and sensitive methods" 
(Kehoe, 19 4 9) • 
2. Determination of coproporphyrin III in the urine 
Urinary coproporphyrin III excretion has been shown to be elevated in 
lead ·poisoning (Wyllie, 19 55; Holeck, 19 57; Benson and Chisolm, 19 60; and 
Haeger-Aronsen, 19 60). However, coproporphyrin levels are also increased in 
various forms of anemia, particularly hemolytic anemias, in jaundice whether 
due to diffuse liver damage or to biliary obstruction, in some infectious diseas-
es such as pneumonia and acute poleomyelitis, and in several types of intox-
ication including mercury, bismuth, sulfonal, and sulfonamide poisoning 
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(Haeger-Arons en, 19 60). The upper limit of normal for urinary coproporphyrin 
is 15 µ grams per 100 ml of urine. 
3. Determination of lead in blood and urine 
Most investigators agree that an increased level of lead in the blood 
and urine is the most specific sign of increased lead absorbance. It must be 
remembered, however, that the blood is rapidly cleared of lead and blood 
lead levels are considered of value only in acute cases of lead intoxication. 
Berman (19 66) has reported that the blood lead levels in chronic cases of lead 
poisoning are not remarkable. 
The drawing of blood samples and the analytical procedures for determin-
ing the lead levels in blood and urine are time consuming processes requiring 
skilled personnel and it therefore appears that the determination of lead in 
the blood and urine is not practical as a screening test for early detection of 
increased lead absorption. 
4. Determination of urinary delta-aminolevulinic acid (ALA) and the 
rational for its use 
In 19 5 6 Mauzerall and Granick developed a sensitive colorimetric method 
for the quantitative determination of urinary ALA. Using this method one 
takes an aliquot of random urine (pH 5 to 7) containing porphobilinogen 
(PBG), urea, and ALA and places this on a column of Dowex 2 resin in the 
acetate form. The PBG is retained by the anion-exchanger Dowex 2. The ALA 
is then placed on a cation-exchanger Dowex 50 in the hydrogen form, and 
I 
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washed well with distilled water to wash out the urea. 
After elution from the ion-exchangers, PBG and ALA are demonstrated by 
means of p-dimethylaminobenzaldehyde (DMAB), the former substance directly; 
l 
the latter, after quantitative conversion to 3-acetyl-2-methylpyrrole 4-(3 ) 
propionic acid by heating with acetylacetone. With DMAB in acid solution, 
PBG as well as the pyrrole obtained on condensation of ALA and acetylacetone, 
forms colored complexes which are spectrophotometrically determined. 
Haeger in 1957 using Mauzerall and Granick's technique, reported that 
workers exposed to inorganic lead have considerably elevated ALA levels in 
urine. Since then, numerous other investigators have shown elevated urinary 
ALA levels in cases of clinical adult plumbism and in adult workers exposed to 
lead (Haeger-Arons en, 19 60; de Kretzer and Waldron, 19 63, Klein stein et al, 
1963; Efe, 1964; Cramer and Selander, 1965; Cramer et al, 1966; de Bruin and 
Hoolboom, 1967; Cramer and Selander, 1967; Williams and Few, 1967; Gibson 
et al, 1968; Wada et al, 1969; Selander and Cramer, 1970; Davis, 1970; and 
Haeger-Aronsen, 19 71). 
Urinary ALA levels have been reported to have a positive correlation with 
blood lead levels (Selander et al, 1966 and Davis, 1970), urinary lead excretion 
(Haeger-Aronsen, 1960; Cramer and Selander, 1965), and clinical impression of 
lead intoxication (Craemer and Selander, 19 65). Raised ALA levels in the urine 
have also been found to be closely correlated to raised ALA levels in serum 
(Saita and Moreo, 1961; Chiesura and Brugnone, 1963). Blood and urinary ALA 
------------ -------~"-·"------· ... ---------------w .... r 
levels remain significantly increased for up to three x_ec:i:r_§ 9Jter cessation of 
lead exposure (Saita and Moreo, 1964). 
An increased ALA excretion has been reported to be an earlier sign of 
lead exposure than an increased coproporphyrin excretion (Singerman, 1964; 
Djuric et al, 19 6 6) and several investigators have stated that an increased 
ALA excretion is the earliest sign of an increased lead absorbance (Efe, 19 64 
and Djuric et al, 19 66). An increased urinary ALA level also appears to be 
pathognomonic of elevated lead absorption since the only other conditions 
known to result in an increased ALA excretion are acute intermittent porphyria 
and certain liver diseases. Haeger-Aron sen (19 60) determined the urinary 
ALA content of patients with either biliary disease, acute hepatitis, cirrhosis 
of the liver, hemolytic anemia, pernicious anemia, malignant tumor, leukemia, 
diabetes mellitus, nephropa thy, or drug intoxication. The concentration of 
ALA in the urine was normal in all cases except three. Two of these were 
patients with acute hepatitis and one was a man with bronchial cancer. 
Schlenker et al {19 64) determined the urinary ALA content of patients with 
Hodgkin's disease, cirrhosis, leukemia, multiple myeloma, sickle cell anemia, 
or cancer and the only patient showing a minor elevated urinary ALA level was 
the one with cirrhosis. Griggs (19 64) compared the urinary ALA levels of 
patients with lead toxicity, acute intermittent porphyria, iron deficiency 
anemia, hemolytic anemia, pernicious anemia, or liver disease and found 
that elevated levels are seen only in patients with lead poisoning, acute 
intermittent porphyria, and occasionally liver disease. 
E. HEME BIOSYNTHESIS 
l. Normal heme biosynthesis 
The biosynthetic sequence of heme has been elucidated as a result of 
the research conducted mainly in the laboratories of Shemin and Granick in 
the United States and Neuberger and Rimington in Great Britian. As early as 
1948 it was found that avian red blood cells can synthesize heme in vitro 
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(She min et al, 19 48) and soon after, cell free extracts of duck erythrocytes 
were found to synthesize heme from the proper substrates (Shemin et al, 1955). 
When chicken cells, rabbit reticulocytes, and human red cells from erythroblas 
tosic fetalis are hemolyzed, a number of the enzymes of the heme biosynthetic 
pathway are found to be soluble and can be separated from each other by zone 
electrophoresis on starch (Granick and Mauzerall, 19 58). These soluble 
enzymes are localized in the cytoplasm and include delta-aminolevulinic acid 
dehydrase (ALAD}, porphobilinogen (PBG) deaminase, uroporphyrinogen (UPG) 
isomerase, and uroporphyrinogen decarboxylase. The insoluble enzymes are 
loca1ized in the mitochondria and include ALA synthetase, coproporphyrinogen 
(CPG) oxidase, and heme synthetase (Sano and Granick, 19 61). 
The first step in heme synthesis is the condensation of succinyl Co A 
with glycine (Shemin et al, 1955; Gibson et al, 1958; and Kikuchi et al, 1958) 
to form 
-amino- -keto adipic acid which readily decarboxylates yielding 
delta-aminolevulinic acid (Shemin et al, 1955 and Neuberger, 1961). This 
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reaction is catalyzed by the enzyme ALA synthetase and requires pyridoxal 
phosphate as a co-factor (Lascelles, 1957; Schulman and Richert, 1957; and 
Kikuchi et al, 1958). The enzyme ALA dehydrase condenses two molecules of 
ALA forming one molecule of porphobilinogen (PBG) and water (Gibson et al, 
19 55). Three molecules of PBG then combine under the influence of PBG 
deaminase to form tripyrryl methane and this in the presence of UPG isomerase 
is converted to uroporphyrinogen III (Bogorad, 19 58a and Cornford, 19 64). The 
four acetic acid side chains of uroporphyrinogen III are then decarboxylated 
by UPG decarboxylase to produce coproporphyrinogen III (Mauzerall and 
Granick, 19 58). Two propionic acid side chains of coproporphyrinogen III are 
oxidatively decarboxylated to form vinyl groups by CPG oxidase and this re-
sults in the formation of protoporphyrinogen IX (Sano and Granick, 19 61). 
Protoporphyrinogen IX is then autoxidized to form protoporphyrin IX (Sano and 
Granick, 19 61) and hemesynthetase inserts one ferous ion into each molecule 
of protoporphyrin IX forming heme (Goldberg et al. 195 6 and Labbe and Hubbard, 
19 60). This total scheme is shown in figure 8. 
2. Effect of lead on heme synthesis 
Perhaps the first note relative to an effect of lead upon the synthesis 
of heme was that of Binnedijk (1895) in his report of the occurence of porphyrin 
in the urine of a patient with lead intoxication (cit. Haeger, 1960). However, 
it was Watson (1936) who first suggested that this porphyrinuria might be a 
manifestation of an effect of lead upon the synthesis of hemoglobin. It is 
l 
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now known that the urine of patients with lead intoxication consistently con-
tains abnormally large quantities of coproporphyrin, as well as its immediate 
precursor, uroporphyrin (Bashour, 1954). More recently it has been observed 
in elegant studies by Haeger-Aron sen (19 60) that urine from such patients con-
tains large amounts of delta-aminolevulinic acid, although the simultaneous 
rate of excretion of porphobilinogen is normaL As previously discussed, ALA 
has been and is now used widely as a screening test for lead exposure. In 
fact, it is probably the most frequently used test in urban pediatric practice 
for the detection of lead poisoning in children. 
Heme is necessary in the synthesis of cytochrome oxidase as well as 
in the production of red cell hemoglobin. Because the synthesis of heme is 
an essential biochemical pathway for all cells, the effects of lead poisoning 
are much more significant and far reaching than the anemia alone (Avent, 1972). 
A synopsis of the salient features of the influence of lead on heme 
synthesis may be described by the following diagram and paragraphs which 
follow. 
Pb 
SUCCINYL CoA 
l Glycine Pyridoxal-p 
cS-ALA 
l 0 -ALAD 
PORPHOBILINOGEN 
• 
Excessive Excretion 
in Urine 
UROPORPHYRINOGEN III 
... 
COPROPORPHYRINOGEN III__.. Excessive Excretion 
Pb llJt + in Urine 
PROTOPORPHYRINOGEN 
+ 
PROTOPORPHYRIN IX _ ___,_.. Excessive Accumula-
Pb ------•lllt + tion in Erythrocytes 
HEME 
INHIBITORY EFFECTS OF LEAD IN THE BIOSYNTHESIS OF HEME 
As can be seen from the above diagram lead exerts an inhibitory effect 
on several of the enzymes necessary for heme synthesis e.g. ALA dehydrase, 
CPG oxidase, and heme synthetase. ALA dehydrase (Gibson et al, 19 55) and 
heme synthetase (Schwartz et al, 1959) both contain essential sulfhydryl 
groups and a blockage of such groups by lead maybe the cause of the inhibition 
of their activity. 
a. ALA dehydrase 
Several authors have reported that the activity of this enzyme is 
decreased in erythrocytes from lead-intoxicated patients (Lichtman and 
Feldman, 19 63; Bonsignore, 19 66; and de Bruin and Hool boom, 19 67). 
Gibson (1955) isolated and purified ALA dehydrase and demonstrated 
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the inhibitory effect of lead upon the enzyme in vitro. Bonsignore (19 65) and 
de Bruin (1968) were able to demonstrate that in adults occupationally exposed 
to lead, red cell ALA dehydrase activity was reduced appreciably below that of 
control groups. Nakao et al (19 68) found evidence of decreased red cell ALA 
dehydrase activity in adults with clinically evident lead poisoning and also in 
asymptomatic lead workers. Hernberg and his co-workers (1970 a, b) observed 
.an increased correlation between blood lead levels and red cell ALA dehydrase 
activity in adults. Similar correlations between blood lead and rerl cell ALA 
dehydrase have been demonstrated in children by Millar and Battistini (1970). 
Recently Weissberg et al (1971) introduced a micromethod to screen for lead 
poisoning using ALA dehydrase. 
ALA dehydrase is functionally significant when blood lead concentration 
is approximately 10-50 µ gram per 100 ml. It is especially useful because 
it indicates biochemical effects on the general population at exposures 
induced by environmental polluation with lead (Hernberg, 1970 a). Frank 
lead poisoning is considered to be any blood lead level over 60 µ gram per 
100 ml. 
Previous studies concerned with the interrelationship between different 
Parameters indicative of lead absorption have dealt with a rather high exposure 
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level, or even with clinical poisoning. At these levels of absorption (over 60 
P. grams blood lead per 100 ml) the concentration of ALA in urine gives a 
quantitive measurement of the response of the organism to surplus lead (Haeger 
Arons en, 19 60; Davis and Andelman, 19 67; Davis, J. R • .§! al, 19 68; Selander 
and Cramer, 1970, Davis, 1970; and Haeger-Aronsen 1971). 
b. CPG oxida se 
An increased urinary excretion of coproporphyrin from individuals with 
lead intoxication has been known for years. Coproporphyrinogen III is the 
compound that is excreted in the urine, however, it is rapidly oxidized to 
coproporphyrin III (Watson et al, 1951 and Weatherall, 1952). The increased 
urinary excretion of coproporphyrin III in lead poisoning has been postulated 
to be due to destruction in the bone marrow of younq red blood cells containing 
large amounts of coproporphyrinogen III (Schmid et al, 1950). This increased 
amount of coproporphyrinogen III in the young red blood cells is a result of the 
inhibition of the enzyme CPG oxidase by lead. 
c. Heme synthetase 
Erythrocyte protoporphyrin IX levels have been found by Rubino.§!~ 
(1958) to be elevated in 21 of 22 patients with lead poisoning. Increased 
amounts of protoporphyrin IX in the erythrocytes of lead poisoned patients have 
also been found by Vigliani and Waldenstrom (1937). Whitaker and Vietti (1958) 
have shown that children with lead intoxication also have increased amounts of 
Protoporphyrin IX in the erythrocytes. Lead inhibits the in vitro synthesis of 
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heme from protoporphyrin IX and iron of chicken, rabbit, and human erythrocytes 
(Rimington, 19 51 and Jandl et al, 19 59). It has been reported that in humans, 
elevated levels of protoporphyrin IX persist in the erythrocytes up to nine 
years after cessation of lead exposure (Saita and Moreo, 19 64). 
F. BIOSYNTHESIS OF DELTA-AMINOLEVULINIC ACID 
Prior to 1946 little was known about the chemical building blocks 
from which the body synthesizes porphyrins and heme. In that year Shemin 
and Rittenberg observed that after administration of isotopically labeled glycine 
the concentration of the label in the circulating hemoglobin heme rose rapidly, 
remained more or less steady for about 100 days, and then rapidly declined. 
The disappearance of the label from the circulating heme was accompanied by 
a marked though temporary increase in the fecal excretion of labeled urobilino-
gen (London, et al, 1949 and Gray et al, 1950). These observations permitted 
the conclusions that (1) glycine is a specific precursor of heme; (2) hemoglobin 
of the circulating erythrocytes remains outside the general metabolic pool of 
protein interchange; (3) most of the normal red cells have a mean life span of 
about 120 days; (4) a large fraction of the fecal urobilinogen is derived from 
the breakdown of circulating red blood cells; and (5) the metabolites of heme 
protoporphyrin are not reutilized for the synthesis of hemoglobin in newly form-
ed erythrocytes. 
These results of synthesizing labeled heme from glycine _l4c and the 
classic work of the intermediate, which is formed by the condensation of 
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glycine and succinate, is the five-carbon aminoketone - ALA. 
The condensation of glycine with "active" succinate to form ALA 
requires the enzyme ALA synthetase. This reaction has been demonstrated 
in vitro in systems containing some particulate matter which is present in 
nucleated avian red cells and in mammalian reticulocytes, liver, and kidney 
(Granick and Urata, 1963, Granick, 1963, Shemin and Russel, 1955, Laver et 
al, 1958, Gibson et al, 1958, Granick, 1958, and Sano et al, 1959) but is 
absent from mature mammalian erythrocytes (London, 1950). These observations 
strongly suggest that the enzyme ALA synthetase is bound to mitochondria 
(Granick and Urata, 1963 and Granick, 1963). Synthesis of ALA synthetase 
can be induced in mammalian liver cells by a variety of compounds, which 
are also known to produce experimental porphyria in animals (Granick and 
Urata, 1963 and Granick, 1963). 
The primary product obtained on condensation of succinyl CoA with 
glycine would be expected to be o<.-amino-,8-ketoadipic acid (Shemin, 1955, 
Shemin and Russell, 1953, and Neuberger and Scott, 1953). Although the 
ease with which this compound undergoes spontaneous decarboxylation has 
prevented its isolation (Gibson, et al, 1958), the observed conversion of its 
diethyl ester to PBG in vivo is in line with this concept (Weliky and Shemin, 
19 57). 
The condensation of glycine with succinyl CoA maybe the prototype of 
glycine and succinate, is the five-carbon aminoketone - ALA. 
The condensation of glycine with "active" succinate to form ALA 
requires the enzyme ALA synthetase. This reaction has been demonstrated 
in vitro in systems containing some particulate matter which is present in 
nucleated avian red cells and in mammalian reticulocytes, liver, and kidney 
(Granick and Urata, 1963, Granick, 1963, Shemin and Russel, 1955, Laver et 
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al, 1958, Gibson et al, 1958, Granick, 1958, and Sano et al, 1959) but is 
absent from mature mammalian erythrocytes (London, 1950). These observations 
strongly suggest that the enzyme ALA synthetase is bound to mitochondria 
(Granick and Urata, 1963 and Granick, 1963). Synthesis of ALA synthetase 
can be induced in mammalian liver cells by a variety of compounds, which 
are also known to produce experimental porphyria in animals (Granick and 
Urata, 1963 and Granick, 1963). 
The primary product obtained on condensation of succinyl CoA with 
glycine would be expected to be ol-amino-~-ketoadipic acid (Shemin, 1955, 
Shemin and Russell, 1953, and Neuberger and Scott, 1953). Although the 
ease with which this compound undergoes spontaneous decarboxylation has 
prevented its isolation (Gibson, et al, 1958), the observed conversion of its 
diethyl ester to PBG in vivo is in line with this concept (Weliky and Shemin, 
19 57). 
The condensation of glycine with succinyl CoA maybe the prototype of 
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a more general reaction involving glycine metabolism (Shemin, 1955). Distinct 
mitochondrial enzymes appear to catalyze the condensation of glycine with 
other acyl CoA substrates such as acetyl CoA and propionyl CoA, forming 
aminoacetone and other aminoketones (Urata and Granick, 1963). Thus it 
became of great interest to determine the aminoacetone in the urine and tissues 
of the lead poisoned rabbits. 
The biosynthetic pathway of ALA formation can be summarized briefly 
by saying that ALA synthetase catalyzes the condensation of succinyl CoA 
with glycine to form ALA. The initial reaction of this pathway requires a 
functioning tricarboxylic acid cycle and thus is oxygen - dependent; the 
condensing enzyme sys tern is operative under anaerobic conditions. The lack 
of mitochondria in mature mammalian erythrocytes precludes formation of 
succinyl CoA and of ALA. 
G. BIOSYNTHESIS OF PORPHOBILINOGEN 
The establishment of ALA as an obligatory intermediate in porphyrin 
and heme biosynthesis has allowed studies of the subsequent enzymatic 
steps to be greatly facilitated. The enzyme ALA dehydrase was found to 
catalyze the condensation of 2 moles of ALA to form a precursor pyrrole 
(Granick, 1954, Schmid and Shemin, 1955 and Gibson, et al, 1955). The 
theoretical formulation of the structure of this pyrrole (Shemin and Russell, 
19 53) yielded the same structure as porphobilinogen (PBG), the chromogen 
excreted in the urine of patients with acute porphyria (Waldens tram, 193 7). 
PBG was first isolated by Westall in 1952. 
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The soluble enzyme ALA dehydrase has been purified from a number of 
sources, including duck erythrocytes (Schmid and Shemin, 1955), chicken 
erythrocytes (Dresel and Falk, 1956) and ox liver (Gibson, et al, 1955, and 
Gibson, 19 5 5). SH-group inhibitors such as iodoacetamide and p-chloromer-
curibenzoa te have an inhibitory effect (Gibson, 19 5 5) which can be reversed 
by the addition of reduced glutathione (Gibson, et al, 1955 and Gibson, 1955). 
Two molecules of ALA are required for formation of one mole of PBG 
(Shemin, 1955 and Schmid and Shemin, 1955). Heme synthesized from labeled 
ALA has twice the specific activity of that formed from an equimolar amount 
of PBG with the same radioactivity (Shemin, 1955 and Schmid and Shemin, 1955). 
These findings confirmed the earlier reports by Falk et al (19 53) and by 
Bogorad and Granick (1953) that PBG is a specific precursor and an obligatory 
intermediate in the biosynthesis of porphyrins and of heme. 
H. METABOLISM OF ALA AND PBG IN THE INTACT ORGANISM 
In man, approximately 2 mg of ALA is excreted in the urine per day 
(Haeger, 19 58, Mauzerall and Granick, 19 56, Dean and Barnes, 19 59 and 
Malooly and Hightower, 1962). There is no data available for ALA excretion 
in bile, but it is believed to be negligible (Scott, 1955, Berlin, et al, 1956, 
Berli11 et al, 1956 and Granick and Van der Schrieck, 1955). As has been 
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described earlier, significant amounts of ALA is excreted in the urine in lead 
poisoned humans. 
Injection or oral administration of labeled ALA to man and to animals 
results in the excretion of a large portion of the unaltered compound in the 
urine (Scott, 1955 and Berlin, et al, 1956). Smaller fractions are converted to 
PBG, to protoporphyrin, and to stercobilin, the first being excreted in the urine 
the latter two in the bile (Scott, 1955; Berlin et al, 1956; Berlin, et al, 1956; 
and Granick and Van der Schrieck, 1955). ALA-1, 4_14c gives rise to labeled 
co2 in the breath (Scott, 19 55), a small fraction of the injected ALA is 
used for heme biosynthesis in immature rer:J blood cells (Scott, 1955; Berlin 
et al, 1956; and Berlin et al, 1956), but in contrast to the observations 
in vitro, incorporation of ALA into heme of circulating erythrocytes is several 
times less than that found with equivalent amounts of labeled glycine (Berlin, 
et al, 19 56). This may be explained in part by the rapid renal excretion of the 
injected ALA, either in unchanged form or after its conversion to PBG. In 
addition, penetration of ALA into immature red blood cells may be a rate-
limiting factor (Berlin, et al, 19 5 6) • 
Investigations reported very recently indicate that in man and dogs 
injected ALA-4-c14 is efficiently incorporated into the early-labeled bile 
Pigment fraction (Yamamoto et al, 19 65 and Schwartz et al, 19 64). Since 
this radioactive precursor also rapidly labels the "easily-split" heme fraction 
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where endogenous PBG production is increased it does escape from the cells 
and gain access to the urine. Thus, in acute porphyria of man and in Sedormid 
porphyria of animals, large amounts of PBG are derived from the liver and 
excreted in the urine (Schmid and Schwartz, 1955; Schmid et al, 1954; and 
Goldberg, 1955). 
I. PORPHYRIA 
The porphyrias are genetic abnormalities of the regulation of heme 
synthesis in which large amounts of heme precursors (ALA and PBG) are 
excreted in the urine. It is now clear that porphyrins are intermediates in 
the synthesis of protoporphyrin of heme and are not, as was suspected some 
years ago, breakdown products of heme. 
There are two major forms of erythropoietic porphyria which is character-
ized by the porphyrins being elevated in the bone marrow. These are three 
main forms of hepatic porphyria which is characterized by having elevated 
porphyrins in the liver. 
To refresh ones memory, porphyrins are pigments that possess a 
basic structure of four pyrrole rings linked by methene (=C-) bridges. The 
individual porphyrins differ from each other according to the nature of the 
eight possible side chains. Porphyrinogens are colorless compounds (reduced 
porphyrins) with a basic structure of four pyrrole rings linked by methylene 
(-CH 2-) bridges. 
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The most important of the naturally occurring porphyrins are uroporphyrin 
(isomer types I anri III), coproporphyrin (types I and III), and protoporphyrin 
(type III) • 
Protoporphyrin III is present in hemoglobin and is, therefore, the most 
important of the porphyrins from the physiological standpoint. It is not found 
in the urine. 
Coproporphyrin is the predominant porphyrin in urine and feces under 
normal circumstances. The compound occurs in urine in a variety of clinical 
conditions, such as has been mentioned previously in lead poisoning, 
poliomyelitis, liver disease, acute alcoholism, hemolytic anemia, and 
Hodgkin's disease. Abnormally high fecal coproporphyrin values are found 
in patients with hemolytic anemia and low values occur in patients with liver 
disease. 
Uroporphyrin is normally excreted in urine in only trace amounts. 
The urinary excretion of this porphyrin is moderately increased in lead poison-
ing and is greatly increased in patients with certain types of porphyria. 
1. Erythropoietic porphyrias 
a. Uroporphyria 
This is a very rare disorder inherited probably as a recessive Mendel-
ian characteristic. The disease is characterized by the excessive deposition 
of porphyrin in the tissues, leading to pronounced photosensitization. This 
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problem only occurs with skin exposed to light. 
It is because of the demonstration of large quantities of uroprophyrin 
and coproporphyrin in the normoblasts in the bone marrow that it has been 
suggested that in this type of porphyria the excessive quantities of uroporphy-
rin are formed in the marrow. 
Goldberg and Rimington (1962) have determined that the excretion of 
uroporphyrin and coproporphyrin is predominantly of the unphysiological 
series I type. The biochemical abnormality appears to be caused by the lack 
of the enzyme uroporphyrinogen isomerase in red blood cells. 
b. Protoporphyria 
Erythropoietic protoporphyria is the most common form of erythropoie tic 
porphyria. It was first reported by Ma gnu~ et al in 19 61. The disease is 
transmitted as an autosomal dominant characteristic. Uroporphyria and 
protoporphyria are manifest in childhood and like uroporphyria protoporphyria 
is characterized clinically by skin photosensitivity but to a lesser degree 
than uroporphyria. 
Biochemically, the disorder is characterized by an increase in the 
protoporphyrin content of the normoblasts and erythrocytes, an increased 
level of plasma protoporphyrin, and an increased excretion of protoporphyrin 
in the feces. The urinary excretion of Af.A, PBG, coproporphyrin, and uro-
porphyrin is not increased. 
---~----..... ··~· ·~·--,_,,~1"--~""~~ -~----------
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2. Hepa tic porphyria s 
a. Acute intermittent porphyria 
This is the most important member of the group of porphyria diseases 
and is characterized clinically by (l) periodic attacks of intense abdominal 
colic, usually accompanied by nausea and vomiting; (2) obstinate constipation; 
(3) neurotic or even psychotic behavior; and (4) neuromuscular disturbances. 
The mortality rate for this disease is very high. In the acute and latent 
phases of this disease and often in states of remission, patients excrete 
in urine an excessive quantity of PBG and ALA (Haeger, 1958). In contrast to 
the erythropoietic porphyrias acute intermittent porphyria (AIP) has an absence 
of skin photosensitivity because the prophyrin precursors are excreted in the 
urine. 
Freshly voided urine collected from patients with AIP is frequently 
normal in color and on standing in the sunlight turns to a Burgundy wine color 
or even black. This color change can be hastened by adding a small amount 
of acid to the urine and boiling for 3 0 min. The explanation for these color 
changes is that PBG (colorless) and not uroporphyrin (red) is excreted in the 
urine. Heating of PBG in an acid medium results in the nonenzymatic formation 
of uroporphyrin, together with a dark-brown or reddish-brown nonporphyrin 
pigment. 
In AIP during relapse the presence of PBG is a constant feature. 
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Therefore, it is essential that an accurate, rapid method be available to detect 
PBG. The Watson-Schwartz modification of the Ehrlich reaction is no longer, 
in my opinion, a valuable screening procedure. I believe the quantitative 
determination of PBG using the method described in this dissertation will 
serve as an excellent screening procedure. 
1. Causes of porphx:ria 
Acute attacks of porphyria in people who have the trait can be caused by 
drugs, and these attacks are sometimes fatal. Most frequently the barbiturates 
are involved (Eales and Lender, 1962). Drugs that cause this idiosyncratic 
reaction belong to different chemical classes, but the ally! group is common 
to many of them. Diallylbarbiturate, allylisopropylbarbiturate, and allyl-
methylbutylbarbiturate all provoke great increases in porphyrin excretion; 
and allylisopropylacetylurea (Sedormid) was one of the earliest known offenders 
Estrogens, certain 5-{J-H steroid metabolites, griseofulvin, some anti-
convulsants, chloroquine, sulfonamides, aminopyrine, hexachlorobenzene, 
and other drugs without the ally! group have also been implicated (Granick, 
19 65). For obvious reasons it is important to know which drugs do not induce 
attacks of porphyria; known to meet this criterion are ether, morphine, 
chloral hydrate, and penicillin. A catalog of "safe" drugs would be useful, 
not only for pa ti en ts with porphyria, but for all who have genetic defects 
in which drug idiosyncrasy is prone to occur. 
2. Biochemical basis of porphyria 
The biochemical basis is evidently an uncontrolled overproduction of 
porphyrins, principally PBG, the first pyrrole on the pathway of heme bio-
synthesis. In the normal patient there is normally a control or inhibitor of 
ALA synthesis in the liver, but this control breaks down in the diseased 
subject. 
The enzyme responsible for the condensation of glycine and succinyl-
CoA is ALA synthetase. The step mediated by AI.A synthetase is rate limiting 
for the whole pathway. Thus, an increased activity of this enzyme would 
lead to an increased rate of biosynthesis of the heme precursors (Granick 
and Mauzerall, 19 58). 
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Several agents that produce acute porphyria in vivo have been shown to 
cause a large increase in the level of ALA synthetase in the liver of experiment-
al animals ( Granick and Ura ta, 19 63). Studies with embryonic 
chick liver cells in vitro have been especially interesting (Granick, 1963). 
Addition of drugs such as mentioned above led to the production of porphyrins 
detectable by fluorescence microscopy. Porphyrins were also readily formed 
if ALA was added. Actinomycin D, added to the cultures, blocked the drug-
induced porphyrin formation but not that caused by ALA. Since the effect of 
actinomycin is to prevent DNA-dependent RNA synthesis, it would appear 
that the direct effect of the drugs was to induce the synthesis of ALA synthetase 
------------~~--------_,.-,,~~--~---------
and thereby to cause an increase in porphyrin production. 
Further elegant studies with the same system of chick-embryo liver 
cells have considerably strengthened this interpretation (Granick, 1966). 
The induction of ALA synthetase was shown to occur only in liver cells and 
to be reversible on withdrawal of the inducing agents. During induction of 
this enzyme there was no general increase in protein synthesis, i.e., the 
inducing effect was a specific one. Moreover, the inducing agents did not 
prevent the normal breakdown of MA synthetase, the half-life of which was 
4 to 6 hours in the presence or absence of inducers. It is postulated that 
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heme synthesis is normally controlled by a regulatory mechanism that represses 
the synthesis of ALA synthetase and thereby maintains a low rate of synthesis 
of heme. Heme itself is supposed to be the repres sor, combining specifically 
with an aporepressor protein to shut down the function of the operator, so 
that the operon coding for MA synthetase will not be transcribed, or will 
be transcribed at a very low rate (Jacob and Monod, 19 61). According to this 
model, the inducing drugs might be expected to displace heme from the apore-
pres sor and thereby increase the rate of transcription. It would be predicted, 
therefore, that heme itself should be able to overcome the effects of inducers; 
this has been demonstrated in vitro in the liver cell system (Granick, 1966). 
There are noteworthy differences between hep a tic porphyria and most 
other genetic diseases of man, perhaps again suggesting that an unusual 
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genetic mechanism is at work. The disease is determined by a dominant gene, 
i.e., the normal allele does not confer protection, as it usually would against 
a defective protein. The disease may not become apparent until adult life 
(according to Goldberg and Rimington, 19 62) the most frequent age of onset 
was the third decade for females and the fourth for males. The youngest 
patient found by these authors was a girl eleven years old, whereas many 
genetic defects are manifest at birth. Finally, porphyria is characterized by 
increased activity of an enzyme, whereas most genetic diseases are due to 
absence or reduced activity of an enzyme or other functional protein. 
b. Porphyria variega ta 
This porphyria is common among persons of European ancestry in South 
Africa (Dean, 1963) and is apparently inherited as Mendelian dominant 
character. Acute attacks similar to those of acute intermittent porphyria occur 
most commonly in affected females, while photosensitivity is found in male 
members of the same family. The photosensitivity present in porphyria 
variegata is due to the accumulation in the body of photodynamically active 
porphyrins. 
c. Porphyria cutanea tarda 
This disease is characterized clinically by cutaneous lesions or 
acute attacks of abdominal colic and not infrequently by both. The disease 
is inherited as a non-sex-linked mendelian dominant. The onset of symptoms 
---------------------~~~~·-·--~----------
34 
is usually between the ages of ten and thirty years. The outstanding biochem-
ical feature of the disorder is the increased excretion of coproporphyrin and 
uroporphyrin in the acute phase of the disease. 
During the latent phase of the disease the patients are entirely asymp-
tomatic. The porphyrin precursors, ALA and PBG, are not excreted. 
During the acute phase the excretion of coproporphyrin and uroporphyrin 
in the urine increases. Both ALA and PBG are excreted in increased amounts 
in the urine. Usually when ALA & PBG appear in the urine all manifestations 
f acute intermittent porphyria may develop (acute phase). 
A summary of the various forms of erythropoietic and he pa tic porphyrias 
and a comparison to lead poisoning is shown in Table 39. 
J. CONTROL OF RED CELL PRODUCTION - ERYTHROPOIETIN 
In the short span of 20 years, the process by which red cell production 
is regulated has, to a large degree, been elucidated. 
Although a humoral stimulator of erythropoiesis was described in 1906 
by Carnot and Deflandre, it was the classical experiment of Reissmann in 
1950 which established the existence of a plasma erythropoietic factor. 
Reissmann reported erythroid hyperplasia in the marrow of both rodents joined 
in parabiosis when one of them breathed gas of reduced oxygen content. The 
most likely explanation - a humoral stimulator produced in the hypoxic animal 
and transferred across the union - undoubtedly is the correct one. Erslev 
(19 53) demonstrated convincingly a factor in the plasma of anemic rabbits 
-----------------------·-~------------... 
which produced a reticulocytosis in normal animals, and after many investi-
gators developed bioassays based upon sound physiological principles, 
brilliant insights, and the use of radioiron (Plzak, et al, 1955; Fried, et al, 
1956; Fried, et al, 1957; and Jacobson, et al, 1957), the stage was set for a 
host of investigators to ask questions and seek the answers which constitute 
the material reviewed here. 
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In addition to its inherent interest and value, the study of erythro-
poiesis takes on wider biological importance because it may serve as a model 
for the control of tis sue development in general. Erythropoiesis represents 
the continuous formation and replacement of a well-differentiated tissue that 
is readily accessible in many of the most highly developed biological species. 
The study of erythropoiesis, therefore, may produce a valuable model for the 
basic study of differentiation of mammalian cells. 
1. The chemistry of erythropoietin 
The major problem encountered by the chemist attempting to define 
the chemical nature of erythropoietin is the difficulty associated with obtaining 
adequate amounts of purified material. As little as 0.4 units of erythropoietin 
probably approximates the normal daily production in the mouse (Alexanian, 
1969). Since small samples with more than 7, 000 units of activity per milligram 
of protein have been produced (Goldwasser and Kung, 19 68). it is apparent 
that man, like a mouse, might be sustained by one or two hundred micrograms 
of active material per day. 
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When in plasma, erythropoietin is resistant to short periods of boiling 
(Borsook, et al, 1954). The conditions were for 15 minutes at pH 5. 5. 
purified preparations are destroyed by trypsin (Borsook, 1959), chymotrypsin 
(Borsook, 1959), pepin ( Slaunwhite et al., 1957), and neuraminidase 
(Winkert and Gordon, 1960). These results indicate the active material is 
probably a sialic acid containing protein (Goldwasser, et al, 1962). Limited 
studies to date have indicated the biochemical properties of erythropoietically 
active concentrates obtained from renal tumors,, renal cystic fluid, or cere-
bellar cyst fluid of patients with secondary polycythemia are quite similar 
to the properties of erythropoietin obtained from plasma and urine of anemic 
mammals. 
Other interesting properties of erythropoietin include treatment with 
alpha and beta amylase, beta glucosidase, cellula se (Lowy and Borsook, 19 62) 
and ribonuclea se, lysozyme and carboxypeptida se (Winkert and Gordon, 19 60). 
All of these agents did not inactivate the hormone. Fluorescein isothiocyanate, 
which substitutes on free amino groups and phenolic hydroxyls, caused com-
plete inactivation indicating that these groups may be important for biological 
activity (Goldwasser and Kung, 1968). Anhydrous formic acid did not inactivate 
the hormone, suggesting that serine and threonine hydroxyl groups, where 
formate esters are formed, are not important for the hormone's activity 
(Goldwasser and Kung, 1968). P-chloromercuribenzoate did not destroy the 
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biological activity, indicating that sulfhydryl groups may not be necessary 
for this function (Goldwas ser and Kung, 19 68). The application of Koshland' s 
reagent (2-hydroxy-5-nitrobenzylbromide), which reacts with tryptophan, to 
an erythropoietin preparation, resulted in a complete loss of biological 
activity (Lowy and Keighley, 1968). This suggests that tryptophan is 
exposed in the erythropoietin molecule and is important for biological activity 
(Lowy and Keighley, 1968). Goldwasser and Kung (1968) have postulated that 
the sialic acid residue of erythropoietin may play a role in binding the hormone 
to a carrier and thus act to preserve the hormone's stability or retard its 
excretion in vivo. 
It is therefore not clear which of the characteristics attributed to 
erythropoietin, including molecular weight estimates varying between 27, 000 
(Rosse, et al, 1963) and 70, 000 (Goldwasser and Kung, 1968), might in reality 
be properties of one or more carrier proteins or other extraneous substances. 
Clearly much work remains before the chemical characteristics of erythro-
poietin can be defined with assurance. 
2. Erythropoietin metabolism and marrow utilization 
Erythropoietin disappears rapidly from the blood stream of animals 
and man. Disappearance curves of exogenous erythropoietin are biphasic 
in the rat, presumably because substantial amounts of the hormone must 
dilute the extrava scular space before equilibrium is established (Reis smann, 
38 
et al., 19 65). The half-life of endogenously produced erythropoietin is about 
z. 5 hours (Stahlman and Brecher, 1959 and Reissmann et al., 1965). 
The fate of erythropoietin is not well understood. Urinary excretion 
appears to parallel plasma concentrations at both low and high levels 
(Novassaghi et al., 1967 and Weintraub et al., 1964). When plasma titers 
are high, excretion may be highly dependent on urinary pH (Marver and Gurney, 
1968). The level of erythropoietin has been found to fall substantially follow-
ing perfusion through the liver (Keighley, 1962), but the degree to which 
hepatic metabolism participates in degradation of small amounts of endogenous 
ly produced erythropoietin remains to be ascertained. 
Utilization, destruction, or inactivation of erythropoietin by an 
erythroid marrow is a matter of some debate. Plasma levels have been found 
to decline more slowly in irradiated rodents (Stahlman and Brecher, 1959), but 
the disappearance of injected erythropoietin does not appear to be influenced 
by the administration of 700 R (Naets and Witteck, 1965). It has been suggest-
ed that the decline of plasma titer from peak levels reached 12-18 hours after 
continuous severe hypoxia reflects utilization by an erythropoietically active 
marrow. However this decline is probably a reflection of decreased production 
of the hormone since a respite at ambient conditions for a few hours is suffi-
cient to restore the animal's ability to again elevate the plasma level (Fried 
.§l_tl.' 19 67) . 
From these experiments it seems clear that there is insufficient evi-
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dence to be certain that the marrow is the principal site for the inactivation or 
degradation of erythropoietin. Certainly the marrow reacts with a physiological 
response to the hormone, but the amount it consumes in relation to the daily 
production has not been clearly measured. A decline in the injected plasma 
erythropoietin level itself may not represent actual consumption since the 
volume of distribution also is an important factor (Alpen, 1962). Furthermore, 
a fall in plasma erythropoietin level after erythropoiesis is increased need not 
represent consumption since production of the hormone may also vary (Fried 
et al., 19 67), and the animal may partially adjust or acclimatize to the hypoxic 
situation in diverse ways (Siri et al., 1966). The difficulty in these experi-
ments, as I see it, has been the lack of direct methods for measuring actual 
marrow metabolism of the hormone, and the inability to be certain that other 
variables, such as hormone production, shifts within compartments of distri-
bution, and renal excretion, remained constant while declining plasma levels 
were measured. 
3. Tissues, neoplasma and fluids having erythropoietin 
A plasma factor acting to increase erythropoiesis under hypoxic con-
ditions has been documented in rats (Erslev and Lavietes, 1954, Fried .§.t ~·, 
1956; Plzak et~ .• 1955 and Prentice and Mirand, 1957). 
An erythropoiesis - stimulating factor has been identified in the follow-
ing body fluids following hypoxia: urine (Adamson, 19 6 6, Piliero et al., 19 56 
--
and Winkert et~ •• 1957), lymph (Keighley, 1962), amniotic fluid and fetal 
---------~~--"__.,,__ _________ _ 
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blood (Finne, 19 64, Finne, 19 6 6 and Halvorsen and Finne, 19 65), and breast 
milk (Grant, 1955). Renal cyst fluid (Donatig, et §l., 1963, Penington, 1962 
and Waldmann, 1964) and cerebellar hemangioblastoma fluid (Hennessy~ §l., 
19 6 7, Race ~ .§.!._., 19 64 and Waldmann, 19 61) have been shown to contain an 
erythropoiesis - stimulating factor with many chemical - physical properties 
similar to serum or urinary erythropoietin (Rosse and Waldmann, 1963). 
An erythropoiesis - stimulating factor has been extracted from various 
neoplasma such as renal cell carcinoma, hepatic cell carcinoma and undiffer-
entiated carcinoma of the lung (Donati ~§l., 1963). Primary hepatoma 
(Schonfeld ~al., 1961), cerebellar hemangioblastoma (Brody and Rodriquez, 
1961, Waldman and Levir, 1960), Wilms' tumor in children (Shalet et&~. 1967), 
polycystic kidney disease and renal malignancy (Gurney, 1960), and primary 
hepatocellular carcinoma (Nakao et .§1., 1966 and Kan et .§1., 1961) have also 
been documented to have an erythropoie sis - stimulating factor. 
There are no reports of any studies on animals bearing the Walker 256 
Carcinosarcoma. 
Thomson and Marson (1953) reported on the stimulating factor produced 
by fibroids of the uterus as well as did Horwitz and McKelway (1955) report 
on polycythemia associated with uterine myomas. Both of these conditions 
are considered to be benign. 
The major site controlling the production of erythropoietin is the 
kidney. This was proven by Jacobson et.§1._in 1957. He was the first to demon 
s tra te that bilaterally nephrectomized rats or rabbits no longer responded to 
bleeding or cobalt administration with markedly increased levels of plasma 
erythropoietin (Jacobson et&., 1957, Jacobson..§.!&., 1957, and Jacobson 
et ..fil_., 19 60) and that the increased erythropoietin levels which followed 
phlebotomy of rabbits fall to near normal soon after nephrectomy (Jacobson 
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et ..fil_., 1957). Controls for these experiments consisted of ureter-ligated rats 
which developed similar blood urea nitrogen levels, but retained their capacity 
to respond to cobalt or phlebotomy. Further experiments showed that neph-
rectomized rats responded slightly to hypoxic hypoxia with a small increase 
in erythropoiesis (Goldwa sser et&., 19 58), and nephrectomized mice exhibited 
a very slight response to a phenylhydrazine - induced anemia (Jacobson..§.!&., 
1959). From these experiments it was estimated that 10 percent of erythropoie-
tin production was controlled by extrarenal sources (Jacobson, 19 62, and 
Jacobson..§1.tl_., 1959). 
4. Site and mechanism of action of erythropoietin 
Erythropoiesis can be divided into two stages: the development of the 
erythron (i.e., the red cells and the erythrobla sts in the marrow or spleen) and 
the development of the stern cells (i.e., those cells which reproduce them-
selves and give rise to the erythron) (Laj tha, 19 6 6). It was suggested that a 
stimulus for increased red cell production might act on the stem cells, since 
in human beings there is an interval of five days between such stimulation 
and the appearance of an increased blood reticulocyte count, and five days is 
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the length of time required for '11a tura tion of erythroblas ts from the earliest cell 
to the reticulocyte (Yoffey, 1957). 
Since the initial work on the polycythemic mouse (Jacobson et al., 
1957) several investigators have studied the morphological sequence of events 
which followed the administration of erythropoietin to such an animal 
(Filmanowicz and Gurney, 1961, Ito~~ •• 1964, Nakao~ al., 1966, and 
Reissmann, 1966). Within ll to 18 hours an increased number of large cells 
with fine chromatin and an intensely basophilic cytoplasm appeared (Gurney 
et al., 19 65 and Nakao et al., 19 66). These cells have been described as 
similar to large lymphocytes (Gurney~&., 19 65) or reticular cells (Nakao 
et&,, 19 66). A timed sequence of erythroid maturation followed, beginning 
with the appearance of proerythroblasts by 24 hours (Nakao~& •• 1966 and 
Filmanowicz and Gurney, 19 61). This was followed by successive increases in 
basophilic, polychromatophilic, and orthochromatic erythroblasts over 51 to 
75 hours as the proerythroblasts declined, and a blood reticulocyte peak at 
72 to 96 hours while the late erythroblasts declined (Filmanowicz and Gurney, 
19 61) . 
The response of primitive marrow cells to erythropoietin depends not 
only upon the dose of the hormone but also upon the duration of stimulation. 
A given amount of erythropoietin yields a progressively greater response as it 
is fractionated progressively into a larger number of doses (Schooley, 1965 and 
Fogh, 19 6 8) • 
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if anti-erythropoietin antibody is given to polycythemic mice one day 
after the hormone, the wave of erythropoiesis advancing through the hemato-
poietic system and culminating in a reticulocytosis continues unabated (School-
ey and Garcia, 19 62). Hence continued maturation of erythroblasts is not 
dependent upon the continued presence of erythropoietin in the plasma. It has 
been proposed, however, that erythropoietin accelerates maturation of develop-
ing erythroblasts, since its administration leads to an increase in reticulo-
cytes, often demonstrable within a day (Gallagher and Lange, 1962; Eskuche 
and Hodgson, 19 66; and Stahlman et al, 19 63). 
The limited information available at this time on the mechanism of 
action of erythropoietin comes, to a large degree, from marrow culture studies. 
Perhaps the earliest observable effect is enhanced 14C-uridine incorporation 
by RNA of marrow cells after the hormone is added to cultures (Krantz and 
Goldwasser, 19 65). Actinomycin D, which blocks DNA - dependent RNA for-
mation, inhibits this early effect. Formation of several different species of 
RNA appear to be enhanced by erythropoietin (Gross and Goldwasser, 1968), 
and although the importance of these various RNAs remain to be elucidated it 
is reasonable to suspect at least one of them may be a messenger for hemo-
globin formation. 
Delta-aminolevulinic acid synthetase increases in the spleens of 
animals with distention of its blood vessels due to extra blood. ALA synthe-
tase is increased within 8 hours after erythropoietin is injected (Nakao et al., 
1964) ALA synthetase may be de-repressed by erythropoietin, and in this 
manner the first of a whole series of inter-related events might be initiated 
(Goldwasser, 1966). 
44 
As yet, however, no single primary effect of erythropoietin has clearly 
delineated, and no unifying hypothesis accounting for all the recognized bio-
chemical effects of the hormone has been proposed. 
K. RETICULOCYTES 
Reticulocytes were first observed by Ehrlich early in his career. 
The reticulum of reticulocytes cannot be seen, even by darkground 
illumination or by phase contrast microscopy unless stained. However, exam-
ination by ultraviolet light with the wavelength that is absorbed by nucleic 
acids and observation of the effect of ribonuclease on the basophilic material 
(Dustin, 1943) indicated that the reticulum is composed of ribonucleoproteins. 
The precipitation of ribosomes by cresyl blue or by New Methylene Blue N 
produces the reticular network visible by light microscopy. 
In reticulocytes the reticulum may appear as a narrow band traversing 
the cell, it may be evenly distributed throughout the cell or it may be so 
densely packed as to give the appearance of a nucleus. 
Reticulocytes are larger than fully matured red corpuscles, perhaps 
20 percent greater in volume (Killmann, 1964). It was assumed at one time 
that red corpuscles decrease in size when they mature beyond the reticulocyte 
stage. However, there is good reason to believe that the large reticulocytes 
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which appear in the blood as the result of erythropoietic stimulation are the 
outcome of skipped divisions and have a short life-span (Brecher and Stohlman, 
1962). This idea is consistent with the rapid rise and fall of the reticulocyte 
count following specific therapy of anemias and the subsequent rise of hemo-
globin which is only gradual. 
Reticulocytes are more adhesive than adult corpuscles and move 
about in currents at a much slower rate than mature cells (Davidson, 1930). 
This adhesive property, like that described for more primitive cells (Isaacs, 
1937), may account for their tendency to remain within the bone marrow under 
normal conditions. It has been reported that there is a coating of globoulin 
(Sutherland et&., 1963), at least part of which is transferrin (Jensen et&., 
1965). Their specific gravity is lower than that of adult corpuscles (Key, 1921) 
and they tend to collect in the upper portions of suspensions of corpu_scles. 
Reticulocytes do vary in their resistance to hypotonic solutions (Daland and 
Zetzel, 19 3 6) • 
The time required for development from the proerythroblast stage to 
the last normoblast division may be 2 to 5 days. The marrow reticulocyte 
time may be about 36 to 44 hours, or less, while the time for maturation of 
reticulocytes in the circulation is about 24 to 29 hours (Finch, 19 59). After 
hemorrhage, the reticulocyte response begins by the third or fourth day. It 
seems likely that the increased rate of erythropoieosis in response to various 
stimuli is not mediated by shortening the generation time of the pronormoblast 
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but more probably is the result of a rapid increase in the rate of differentiation 
of the multipotential stern cell (Al pen and Cranmore, 19 59). 
1. The orderly reticulocyte response 
In response to an appropriate stimulus the percentage of reticulocytes 
rises, usually within 2 to 10 days and, increasing rapidly, their number 
reaches a maximum within a period of 3 to 10 days. This rise is a steady and 
progressive one and is followed by a slower and some what less regular de-
cline. The first reticulocytes which appear are 11 young, 11 with large amounts 
of reticulum, while later the cells contain less and less reticulum - presumabl 
older forms. Up to the peak of the reticulocyte curve, the increase in the 
total red cell count is only such as can be accounted for by the increment of 
reticulocytes. The decline of the reticulocyte curve to normal values is 
followed by a rise in the quantity of mature corpuscles. Thus all the morpho-
logic changes which occur are in the direction of the restoration of normal 
conditions with mature red corpuscles replacing the young and probably less 
efficient forms. 
2. Factors governing the reticulocyte level in the blood 
These include the rate of production of red cells, the stage of their 
release from the marrow, the rate of intrava scular reticulocyte maturation, 
the rates of reticulocyte as compared with older red cell destruction by exter-
nal causes and the possible role of the spleen in reducing the number of cir-
culating reticulocytes (Cline and Berlin, 19 63). 
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The classic reticulocyte response, on the other hand, appears to be 
governed mainly by three factors; namely, the size of the stimulus, the quantit 
of blood-building material available and the reactive state of the bone marrow. 
3. Summary 
The factors which goven reticulocyte level in the blood may be tabulated 
as follows: 
Increase in reticulocytes: 
Physiologic: 
At birth 
Menstruation 
Pregnancy 
In Disease: 
Erythropoietic response following treatment of anemias 
with Fe, vitamine B12, folic acid 
Blood intQxication 
Erythroblas tic anemias 
Hemolytic anemias 
Following hemorrhage 
Severe lead poisoning 
Leukemia 
Malaria 
Pernicious anemia and sprue following folic acid therapy 
(as a response to treatment) 
Polycythemia vera 
Sickle cell anemia 
Splenic tumor 
In typhoid fever - occasionally 
Many parasitic infestations 
Low or absent: 
Idiopathic aplastic anemia 
Acute benzol poisoning 
In anaplastic crises of hemolytic anemias 
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L. EARLY HISTORY OF THE WALKER TUMOR STRAIN 
The tumor was first found by Dr. George Walker of Baltimore, Maryland, 
in 1928, and was carried on by successive subinoculation into rats. The 
following description of the tumor discovery was told to Earle (1935) by Walker: 
"On February 12, 1928, a mass about the size of a large pecan nut was 
found on the lower left side of the abdomen of a well grown female rat apparent 
ly about ten months of ~ge. The animal was pregnant and soon after the tumor 
was discovered delivered a litter of eight males. During the period of lacta-
tion the mass regressed to a point where it had almost disappeared, but after 
weaning it began to grow again and increased in size with great rapidity. The 
animal was mated with a male but failed to become pregnant. She was killed 
March 23, 1928, and the mass was removed. It was the size of a small egg, 
firm in the upper portion but soft and almost fluctuating in the lower half. It 
apparent! y originated from a breast. It was enuclea ted with some difficulty, 
since in places it had broken through the capsule and had infiltrated the sur-
rounding tissues. 
"On section the lower portion of the tumor was found to be hemorrhagic 
and necrotic and to contain some free bloody fluid; the upper half was firmer, 
granular, grayish red, with small necrotic foci here and there. Some of the 
tissue was fixed in formalin and sectioned. Portions of the remaining tissue 
were implanted into 16 young rats of both sexes of about 40 grams each. Im-
plantation was by trocar in the left breast." 
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A histologic section of the original tumor was submitted by Dr. Walker 
to Dr. W. G. McCallum of Johns Hopkins University and was diagnosed by 
him as a carcinoma. 
The tumor was transplanted approximately every two weeks, by trocar, 
in Dr. Walker's laboratory until the laboratory was closed in 193 2. The Doure 
Doure strain of rats was generally used for this implantation, other strains 
were also tried. With all strains tried the tumor growth was nearly 100 per 
cent successful. The tumor was quite virulent and usually killed the animal 
in 4 to 5 weeks. During all of the transfers in his laboratory from 1928 to 1932, 
Dr. Walker found only 4 instances of regression of the tumor. 
The 8 sons of the rat which showed the original tumor were mated 
with females of the same general strain. In the third generation which resulted 
from these matings a tumor was discovered in the breast of a female thirteen 
months of age. Microscopic examination showed it to be identical with the 
original tumor. In the fifth generation a second tumor was discovered in the 
breast of a female nine months old. A third was found in a female of nine 
months in the seventh generation. This too was like the original tumor. These 
tumors were implanted into other rats and grew." 
M. BLOOD ENZYMES IN CANCER AND OTHER DISEASES 
Warburg (19 09) observed that the oxygen consumption of erythrocytes 
was associated chiefly with the presence of reticulocytes. Harrop (1919) was 
the first to correlate oxygen consumption of human blood with the concentration 
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of reticulocytes. By defibrinating the blood he greatly reduced the number of 
leucocytes and platelets, thus eliminating the effect of these fixed elements 
on oxygen consumption. In several patients with anemia but with low reticulo-
cyte counts, 0. 5 to 1. 0%, the oxygen consumption was about l to 3% of the 
oxygen content of the saturated blood. When the reticulocyte count rose to 
about 3%, the oxygen consumption rose to about 10% of the available oxygen, 
and at reticulocyte levels of 12 to 13%, the oxygen consumption was 30% of 
the oxygen content of the saturated blood. A more precise quantitative relation 
ship was elicited by Wright (1930) in rabbits rendered anemic by the injection 
of phenylhydrazine. In one experiment the reticulocyte count rose from 1. 5 to 
3 3% and then receded; the oxygen consumption rose and fell proportionately, 
amounting to about 60 cu. mm. per 109 reticulocytes per hour. 
1. The enzymes of the reticulocyte 
The marked respiratory activity of the reticulocyte in contrast to that 
of the erythrocyte indicates the presence of the enzymes of the citric acid 
cycle in the reticulocyte. Sherwood Jones et al. (1953) found that fluoracetate 
decreased oxygen uptake and favored the accumulation of citrate. The reticulo-
cyte possesses other metabolic sequences such as that of the incorporation of 
amino acid into protein (Borsook et al., 19 52) which are lacking in the mature 
erythrocyte. 
Succinic dehydrogenase, cytochrome oxidase, and NADase were found 
predominantly in the particulate fraction, where as glucose-6-phosphate de-
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hydrogenase, fumarase, hexokina se, and pyrophosphata se vvere present chiefly 
in the stroma-free hemolysa te. Calculation of the ratio of enzyme activities 
in reticulocytes to that in normocytes showed that NADase, lactic dehydro-
genase, glucose-6-phosphate dehydrogenase, and isocitric dehydrogenase 
were of approximately the same activity in the reticulocyte as in the mature 
erythrocyte. In contra st, some enzymes were present in much greater con-
centrations in the reticulocytes. The ratios were as follov's for these enzymes: 
malic dehydrogenase, 2.. 7; fumarase, 13. 2; hexokina se, 13. 7; and pyrophos-
pha tase, 19. 3. Succinic dehydrogenase, aconita se, and cytochrome oxidase 
were not measurably present in the mature erythrocyte. 
The presence of certain enzymes being characteristic of reticulocytes 
was further demonstrated by Rubinstein et al. (1956) in in vitro experiments. 
The incubation of reticulocytes at 37 C with glucose and penicillin for 12 hours 
resulted in a substantial fall of reticulocytes as a result of conversion into 
mature erythrocytes. It was observed that the decreases in activity in NADase, 
malic dehydrogena se, and lactic dehydrogenase were only about 0 to 2.0%, 
whereas the decreases in reticulocyte characteristic enzymes such as pyro-
phosphatase, succinic dehydrogenase, aconitase, and cytochrome oxidase 
were substantially greater. 
2. Reticulocyte enzymes in disease 
When the hematopoietic system is stimulated, the number of reticulo-
cytes in the circulation rises, reaches a maximum, and may then decline. The 
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first reticulocytes which appear are "young" and contain large amounts of 
reticulum, while later the cells contain less and less reticulum and are pre-
sumably "older" cells. The reticulocyte may be considered as a stage in the 
development from the primitive nucleated cell in the marrow to the mature 
erythrocyte, and several studies in the literature show that a progressive 
diminution of metabolic activities accompanies this maturation. 
Bernstein (1959) employed centrifugation procedures to separate the 
young human erythrocytes, including reticulocytes, from the older cells; the 
former aggregated in the top layers of a packed red cell column, and the older 
cells stratified at successively lower levels. The reticulocyte count decreas-
ed with the depth of the layer, and this decrease paralleled decreases in the 
utilization of glucose, the formation of lactic acid, and the activities of phos-
phohexose isomera se and aldolase. 
It would appear quite likely, therefore, that changes in the enzyme 
activities of reticulocytes in many diseases, including cancer, ·1rould merely 
reflect the presence and degree of hematopoietic stimulation and, in turn, the 
age distribution of the circulating reticulocytes and erythrocytes. 
To the best of my knowledge, no investigator has studied the enzyme 
ALA dehydrase in relation to cancer and no one has studied this hematopoietic 
enzyme in the animal bearing the Walker 2 5 6 carcinosarcoma. 
N. DEFINITION AND SOME CHARACTERISTICS OF TUMORS 
Tumors may be defined as growths of cells which are largely or wholly 
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independent of the organism which supplies their nutrition, which frequently 
possess an atypical structure, and which reach no definite limit to growth • 
. 
These aberrations of tissue growth are common to all living multicellular 
forms, both animals and plants. 
Tumors arise from the cells of the host by a transform a ti on at present 
unknown, and once this transformation has occured it is apparently not rever-
sible. Most adult mammalian tissues cultured in vitro fail to grov· except 
during a brief early period, '\Nhereas most cancerous tissues under the same 
conditions exhibit continuous gro\l'rth over many years. To all indications, the 
capacity for growth of the tumor lies largely within itself and although it may 
superfically resemble the grovvth and regenerative capacities of normal tissues, 
has certain qualities peculiar to itself. 
Normal tissue growth occurs in an orderly, generally logarithmic, 
fashion without injury to surrounding tissues. Cancerous tissue growth, al-
though progressive, may occur at different rates throughout its course. Normal 
tissues do not affect neighboring tissues whereas cancerous tissues often in-
vade, destroy, and replace neighboring normal tissues. Normal tissues trans-
planted to other sites in the organism may grow or be maintained briefly for a 
while, but they ultimately necross and completely regress. Such a transplan-
tation is incompatible with the harmonious balance of the organism. In cancer, 
any extension of the original, primary tumor is called a metastasis. Accord-
ing to Erving (1940), there is often a gradual loss in structural differentiation 
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in metastatic tumors. They become more a nap las tic, i.e., they resemble to a 
decreasing degree the normal tissues of origin, so that metastatic grov.1 ths 
from primary tumors of different kinds of normal tissues are sometimes indis-
tinguishable. The presence of these transplanted cells is also incompatible 
with the harmonious balance of the organism, but the latter apparently dis-
plays little successful protective reaction against the destructive growth. 
Cancerous growth capacity is independent of the organism, and, hence, 
the growth capacity of the tumor is a nearly unique property of the tumor it-
self. This property of autonomous growth is the most striking characteristic of 
tumors as a class, and within the factors responsible for this property lies the 
secret of control of this growth. 
1. Classification of animal tumors 
Tumors arise in certain tis sues through the agency of certain factors, 
some known, some suspected, and many of them unknm .... rn. Tumors may, there-
fore, be classed according to either (a) their known etiology or (b) the normal 
tissue from which they arise or most resemble. The classification of tumors 
was originally designed to be applied to human tissues but, V'rith minor modi-
fications known to the experienced judgment of the histologist, may also be 
applied to tumors arising in the lower animals. 
The term carcinoma may be applied to tumors which arise from epithelia 
tissue, whether pavement or glandular. 
The term sarcoma may be applied to tumors arising from connective 
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and muscle tissues. 
Tumors characterized by the terms carcinoma and sarcoma are frequently 
anaplastic and often bear relatively little resemblance in histological structure 
to the normal tissues of their origin. The suffixes carcinoma and sarcoma are 
generally applied to what may be called malignant growths. Malignant gro·1rths 
are frequently invasive in character, destructive to neighboring normal tissues, 
and prone to give rise to metastatic lesions elsewhere in the host. 
2. Growth and vascular reactions of tumors 
Most microscopic studies of tumor growth are performed on fixed, 
sectioned, and stained material. Such studies are limited to discontinuous 
stages in the growth of cells obtained from different animals killed at various 
intervals. The disadvantages inherent in this procedure are obvious. 
Newer techniques have been developed which permit the cultivation 
and direct microscopic observation of tumor cells within the living animal, 
thereby making it possible to carry on continuous or intermittent examination 
of the same group of cells over a prolonged period of time. Lucke' and 
Schlumberger (1939) used a method based on slit-lamp microscopy on anterior 
charrber implants of a carcinoma of the frog. A transparent-chamber technique 
was developed for the rabbit ear by Sandison (1928), Clark et al. (1930), Ebert 
et al. (1939), and Williams (1934), and was adapted to the mouse by Algire 
(1943). The application of this technique to tumors has been made by Ide et al. 
(1939), who observed the vascularization of the Brown-Pearce rabbit epitheliom , 
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and by Algire (1943) and Algire and Chalkley (1945), who studied the vascular 
reactions of transplanted tumors in the mouse. The basis of the method, as 
adapted to the mouse, rests upon the insertion of a transparent chamber into 
a skin flap in the animal. Under the experimental conditions used, the tumor 
cells are maintained under normal environmental conditions of groirth and 
nutrition. 
The results of these investigations indicated (a) that the rapid growth 
of tumor transplants is dependent upon the development of a rich vascular 
supply, and (b) that an outstanding characteristic of the tumor cell is its 
capacity to elicit continuously the gro"'rth of new capillary endothelium from 
the host. The s timula ti on of vascular proliferation is fundamentally a property 
shared by traumatized tissues and by transplants of normal tissues as well as 
by tumors. This stimulation is only temporary in normal tissues whereas it is 
continuous in tumors. Cancer cells thus seem to be able to provoke a contin-
ued vascular proliferation from the surrounding host tissue, and this property 
may be, in part at least, responsible for their autonomous nature (Lindgren, 
1945). The identity of the provoking substance elaborated by the tumor has 
been termed 11 tumor angiogenesis factor (TAF) 11 • It is postulated, today, that 
if TAF could be inhibited the tumor would die due to the lack of nutrition and 
the means to elemina te waste products. It is obvious this is a very fertile 
area for sound research. 
0, GENERAL CONCEPTS - CHEMISTRY OF TUMORS 
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Every normal tissue carries on a specific and unique function. To 
effect this function, the particular tissue is metabolically (as \111ell as mor-
phologically) differentiated and possesses a chemical structure and pattern of 
enzymatic catalysis peculiar to itself. Life thus represents the harmonious 
integration of a number of individual metabolic mosaics. 
The metabolic pattern is as distinguishing a feature of each tissue as 
is the gross or microscopic morphology and constitutes a functional characteri-
zation of the tissue. Each of the enzymes behaves qualitatively in much the 
same way in all tissues. Quantitatively, however, the distribution of the 
enzymes varies in each of the tissues, and it is this quantitative distribution 
which constitutes the individual mosaic of each tissue. Although the pattern 
itself is based on a quantitative distribution of each of the enzymes, the net 
biological result of the various catalytic systems in each intact tissue is 
actually a qualitative one, for these systems are not independent but inter-
related, and the particular direction which the individual metabolism of each 
tissue will take may be dependent upon, among other factors, the relative 
proportion of rate-determining sys terns. 
Tumors, like the normal tissues from which they arise, possess chem-
ical substances, enzymes, etc., and their existence, too, must be at least 
partially explicable in terms of a chemical and metabolic pattern. A compar-
ison of the pattern of a tumor with that of the normal tissue from which it arose 
may be expected to reveal the metabolic and chemical changes ~Nhich are the 
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consequence of neoplasia. Such a comparison has its limitations, for, among 
other things, the normal tis sue under scrutiny is, unlike the tumor, a res ting 
non-growing tis sue. To make the comparison more valid, a normal, grovdng 
tissue, such as fetal or regenerating tissue, must be included. It is impos-
sible to assume, ~priori, that the neoplastic transformation of one type of 
tissue is the same for every other type of tissue, and, therefore, such com-
parative studies should include all available sets of homologous tissues in 
as many species as are available, such as, liver and hepatoma, skin and 
epidermal carcinoma, lymph nodes and lymphoma, etc. Furthermore, it is 
equally unwise to assume that each enzyme or chemical component alters 
during the neoplastic trandormation in exactly the same way, and, therefore, 
as many such systems must be investigated as is possible. 
The lack of cellular homogeneity, whether in normal or in tumor tis sues, 
is hardly a deterrent to investigation, but its recognition is necessary. Such 
inhomogeneity is uniform among normal tissues of the same kind and almost 
invariably uniform among tumors in late generation transplants. The chemical 
study of such tissues presents few difficulties from this angle. On the other 
hand, the tumor arising directly from the normal tissue, or in relatively early 
generation transplants when alterations may sometimes occur, requires micro-
scopic criteria as controls for both a qualitative description of the tumor it-
self and for a basis of knowledge of the principal contribution factors (pro-
portion of active cells) to the chemical properties of the tissues. 
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Cancer is a problem of abnormal growth, and it might be expected that 
study of the energetics of the cati\lytic systems concerned with intracellular 
synthetic reactions would be highly revealing. To date, however, this would 
still be considered a problem for the future. Research on the phenomena of the 
cancer cell can progress little faster than comparable research on normal cell 
mechanisms. Thus far, the analytical chemist has only the task of uninspired 
digging 'itdthin the cancer cell, of mapping the chemical spectrum of the cancer 
cell, and, to further mix the metaphor, of running, among other things, the 
enzyme gamut from A for aconitase to Z for zymase. To date, no evidence for 
a "cancer enzyme" has emerged. There may be a "cancer pattern" of several 
enzymes within cancerous tissues. Little by little the outline of the pattern 
has slowly come into view, and the interesting regularity and uniformity of 
this pattern has perhaps been even more than might have been expected. 
P. EN2YMATIC PROPERTIES OF CANCEROUS TISSUES 
Numerous investigations by biochemists have supplied a considerable 
amount of information on the enzymatic activity of different types of tumors. 
Epidermis of the mouse is unusual in that some of the enzymes have a very low 
activity. For example, the activities of succinic dehydrogenase (Carruthers 
and Suntzeff, 194 7) and of apyrase are very lovr in epidermis but very high in 
the squamous-cell carcinomas (Roberts and Carruthers, 1948). A study of 
cytochrome C content in epidermis and carcinomas by a polarographic procedure 
(Carruthers, 1947) revealed that its content was lower in carcinomas than in 
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epidermis (Carruthers and Suntzeff, 1948). In an anaplastic squamous-cell 
carcinoma the arginase activity was 6 times greater than normal and in a highly 
differentiated tumor of this type the arginase activity was 18 times greater 
than that of normal epidermis (Roberts, 1948; Roberts and Frankel, 1949). The 
activity of cytochrome oxidase of normal epidermis is less than that of squam-
ous-cell carcinomas (Carruthers and Suntzeff, 1947). Although the activity of 
the enzymes listed above is higher in the carcinomas than in epidermis, the 
values found for these tumors and in general agreement with those for other 
kinds of tumors • 
The activity of some enzymes, such as alkaline phosphatase and de-
soxyribonucleodes-aminase, are greatest in transplantable rat he pa tom as and 
show decreasing activity in the primary tumor and least activity in the liver. 
Other examples could be cited, but it is quite apparent that the activity of a 
particular enzyme will depend upon its function v'.'ith respect to the place of 
origin of the new growth in a normal tissue and the events follovring this func-
tion as tumors arise. No enzyme has been discovered yet which is character-
istic for only growing tissues - embroyonic and neoplastic. 
In general, the study of the enzymology of tumors has led to no strik-
ing discoveries, but has indicated for most tumors a much lower activity of 
many enzymes than that possessed by the tissue of origin of the tumors; com-
plete or near disappearance of some enzymes probably associated with mor-
phological alterations; and an increase in enzyme activity associated with say, 
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more rapid cell division, etc. Greenstein (194 7) has ably summarized the re-
sults of the many investigations on enzymology in tumors, and his general 
conclusions are given below: 
(1) Each normal tissue is characterized by the possession of an individ-
ual pattern of enzymatic activity which may be characteristic for that tissue. 
(2) Qualitatively tumors have the same enzymes as do normal tissues 
except where a particular enzyme is native to some tis sue component which 
may be lost, resulting in a lack of the enzyme, as for instance, cysteine 
disulfura se in the liver. 
(3) The range of activity of each enzyme and the content of various 
components as vitamins {Greenstein, 194 7 and Pollack et al., 1942) and free 
amino acids (Roberts and Frankel, 1949) is much narrower among tumors than 
among normal tissues. These considerations appear to be independent of the 
host, site, method of induction or species in which the tumor grov·s. 
(4) Enzymatically tumors have much in common biochemically. 
Investigations have also demonstrated that qualitatively tumors have 
many of the same enzymes as do normal tissues. For example, Wenner et al., 
(1952) have demonstrated in a series of transplanted mouse and rat tumors that 
enzymes of the citric acid cycle and related enzymes were present. Lactic, 
malic and isocitric dehydrogenu.ses, fumarase, oxalacetic carboxylase and the 
condensing enzyme were present in tumors in amounts similar to those found in 
some normal tis sues. The activity of aconita se and d.-ketoglutara te dehy-
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drogenase were lower in the tumors than in the normal tissues examined. 
Weinhouse ~ i!.l. (1951) have also shown that transplanted tumors of various 
types are able to oxidize isotopically labeled glucose, lactic acid and pal-
mitic acid at a rate comparable to a representative group of normal tissues. 
Finally Le Page, Meyerhof and others have shown that the rapid conversion of 
glucose to lactic acid in tumors occurs by way of the phosphorylated inter-
mediates of the Embden-Meyerhof scheme (U. R. Potter, 19 51). 
Q. BLOOD FLOW TO TUMORS 
The vascular morphology of spontaneous and transplanted tumors has 
been of interest for at least 80 years. Different concepts have been accepted 
from time to time. Algire and Chalkley (1945) shovred that transplanted solid 
tumors had a blood supply that was superior to that of the surrounding normal 
tis sue. 
Aligire (1947) considered that "an outstanding characteristic of the 
rapidly growing tumor is its capacity continuously to elicit the production of 
new capillary endothelium from the host"~ that it might in fact "be the real 
underlying factor responsible for the autonomous growth inherent within the 
tumor cells." Algire (19 54) offered a complete picture of the reactions that 
occur by using a transparent chamber. Coincident with establishment of a 
blood supply, the isograft became increasingly translucent, capillaries took 
on an irregular pattern, sinusoids developed, little differentiation into arte-
rioles and venules occurred and within 5-8 days, the blood vessels had reach-
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ed a constant 40-50 percent of the total tumor volume. 
Goldacre and Sylven (19 59 and 19 62) and Owen (1960) used lissamine 
green to map regions of tumors not supplied by blood. These regions suddenly 
appeared in tumors at a critical age, which in the transplanted mouse tumors 
studied (mammary carcinoma, sarcoma 37) was about 12 days, and in the rat 
Walker 2 5 6 carcinosarcoma about 5-10 days, depending upon the type of host. 
The uncolored zones, which remained after dye injection to vessels supplying 
the tumor area, contained living cells as shown by vital staining, tissue 
culture, and particularly by transplantation into new hosts. 
1. The rate of blood flovr to tumors 
Bierman and co-workers (1951and1952) demonstrated that when fluores-
cein was given intraarterially, this appeared most rapidly in primary skin 
tumors and remained longer and in higher concentration than in the adj a cent 
normal tissue. This increased vascularity was most prominent at the periphery 
or advancing edge of the neoplastic lesions. Gullino and Grantham (19 61) 
were the first to publish results of measurements of the magnitude of blood 
flow in tumors. The first method they used was a direct one in v·hich the 
effluent blood flow from the tumor was measured. The second or indirect met-
hod was based on the fractional distribution of two indicators, potassium-42 
and rubidium-86. By these methods, they found that in rat tumors the blood 
flow followed a uniform pattern independent of the histologic type, site of 
implantation and size of the tumor. They showed that contrary to what Bierman 
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et al. (1951and1952) concluded, the blood flow to tumors v1as unusually low. 
A hepatoma had a blood supply roughly one-twentieth that of the host liver. 
2. Tumor perfusion and tumor size 
Cataland et al (1962) showed that in transplanted tumors, by using the 
indirect method of Sapirstein (1958) with rubidium-86, there exists an inverse 
relationship between tumor perfusion and tumor size; the smaller the tumor, 
the greater the perfusion. 
R. ANEMIA IN CANCER 
1. Introduction 
The etiology of anemia in cancer patients has been a challenging pro-
blem to investigators for many years. Callens and Rose (1948) agreed with 
Forkner (193 8) that defective blood formation, blood loss, and increased blood 
destruction may each play a part in the mechanism of anemia in cancer. 
Anemia is most accurately defined as a reduction in the circulating red 
blood cell mass. Anemia is defined in terms of concentrations per unit volume 
of blood. In these terms, anemia is a reduction below normal in the volume of 
packed red blood cells per 100 ml, the blood hemoglobin concentration per 
100 ml, and/or the red blood cell count per cubic millimeter. Under most 
clinical circumstances, these measurements accurately reflect changes in the 
red blood cell mass because the total blood volume tends to be kept within 
relatively narrow limits by a variety of physiologic mechanisms. 
The anemia that one observes in the Walker 256 Carcinosarcoma tumor 
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bearing animal has been judged, by me, to be a hemolytic anemia. I have 
used the excellent work of Haut and Wintrobe (1970) as the basis for this 
classification. 
They define hemolytic anemia as (1) reticulocytosis sustained for weeks 
without relief of the anemia; (2) persistent reticulocytosis with minimal anemia; 
and (3) rapid aggravation of the anemia with accompanying reticulocytosis. It 
will be shown that the experimental animals used for the data of this disser-
tation do, in fact, follow the above 3 points. 
It is obvious in all the situations just named, both overt and covert 
blood loss must be excluded before hemolysis can be said to be present. Whe 
reticulocytosis persists, it may be deduced that abnormal blood destruction 
(or blood loss) is occurring only if the expected result of accelerated produc-
tion, i.e., a rise in the volume of packed red blood cells, does not occur 
(Haut and Wintrobe, 1970). 
Low hemoglobin concentration and hematocrit values are common find-
ings in patients with malignancy. Shen and Hom burger (19 51) reported that 65% 
of 193 pa ti en ts with advanced carcinoma had a hemoglobin concentration of les 
than 80% of the normal value of 15. 6 g/100 ml. (g%). Of their 116 cases with 
low hemoglobin, 52 cases (44. 8%) had a hemoglobin concentration between 
70-80% of normal, 42 cases (36.2%) were 55-69% of normal, and 22 (19%) 
were below 55% of normal. Samuels and Bierman (1956) reported that in a 
group of 158 patients with various malignant neoplasms, a hemoglobin concen-
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tration below 80% of the normal value of 12. 9% v..ras found in the following 
frequency: carcinoma 55%, lymphoma, 7 7%; chronic lymphocytic leukemia, 7 5% 
chronic granulocytic leukemia, 95%; and acute leukemia, 97%. 
These figures can only give a general estimate as to the prevalence of 
the decreased hemoglobin concentration in patients with various types of neo-
plasms. It is obvious that details as to the stage of the disease and the gen-
eral condition of the individual patient greatly influence the percentage of 
patients with low hemoglobin concentration in any given group. 
In studies on tumor-bearing animals, decreased hemoglobin concen-
tration, red cell count, and hematocrit values have been correlated with the 
growth of both induced and transplanted tumors in the rat (Dunning and Reich, 
1943), the mouse (Taylor and Pollack, 1942), and the embryonic chick (Taylor 
et al., 1943). 
A hematological picture similar to that of leukoerythroblastosis v·as 
found in animals bearing far-advanced transplanted tumors (Sterling et al., 
1958). It was found that animals bearing rat hepatoma 3683 and lymphosarcoma 
R2788 had large numbers of immature and nucleated red cells in the circulating 
blood, \Nhich had been formed in response to a severe process of red cell de-
struction in the tumor-bearing animal. In some of the rats bearing these tumors 
reticulocytes and immature cells accounted for over 90% of the red cells. The 
hematological picture in these animals was not associated with any evidence 
of physical interference with the bone marrow. Although the marrow was ex-
---
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truded from the femurs intact and fixed as a tissue, there were no tumor cells 
found, and the bone marrow was hyperplastic with a predominance of immature 
cells of the erythroid series. 
The evidence indicates that a majority of patients with cancer, although 
possessing the ability to synthesize cells at a normal rate, do not compensate 
for the increased destruction of red cells by a greatly stimulated red cell pro-
duction. Only in the exceptional case does the turnover rate double that of the 
normal individual. 
2. Role increased erythrocyte destruction 
Evidence for increased blood destruction in patients vrith solid tumors 
and leukemia has been accumulated slowly over a period of half a century. 
Hirschfeld in 19 06 observed a marked increase in hemosiderin in a leukemic 
patient with severe anemia and considered the possibility of an increased rate 
of blood destruction. Paschkis (19/.7) observed that the very dark stools in 
myeloid leukemia were suggestive of increased red cell destruction. Many 
others reported the existence of hemolytic anemia in cancer (Berlin, 19 51 and 
Dacie, 1954) and from these works I was better able to understand the anemia 
of the Walker 256 tumor bearing animal. 
With the exception of G. M. Erown (1950), all of the earlier red cell 
survival studies were limited to patients with leukemias and lymphomas. A 
number of more recent investigations have extended these studies to patients 
with carcinomas. 
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G. M. Brown (1950) in his first report described the Ashby radiochromate 
curves of 5 patients with carcinoma of the lung, parotid, prostate, breast, and 
uterus. He found their 50% survival values to be 39, 33, 53, 33, and 16 days, 
respectively, as compared to a normal value of 60 days. 
In 1954, Hyman presented the first of several comprehensive studies 
which demonstrated that a shortened red cell survival was commonly found in 
patients with a wide variety of neoplasms. 
In 1954 and 1955, Renfer published two reports relating the anemia of 
cancer patients to the rate of .increased blood destruction and to the spread of 
the neoplasm. Their investigations were based on studies in 19 patients with 
a wide variety of malignant tumors. The patients presented with bronchogenic 
cancer, mammary cancer, Ewing's sarcoma, lymphatic leukemia, cancer of 
the tongue, cancer of unknown origin, a round-cell sarcoma, a lymphosarcoma, 
a reticulosarcoma and a treated x-ray-sensitive tumor of unstated origin. 
Others presented with multiple myeloma, a :xonchogenic cancer, a tumor of the 
brain stem, an astrocytoblastoma, a chronic lymphatic leukemia, a lymphoid-
cell reticulosarcoma, a mammary cancer under treatment, and a treated meta-
static x-ray-sensitive tumor of unknown histology. Renfer concluded from 
these studies that the close relationship between the degree of the anemia, the 
spread of the tumor, and the patient's red cell survival time pointed to the dom 
inating cause of the "tumor-anemia" as being the result of increased erytho-
cyte destruction. 
·------~----------------· ·----·-----------... 
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Sohier et al. (1957) have reported a detailed investigation in which 
serial red cell survival studies were performed on 4 patients with metastatic 
carcinoma of the breast. Although the initial life span studies were nearly 
normal, signs of increased destruction appeared in later studies which became 
very marked in the month before death. The initial life span of 120 days fell 
to 105 days and then to 50 days just before death. When 30% of the labeled 
red cells disappeared within a 2 week period the hemoglobin concentration fell 
by 17% followed by an elevation of the reticulocyte count to about 8%. It 
would seem that this sequence of events might represent the transient appear-
ance of the destructive process which became so pronounced toward the end 
of the study. At death, one of the patients had a hemoglobin of about 7 grams 
% and a markedly elevated reticulocyte count of over 5 0%. 
It would seem that this excellent and detailed study should provide a 
pattern for future investigations in that by continuously following the rate of 
disappearance of tagged cells during serial studies it is possible to more 
accurately locate and measure fluctuations in the rate of the destructive pro-
cess and to correlate these fluctuations with the clinical status of the patient. 
3. Nature of the destructive process 
There are four main pathways by which red cells may l::le destroyed within 
the body in pathological conditions: 
(1) Lysis. They may be lysed within the blood stream. The hemoglobin 
released binds to the haptoglobin in the plasma (Jayle and Boussier, 1955), 
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which leaves the blood stream slowly and is presumably removed by the 
reticulo-endothelial sys tern in the liver. Hemoglobin in excess of the hapto-
globin-binding capacity of the plasma is excreted by the kidneys, causing 
hemoglobinuria (Laurel! and Nyman, 1957). 
(2) Phagocytosis. They may be phagocytized directly from the circulatin 
blood by components of the reticulo-endothelial system in the spleen, liver, 
bone marrow, and lymph nodes. 
(3) Hemorrhageo They may escape from the blood stream through breaks 
in the vascular wall and be either lysed, phagocytized, or lost from the body 
by external hemorrhage. 
(4) Thrombosis. When a defect occurs in the vascular wall, a thrombus 
is formed. Entrapped red cells are lysed or phagocytized within the thrombus. 
Although the destruction here occurs within the vascular tree, it is not within 
the circulating blood. 
Regardless of the pathway involved most of all of the hemoglobin not 
lost through the urine appears eventually in cells of the reticulo-endothelial 
system, where it is degradedo The ring of the porphyrin moiety is opened and 
converted to bilirubin. The bilirubin passes to the liver where the glucuronide 
is formed (Schmid, 1956) and excreted through the bile into the intestines, 
where it is converted by bacteria into a complex group of compounds labeled 
"urobilinogen." 
4. Evidence for tumor toxins and hemolysins 
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One of the main pathways pursued by early investigators on anemia in 
cancer was the possibility that tumors produced toxins which had a destructive 
action against red cells. Much of this history has been reviewed by Weil 
(1907). At the turn of the century, Metchnikoff had been studying the hemolyti 
action of extracts of various normal tissues. In describing the approach of 
these early investigators to the problem, Weil reports "It had always been 
common knowledge that a characteristic of malignant tumors was to produce 
" cachexia and secondary anemia in their victims. Marchand (1902) interpreted 
the necroses, thromboses, hemorrhages, and round cell infiltrations as 
evidence of a toxic influence. He went even further; he suggested that the 
disturbance of tissue equilibrium, to which Weigert had attributed the rapid 
advance of tumor cells, was due to the destructive influence of this toxic sub-
11 . 
stance on the surrounding tissues. It has frequently been suggested that the 
anemia of tumors is probably due to the action of some toxin elaborated by the 
tumor and diffused into the circulating blood." Panzacchi (1902) was the first 
to demonstrate the lysis of erythrocytes by tumor extracts. This was 
followed by reports of Micheli and Donati (1903) and Kullmann (1904). Kull-
mann prepared extracts of tumors of the breast and uterus, and on testing 
them against washed red cells of man, rabbit, sheep, and dog obtained he mo-
lysis in every case, indicating that the toxin of tumors was a general rather 
than specific hemolysis. In his own paper, Weil (1907) demonstrated that 
extracts of normal organs (liver and kidney) thoroughly freed from blood was 
very low in. hemolytic activity and in some cases was entirely absent. In 
studies on tumors, Weil found that necrotic were much more hemolytic 
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than non-necrotic ones. He concluded that the anemias of malignant tumors 
are probably due in part to the hemolytic and toxic action of such products of 
necrosis. 
Little of further significance happened in this field for 40 years. In 
194 7, Gross reported experiments suggesting 11 a direct destructive action of 
a filterable substance contained in the tumor cells, on the erythrocytes of the 
host. 11 His detailed studies were summarized in a later paper (Gross, 1948). 
My reading leads me to conclude that evidence that substances from 
neoplastic tissues play a significant role in vivo in the destruction of 
circulating erythrocytes is still circumstantial. It is obvious that more work 
is required to firmly establish a place for them in the etiology of anemia in 
cancer. 
S. TUMOR - HOST RELATIONSHIPS - PATHOGENESIS OF CACHEXIA IN 
CANCER 
Weight loss is a very frequent clinical finding in patients or animals 
with cancer; it may be one of the presenting symptoms or it may occur with 
advancing disease. 
Several factors are responsible and contributory to the tissue wasting 
and the eventual cachexia. Such factors are anorexia, nausea, dysphagia or 
mechanical obstruction of the gastrointestinal tract, malabsorption, hemorrhage 
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necrosis, ulcerations, proteinuria and gastrointestinal loss of albumin, 
impairment of function or destruction of vital tissues and organs, therapeutic 
removal of effusions and bacterial, viral, or fungal infections. 
It is accepted by some that the described factors account for the path-
ogenesis of all cases of cancer cachexia (Ewing, 1941 and Willis, 19 60). 
There are, however, several instances where weight loss is one of the earliest 
manifestations of malignancy inducing the patient to seek medical advice, or 
other cases where the weight loss is observed with advancing cancer with more 
than adequate food intake and in the absence of other contributory factors 
(Donovan, 1954 and Nebenzahl, 1932). In the latter cases, the cachexia has 
been attributed to systemic effects produced by the tumor on the tumor-free 
tis sues of the host. 
The growth of the tumor alters markedly the metabolism and induces 
measurable biochemical changes in various tissues and organs of the host 
(Busch, 1962; Greenstein, 1954; and Theologides, 1967). The clinical 
features of cachexia characterized by anorexia, marked asthenia, significant 
loss of body fat, protein, and other components, anemia, water and electro-
lyte abnormalities, and increased basal metabolic rate and energy expenditure 
despite the reduced dietary intake are the most obvious manifestations of a 
profound systemic derangement of the host metabolism. 
1. Observations in Animals 
A short period after inoculation with a tumor the total weight of the 
74 
animal (animal plus tumor) starts increasing (Medigreceanu, 1910 and Murray, 
1908). This continues up to a few days before death when the total weight 
starts decreasing (McEven and Thomsom, 1933). The weight of the carcass 
(animal minus tumor) might remain stable or even increase for a very short 
initial period but then decreases progressively (Medigreceanu, 1910 and 
Murray, 1908). The tissues and organs that lose nitrogen and weight during 
starvations are the ones that lose nitrogen during the tumor growth (Sherman 
et al., 1950). The alimentary canal weight maintains the normal ratio to 
total body weight (Medigreceanu, 1910). The heart shows hypertrophy in most 
animals and the liver in all (Babson, 1954; Theologides, 1970; and Yeakel, 
1948). It remains unexplained why in cancer the liver gains weight while all 
other tissues lose weight in contrast to starvation where the liver too loses 
weight. 
The initial increase of the carcass weight is the result of an increase 
in the water content of the body of tumor-bearing animal (Rechcgl et al., 1961). 
The carcass of the tumor-bearing animal contains less nitrogen and less fat 
but has an increased content of phospholipids and cholesterol (Bloor and 
Haven, 1955; Boyd et al., 1953; Costa and Holland, 1962; Haven et al., 1949; 
Mider et al., 1949; and Mider et al., 1948). 
These animals retain a positive nitrogen balance for the initial period 
of tumor growth (Cramer and Pringle, 1910), and they exhibit a higher retention 
of water and sodium than the controls (Rechcgl et al., 19 61). With further 
:i1 
'II! 
I
'll 
i
1
il 
growth of the tumor, the animals go into a negative nitrogen balance. The 
creatine and uric acid excretion in the urine is higher in rats bearing Jensen 
sarcoma, but the creatinine excretion is lower (Ordway and Morris, 1913). 
Terminally, the urea excretion is also significantly increased in tumor-
bearing animals (Sherman et al., 1950). 
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Because the tumor continues to grow despite the carcass weight loss, 
it was suggested that the neoplasm obtains "foodstuffs" or building 
materials from normal tissues (Moldave, 1956). Mider et al. (1948) showed 
that the amount of nitrogen in large tumors exceeded the total dietary nitrogen 
stored during the period of growth of the neoplastic tis sue. The balance of 
the tumor nitrogen was provided by the animal carcass, and the tumor's need 
took priority over the requirements of normal carcass. The nitrogen in the 
tumor becomes "trapped" and does not become available to a significant 
extent to normal tissue (Mider et al., 1948), although the tumor contributes 
a small quantity of amino acids to the host metabolic pool (Babson and Winnick, 
1954). However, within the tumor cell, a dynamic equilibrium exists between 
proteins and amino acids (Moldave, 1957). 
The retention of nitrogen during force feeding is short-lived and tran-
sient, with a tendency for the nitrogen balance to approach equilibrium 
rapidly and then to move to a negative phase (Terepka and Waterhouse, 1956). 
2. Comments 
To explain the increased energy expenditure and the inability to 
adjust the metabolic rate in the phase of malnutrition Fenninger et al. (1953) 
and Fenninger and Mider (1954) considered two possibilities. First, the 
growth of malignant tissue proceeds continuously throughout the entire day, 
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in contrast to the diurnal periodicity in the metabolic activity of normal 
tissues and their periodic reduction of caloric expenditure. Therefore, the 
metabolism of the growing tumor imposes greater energy expenditure than the 
normal tissues. Second, a selective removal of nutrients by the tumor results 
in alterations in the pathways of the intermediary metabolism of the host 
and forces the host to use more expensive pathways in terms of energy and 
nitrogen metabolism. Mider (19 5 5) further suggested that some biochemical 
reactions previously available to the host might be denied to him because the 
metabolites involved have been utilized by the tumor. 
T. PURPOSE OF THE DISSERTATION 
There were three basic objectives in conducting the research on delta-
aminolevulinic acid (ALA) in lead poisoned and tumor bearing animals that 
led to this dissertation. 
FIRST: To modify the Davis Urinary ALA test described by Abrahams (1970) 
for the early detection of increased lead absorption in children. 
In parallel with these modification studies, a research plan was 
devised to isolate and quantitate urinary porphobilinogen (PBG) utilizing the 
unique combination of disposable ion-exchange column chromatography and 
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and the easily prepared ALA standard calibration curve. The objective was to 
develop a rapid, accurate, quantitative screening test for adults suspected 
of having the disease acute intermittent porphyria. 
The present studies indicated that urinary urea was being washed free 
of the dual piggyback column in the adult screening procedure for exposure 
to lead poisoning. This afforded us the opportunity to isolate urinary urea 
in a pure state. The present studies were designed to quantitate urinary urea 
for early detection of renal disease states. 
The objective of this first section was to be able to take one 0. 50 
ml. aliquot of a random urine sample and quantitate one, two, or three urinary 
constituents, namely ALA, PBG, and urea. 
Second, The present studies were designed to study the effect of 
lead poisoning on rabbits especially in regards to accumulation of ALA in the 
tissues. The objective of this section was to isolate tissue ALA by using 
disposable ion-exchange column chromatography, and then to quantitate these 
levels. The novel finding of an accumulation of tissue levels of ALA as a 
direct result of a specific inhibitor of heme synthesis hopefully would supply 
the forensic pathologist with a means to make a post-mortem diagnosis of 
lead poisoning. 
Third, In the present studies a unique finding of a tumor-host inter-
ction involving greatly elevated levels of delta-aminolevulinic acid dehydrase 
(ALAD) with a concomitant increase in reticulocyte production led us to 
investigate the effect of the Walker 256 carcinosarcoma on the host. The 
objectives of these studies were 1) to devise a method to detect ALAD in the 
tumor host, 2) to determine if there was any relationship to the ALAD 
enzyme activity and the appearance of reticulocytes, and 3) to determine 
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what occurs hematologically in these tumor bearing animals from the initial 
day of transplantation to the time of the death of the animal (usually 20 days). 
The present studies were expanded to study cell-free water extracts 
of the Walker 256 Carcinosarcoma on normal animals. The objective of these 
studies was to determine if there would be any change in ALAD activity, 
production of reticulocytes, or change in the basic hematological base line 
of the animal. For control purposes cell-free water extracts of normal liver wa~ 
injected into litter mates of the tumor extract animals. 
It therefore became of great interest to study this one aspect of the 
phenomen of cancer and tumor growth to try to arrive at a small answer to the 
question of what occurs in the tumor host in response to tumor growth. 
CHAPTER II 
MATERIALS AND METHODS 
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CHAPTER II 
MATERIALS AND METHODS 
A. ANIMALS 
l. Ra ts 
Male, Sprague-Dawley rats, 80-100 days old at the time of the experi-
ments, obtained from Abrams Small Stock Breeders, Chicago, Illinois. Fed 
ad libitum Rockland Rat Diet. 
2. Rabbits 
Male, New Zealand, white rabbits weighing 3. 3 - 4 .1 Kg at the time 
of the experiments, were obtained from Abrams Small Stock Breeders, Chicago, 
Illinois and fed ad libitum Wayne Rabbit Ration. 
In animal experiments in general, and particularly in chronic toxicity 
tests, as was done in the lead and tumor studies, the variability of individual 
parameters and hence the evaluation and reproducibility of the results depend 
to a large extent on the quality and care of the animals used. Reduced 
variability not only increases the accuracy of the results but decreases 
the number of animals needed, which is an important consideration. 
In order to maintain the highest health and environmental standards, 
and to reduce the variability associated with animal studies, the following 
methods were employed • 
• 
B. PHYSIOLOGICAL STATUS OF ANIMALS 
The physiological status was always constant. The rats were always 
male, Sprague-Dawley derived and 80-100 days old at the time of the experi-
ments. The rabbits were male, New Zealand whites weighing 3. 3 - 4.1 Kg. 
Both species of animals were supplied by the same animal breeder and both 
were housed in our laboratory·' s animal facilities. 
C. ENVIRONMENT 
The environment of the animal quarters was generally controlled by the 
environmental control station within the Loyola University Medical Center. 
The temperature was a constant 73-75 F (22.6 - 24.8 C) and the humidity 
averaged, on a daily basis, 40 percent. The air conditioning operated 
evenly giving a good air circulation but without giving any air turbulence. 
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The light intensity was moderate as supplied by the overhead fluorescent 
bulbs. Daylight cycles were maintained seven days a week to suit the cycles 
of the rats and rabbits. The lights were turned on at 9:00 A. M. and turned 
off at 6:00 P. M. The actual experiments were always performed during a 
specific block of time and were never performed at random times. 
1. Diet constituents 
The RocklandR Complete Mouse/Rat Diet (Teklad Incorporated, Mon-
mouth, Illinois, 61462) had a guaranteed minimum percent analysis of crude 
protein, 24%, crude fat, 4%, and crude fiber of 6% maximum. The whole, 
solid pellets contain soybean meal, ground yellow corn, fish meal, pulverized 
barley, wheat middlings, ground wheat, dehydrated alfalfa meal, pulverized 
oats, feeding oat meal, dried skimmed milk, 1% animal fat (preserved with 
propylene glycol, BHT, citric acid), vitamin A palmitate, irradiated dried 
yeast, niacin, calcium pantothenate, riboflavin supplement, menadione, 
vitamin B-12 supplement, 1% calcium carbonate, 0. 5% dicalcium phosphate, 
1% salt, and traces of manganese oxide, copper oxide, cobalt carbonate, 
iron carbonate, zinc oxide, and calcium iodate. 
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The Wayne Rabbit Ration (Allied Mills, Incorporated, Chicago, Illinois, 
60606) had a guaranteed minimum percent analysis of crude protein 17%, crude 
fat, 2. 0%, and crude fiber of 15% maximum. The small, green pellets contain 
ground yellow corn, ground oats, soybean meal, wheat middlings, dried 
whey, dehydrated alfalfa meal preserved with ethoxyquin, cane molasses, 
vitamin A palmitate, irradiated dried yeast, vitamin B-12 supplement, vitamin 
E supplement, menadione sodium bisulfite, riboflavin supplement, niacin, 
calcium pantothenate, choline chloride, folic acid, ground limestone, 
dicalcium phosphate, salt, manganous oxide, copper sulfate, iron sulfate, 
potassium iodate, cobalt carbonate, and zinc oxide. 
2. Diet quantity 
Adult rats will eat 12 to 15 grams of rat diet per day. Therefore, the 
feeders in the rat cages were designed to hold at least three days supply 
of feed at one time. 
Adult rabbits will require a daily food allowance of ll3 - 142 grams of 
rabbit ration. The feeders in the rabbit cages were also designed to hold 
at least a three day supply of rabbit food at one time. 
3. Mode of application of diet 
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The animals food was placed into feeders that would all ow the animals 
to feed ad libitum. The food was never in contact with the bedding or floor 
of the respective cages thus their never was any contamination from urine 
or feces. 
4. Water 
The water supplied to the animals was administered in clean 8 ounce 
glass bottles (2 per cage) for the rats and 16 ounce glass bottles (2 per 
cage) for the rabbits. The source of the water was from the treated drinking 
water of the Hines Veterans Administration Hospital, Hines, Illinois which 
supplies all the water to the Medical Center. 
The bottles were filled with fresh, cold tap water each day and were 
completely replaced with new, sterile bottles once a week from the time the 
animals arrived in shipment from the breeders through the time of the comple-
tion of the experiment. 
5. Caging 
The caging for housing both rats and rabbits was made of stainless 
steel. The hanging type double width rodent cages measured 18"w x ll"d 
x 8 11 h. The cage sides and back were made of solid metal while the front 
and floor were formed from a single continuous panel of smooth welded 
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rod grid with a 2 x 2 mesh size. Each of these rodent cages had two remov-
able spring steel water bottle holders and one removable feeder. The water-
tight excreta service pans were positioned under the cages and were at least 
l inch below the floor of the cage. 
The spacious stainless steel hanging type rabbit cage measured 18"w 
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x 24" d x 14"h. The slotted back and sides provided excellent ventilation 
for the rabbit. The floor was made from smooth welded rod grid of 2 x 2 
mesh. The rabbit cage was equiped with 2 water bottle holders and a remov-
able feeder. The stainless steel watertight excreta service pans were slipped 
under the cages and were at least 2 inches below the floor of the cage. 
The rectangle-shaped cages were mounted on a mobile galvanized 
steel rack. The rat cage rack had 6 tiers with 3 cages per tier. The rabbit 
rack had 4 tiers with 3 cages per tier. 
6. Bedding 
Soft wood sawdust and wood shavings were used as the source of the 
bedding material. Hardwood products were never used due to the high 
tannic acid concentration. The bedding was changed once a week and 
completely replaced with fresh sawdust. 
7. Cleaning of facilities 
The excreta service trays, the individual animal cages, and the mobile 
cage racks were steam sterilized once a month. 
The animal room floor was swept as required and washed with a 
solution of hot water and detergent once a week. 
D. PRELIMINARIES FOR THE EXPERIMENT 
The animals were transfered from their shipping cartons to the clean 
animal cages supplied with fresh water and food. The rabbits were housed 
individually while the rats were housed in groups of 5 per cage. 
The animals, both rabbits and rats, were allowed to adapt to the en-
vironmental conditions for a period of 10 to 14 days before any experiment 
was begun. 
The adaptation period is short because the animal housing facilities 
and laboratory are under the same roof and on the same floor of the Medical 
Center. This eliminates disturbances of the animals due to transportation, 
and it keeps changes in the environment to a minimum. 
E. PREPARATION OF REAGENTS 
l. Sodium acetate, l. 0 M. 
68g of NaCzH302-3HzO (J. T. Baker Chemical Co., Phillipsburg, N. J., 
catalog no. 3460) is dissolved and diluted with distilled water to 500 ml. 
0.8% boric acid (Baker, catalog no. 0084) is added as a preservative. 
2. Acetic acid, l. 0 N. 
172 ml. of glacial acetic acid (E.I. duPont de Nemours and Company, 
Wilmington, Delaware) is added to one liter of distilled water. This makes 
a 3N solution. Make al to 3 dilution of this stock for lN acetic acid. 
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3. Acetylacetone 
Purchased under the chemical name of 2, 4-pentanedione (Eastman 
Organic Chemicals, Rochester, New York, catalog no. 1088) and used 
undiluted. 
4. Reagents required for the isolation of porphobilinogen (PBG) 
a. Glacial acetic acid (duPont) 
b. Mercuric acetate 15% w/v and 1% w/v 
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Add 15 grams of mercuric acetate (Baker, catalog no. 2584) to 100 ml 
distilled water. Mix for one hour using a magnetic stirrer. Store this solution 
in a glass stoppered amber bottle. The 1 % solution is made the same way 
except 1 gm of mercuric acetate is added to 100 ml.of distilled water. Store 
this solution in an amber glass stoppered bottle. 
c. H2S gas 
Generated by adding 6N hydrochloric acid (duPont) dropwise to 20 gms 
of stick ferrous sulfide (Baker, catalog no. 17 7 4) • 
d. Lead acetate 10% w/v and 1% w/v 
Add 10 grams of the granular lead acetate (Baker, catalog no. 2271) 
to 100 ml. of freshly boiled distilled water that has been allowed to cool to 
room temperature. Store this lead acetate solution in a glass stoppered amber 
bottle. Prepare the 1% solution in the same manner except only add 1 gram 
of lead acetate to the boiled distilled water. Store this solution in glass 
stoppered amber bottle. 
----------------------··-....... ·--·-··--~-~----------
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e. Silver nitrate 20% w/v and 1% w/v 
Add 20 grams of the crystalline silver nitrate (Baker, catalog no. 3426) 
to 100 ml of distilled water. Store this solution in an amber glass stoppered 
bottle. Prepare the 1% solution by adding l gram of the silver nitrate reagent 
to 100 ml. of distilled water. Store this solution in an amber glass stoppered 
bottle. 
f. Ammonium hydroxide 3M. 
Pour 200 ml. of 28% ammonium hydroxide (Baker, catalog no. 9721) 
into one liter of water, mix well. 
g. Acetone 
Purchased as reagent acetone (Baker, catalog no. 9006) and used un-
diluted. 
5. Ehrlich's reagent for determining isolated PBG 
Two grams of para-dimethylaminobenzaldehyde (Matheson, Coleman 
and Bell, Norwood, Ohio, catalog no. 1606) is dissolved in 100 ml. of 6N 
HCl. 
6. Modified Ehrlich's reagent for determining delta-aminolevulinic 
acid (ALA), PBG, and amino acetone (AA) 
10 grams of para-dimethylaminobenzaldehyde (Matheson, Coleman and 
Bell, catalog no. 1606) is dissolved in 420 ml. of glacial acetic acid 
(duPont) and 80 ml. of 70% perchloric acid (G. Frederick Smith Chemical 
Company, Columbus, Ohio) • 
7. Ehrlich's reagent for ALA dehydrase assay 
One gram of para-dimethylaminobenzaldehyde (Ma the son, Coleman 
and Bell, catalog no. 1606) is dissolved in 34 ml. of glacial acetic acid 
(duPont) and 16 ml. of 70% perchloric acid (Smith Chemicals). 
8. Urea stock solution 
Five mg of pure urea standard (Mann Research Laboratories, New York, 
N.Y., catalog no. 9200) is dissolved in 7.0 ml. distilled water. 
9. Reagents for preserving a random urine sample for ALA test 
a. Glacial acetic acid 
Use undiluted glacial acetic acid (duPont). 
b. Tartaric acid 
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Dis solve 90. 05 grams of tartaric acid powder (Mallinkrodt Chemical 
Works, St. Louis, Mo., catalog no. 2314) in 200 ml. distilled water to make 
a 3M solution. 
c. Oxalic acid 
Dissolve 78 grams of oxalic acid (Baker, catalog no. 0230) in 200 ml. 
distilled water to make a 3M solution. 
d. Citric acid 
Dissolve 114 grams of anhydrous citric acid (Fischer Scientific Company, 
Fair Lawn, N .J ., catalog no. A-940) in 200 ml. distilled water to make a 3M 
solution. 
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e. Boric acid 
Dissolve 37. 2 grams of boric acid crystals (Baker, catalog no. 0084) 
in 200 ml. distilled water to make a 3M solution. 
10. 0. 0 OlN acetic acid 
To 500 ml. of distilled water add 0. 03 ml. glacial acetic acid (duPont). 
11. Trichloroacetic acid - 5% 
Dissolve 5 grams of fresh trichloroacetic acid crystals (Baker, catalog 
no. 0414) in 100 ml. distilled water. 
12. Biuret reagent 
Dissolve 1.50 grams cupric sulfate (Baker, catalog no. 1843) and 6.0 
grams of sodium potassium tartrate (Baker, catalog no. 3930) in 500 ml. 
distilled water. Carefully add 300 ml. of a 10% sodium hydroxide solution 
(Baker, catalog no. 3722) and stir well. Dilute to one liter with distilled 
water. 
13. Lead acetate solutions - 5, 10, and 30%. 
Carefully dissolve 30 grams of granular lead acetate (Baker, catalog 
no. 2271) in 100 ml. of freshly boiled distilled water that has been allowed 
to cool to room temperature. For the 5 and 10 percent solutions use 5 and 10 
grams of lead acetate per 100 ml. dis tilled water. 
14. n-Butanol containing 0. OlM ammonium hydroxide 
0.1 ml. of lM ammonium hydroxide (Baker, catalog no. 9076) is added 
to 9. 9 ml. of n-butanol (Baker, catalog no. 9 054) and mixed well. The final 
concentration of the NH40H is 0. O!M. 
15. Glacial acetic acid - methanol reagent 
50 ml. of glacial acetic acid (duPont) is carefully added to 100 ml. 
reagent grade methanol (Baker, catalog no. 9076) to make a 1:2 mixture. 
16. Disodium ethylenediaminetetraacetate (EDTA), 5% 
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Dissolve 5 grams of disodium EDTA (Baker, catalog no. 8993) in 100 ml. 
of dis tilled water. 
17. Tyrodes buffer without Ca++ ions 
Into one liter of distilled water dissolve 8 grams NaCl (Baker, catalog 
no. 3624) and l gram anhydrous, granular D+ glucose (Baker, catalog no. 
1916), shake well. To this solution add 2. 4 ml. of a 25% MgC1 2 solution 
(107 gm MgC1 2-6H 20/200 ml H 20 - Baker, catalog no. 2444), 4. 8 ml. of a 
25% KC! solution (SO gm KCl/200 ml. H2o·- Baker, catalog no. 3040), and 
l. 0 ml. of a 10% NaH 2P04 solu.tion (23 gm NaH 2P04/200 ml H2o - Baker, 
catalog no. 3506). Mix this buffer solution well and use within a period of 
six hours. 
18. Cupric sulfate - 10% trichloroacetic acid 
Capric sulfate crystals (Baker, catalog no. 1843) are added to 100 ml. 
distilled water with stirring until a saturated solution is obtained. 10 grams 
of fresh trichloroacetic acid (Baker, catalog no. 0414) is added to 100 ml. of 
distilled water to make a 10% solution. O. 05 ml. of the saturated Cuso4 
solution is added to l. 0 ml. of the 10% TCA solution. 
·----------~------~--.---.. ··~--~_.,~------------
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19. Reticulocyte stain - new methylene blue N 
Purchased from Harleco Chemicals, Phila., Pa., catalog no. 697 
and used undiluted. The dye is made according to the Brecher formula - 0. 5% 
solution of the dye containing l. 6% dissolved potassium oxalate. 
20. IsotonR diluent for blood cell counting 
Purchased from Coulter Diagnostics, Inc., Hialeah, Florida. Used 
undiluted. 
21. Zap-IsotonR lysing agent 
Purchased from Coulter Diagnostics, Inc., Hialeah, Florida. Used 
undiluted. 
22. Stable cyanmethemoglobin reagent 
Purchased from Hycel, New York, catalog no. 116C and used undiluted. 
23. Sterile saline for tumor transplants 
Sodium chloride, injection, U.S. P., 0. 85% sterile, contains no 
bacteriostat. Purchased from Elkins - Sinn, Inc. Cherry Hill, NoJ., in 5 ml. 
ampules and used undiluted. 
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F. PREPARATION OF ALA STANDARD 
l. Crystalline delta-aminolevulinic acid hydrochloride. Obtained 
from Sigma Chemical Company, St. Louis, Mo., catalog no. A-8879. 
2. Acetate buffer, pH 4. 6 5. 7 ml of glacial acetic acid and 13. 6 
grams of NaC 2H 3o2 . 3H 20 are diluted with water to 100 ml. 
3. A stock solution of ALA is prepared by dissolving 12. 5 mg of ALA 
hydrochloride with acetate buffer, pH 4. 6 to a 100 ml mark. Each ml of 
stock solution contains 125 µg of ALA.HCl which is equivalent to 100 µg of 
pure ALA. 
G. PREPARATION OF AN ALA STANDARD CALIBRATION CURVE 
l. Six aliquots of the ALA. HCl stock solution (O. 01 ml, 0. 05 ml, 0 .10 ml, 
0.20 ml, 0.30 ml and 0.50 ml) are pipetted into test tubes and are used as 
working standards. 
Volume of standard 
stock solution 
0. 01 ml 
0. 05 ml 
0 .10 ml 
0. 20 ml 
0. 30 ml 
0. 50 ml 
µg of ALA per total 
reaction volume 
1 µg 
5 µg 
10 µg 
20 µg 
30 µg 
50 µg 
2. Dilute each of the working standards to 7. 0 ml with 1. 0 M sodium 
acetate. 
3. Pipet 7. 0 ml of l. 0 M sodium acetate into an empty test tube to be 
used as a reagent blank. 
4. Add 0. 2 ml of acetylacetone to each test tube and mix. 
5. Place the test tubes in a boiling water bath for 10 minutes, remove, 
and cool to room temperature. 
6. Add 7 .O ml of modified Ehrlich's reagent to each test tube, mix and 
let stand for 15 minutes for complete color development. 
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7. Read the optical density of the standards corrected for the blank, at 
553 mµ in a spectrophotometer. The optical path of the cuvette is 1.0 cm. 
8. Prepare a standard curve by plotting the concentrations of the 
standards against their optical densities. 
H. ISOLATION OF PBG FROM HUMAN URINE 
The urine was collected from a 22 year old Negro female who had been 
diagnosed as having acute intermittent porphyria after taking a combination 
birth control pill for two months. She had been a patient at Cook County 
Hospital, Chicago, Illinois for a period of 30 days before the present PBG 
isolation experiments were begun. The method, with modifications, is that 
of Cookson and Rimington (1954). 
The collected urine (2 50 ml) containing porphobilinogen was adjusted 
to a pH 4-4. 5 with lN acetic acid. The acid was added dropwise under 
conditions of continuous stirring by means of a magnetic stirrer. The pH was 
monitored with a Sargent pH meter, model L. S. Mercuric acetate (15%, W /V) 
solution was added dropwise until all the PBG was precipitated (negative 
Ehrlich reaction of the supernatant). The precipitate was kept in suspension 
·------~----~-----,------~Ail''~-·-~----------. 
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by using the magnetic stirrer until it was poured into 1 x 3 inch cellulose 
nitrate centrifuge tubes (Beckman, catalog no. 078). The suspended 
precipitate was centrifuged at 600 x g, at room temperature, for 10 minutes in 
an International Centrifuge - model V. This centrifugation step and others 
modifies the Cookson and Rimington method by not using a Bilchner funnel. 
The precipitate pellet was worked three times with mercuric acetate (1%, W/V) 
and then suspended in water and decomposed by H2S gas. The H 2S gas was 
generated by the addition of 6N HCl to sticks of ferrous sulfide. The gas, 
as well as all other additions, was added with constant stirring by means of 
the magnetic stirrer. The gas was pumped into the stirring solution for a 
period of 18 minutes. The resulting black sulfide precipitate was centrifuged 
at 600 x g for 10 minutes. The supernatant was aired - by means of compress-
ed air - for 10 minutes. Excess lead acetate (10%, W /V) was added until no 
further precipitate would form in the supernatant fraction. The deeply 
pigmented precipitate was removed by centrifugation and washed repeatedly 
with 1% (W/V) lead acetate solution. A.11 supernatants from these washings 
were saved and combined. AgN03 (20%, W/V) solution was added to the 
combined supernatants and washings until precipitation was complete. The 
mixture was centrifuged at 600 x g for 10 minutes and the precipitate was 
washed three times with 1% (W/V) AgN) 3 . All the supernatants were combined 
and were treated, without prior removal of Pb and Ag ions, with a slight 
excess of 15% (W /V) mercuric acetate solution. This mercury precipitate was 
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almost white. It was collected by centrifuging at 600 x g for 10 minutes at 
room temperature. The precipitate was decomposed by passing H 2S gas into 
the pellet without the addition of further fluid. HgS was easily removed by 
centrifuging from the pale yellow supernatant, which was freed from H 2S gas 
by aeration. The supernatant was then adjusted to pH 3. 7 with 6N NH40H and 
then to pH 4 with 3N NH40H. A very small amount of porphobilinogen 
crystallized immediately in almost colorless, well formed, crystals .. After 
chilling to 4°c, the solution was filtered and the crystals were washed with 
cold water (4°C) containing a little acetic acid, and then with acetone. The 
yield was approximately 5-8 mg. 
It was very obvious that this small amount of crystalline PBG would 
not be enough for further experiments. The E1
13 
was determined (Rimington, 
cm 
Krol, and Tooth, 1956) as being equal to 1.13 6 x 103. This is the absorption 
of a 1% solution of PBG in a l cm light path at a concentration of 1 mg/ml in 
acetic acid (1 N) before adding Ehrlich's reagent. 
Using this information, and previous published studies of the isolation 
of PBG on anion exchange resins (Westall, 1952 and Mauzerall and Granick, 
1956) it was decided to utilize the supernatant solution that was supposed to 
give PBG crystals. After the supernatant was adjusted to pH 4.0 with NH40H 
a current of air was passed over the beaker, which was shielded from light 
by being covered with a large cardboard box, for a period of 8 hours. This 
concentrated 12. 50 ml volume was called the "PBG-syrup". 
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0. 50 ml of the PBG-syrup was applied to an AG-1-XB resin column 
(2 cm high and l. 6 cm in diameter) and was eluted with 10 ml of l N acetic 
acid. 0.1 ml of the eluted PBG was diluted with 1.9 ml l N acetic acid to 
give a dilution of 1:20. This 1:20 solution was added to 2 ml of Ehrlich's 
reagent made by dissolving 2 grams p-dimethylaminobenzaldehyde in 25 ml 
concentrated HCl and 75 ml glacial acetic acid (Moore and Labbe, 1964). 
The reaction was allowed to proceed for 8 minutes for full color development 
before the optical density was determined at 555 and 525 mµ against a reagent 
blank. If pure PBG is present in a sample a ratio of A525/A555 will be 
approximately 0.83. For this sample the ratio was 0.80. The eluted PBG was 
called "Column Chromatographed PBG". 
The mg of PBG in the PBG-syrup was determined by using the following 
formula: 
mg PBG 
Where As55 
113. 6 
10 
12. 5 
2 
= 
= 
= 
= 
= 
= 
As55x10 x 12.5 2 20 
x x 
!13. 6 
Optical density of the final reaction 
color of PBG and Ehrlich's reagent 
read against a reagent blank, and 
absorption of PBG at a concentration 
of l mg/ml in the acetic acid eluate 
before adding Ehrlich's reagent, and 
dilution of the PBG-syrup aliqust 
with acetic acid, and 
volume of the PBG syrup, and 
factor to correct for the 0. 5 ml aliquot 
of the PBG syrup added to the 
20 = 
AG-1-XS column, and 
the 1: 20 dilution factor 
A standard curve was prepared, using the human PBG, in the following 
manner: 
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l. Three aliquots of the column chromatographed PBG (0.10 ml, 0.20 ml, 
and 0.40 ml) are pipetted into test tubes and are used as working standards. 
Volume of standard 
stock solution 
0.10 ml 
0. 2 0 ml 
O. 40 ml 
µg of PBG per total 
reaction volume 
4. 91 µg 
9. 82 µg 
19. 64 µg 
. 
2. Dilute each of the working standards to 7. 0 ml with l N acetic acid. 
3. Pipet 7. 0 ml of l N acetic acid into an empty test tube to be used as 
a reagent blank. 
4. Add 7. 0 ml of modified Ehrlich's reagent to each test tube, mix well 
and let stand for 15 minutes for complete color development. 
5. Read the optical density of the standards, corrected for the reagent 
blank, at 555 mµ in a spectrophotometer. The optical path of the cuvette is 
1. 0 cm. 
6. Draw a standard curve by plotting the concentrations of the standards 
against their optical densities. 
I. PREPARATION OF SYNTHETIC PBG STANDARD 
l. Porphobilinogen - synthetic, obtained from Bio-Rad Laboratories, 
Richmond, California . 
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2. One normal acetic acid. 
3. A stock solution of PBG is prepared by dissolving 10 mg of synthetic 
PBG in 100 ml of distilled water, pH 7 .5. Each ml of stock PBG solution 
contains 100 µg of pure PBG. 
J. PREPARATION OF PBG STANDARD CALIBRATION CURVE 
l. Four aliquots of the PBG stock solution (0.01 ml, 0.05 ml, 0.10 ml, 
and O. 20 ml) are pipetted into test tubes and are used as working standards. 
Volume of standard µg of PBG per total 
stock solution reaction volume 
0. 01 ml l µg 
0.05 ml 5 µg 
0.10 ml 10 µg 
0.20 ml 20 µg 
2. Dilute each of the working standards to 10. 0 ml with l. 0 N acetic 
acid. 
3. Pipet 10 ml of 1. 0 N acetic acid into an empty test tube to be used as 
a reagent blank. 
4. Add 10 ml of modified Ehrlich's reagent to each tube, mix, and let 
stand for 15 minutes for complete color development. 
5. Read the optical density of the standards, corrected for the blank, at 
5 55 mµ in a spectrophotometer. The optical pa th of the cuvette is l. 0 cm. 
6. Draw a standard curve by plotting the concentration of the standards 
against their optical densities. 
----------~---------~-~~--.. --~----------
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K. PREPARATION OF DISPOSABLE CHROMATOGRAPHY COLUMNS PREPACKED 
WITH AN ION-EXCHANGE RESIN 
1. Two-column ALA and PBG analysis 
In order to isolate ALA and PBG from urine, the urine sample mµst be 
passed through an anionic exchange resin which permits the ALA and urea to 
pass through while retaining porphobilinogen. The effluent passing through 
the anionic resin must then be passed through a cationic exchange resin 
which retains ALA while allowing urea to pass through. The anionic resin 
employed in the following experiments was AG-l-X8, 100 to 200 mesh, acetate 
ionic form. The cationic exchange resin was AG 50W-X4, 100-200 mesh, 
hydrogen ionic form. 
A slurry of either AG-l-X8 resin or AG 50W-X4 resin was made in 
distilled water using 3 grams of the respective resin and 7 ml of water for 
each column to be prepared. A 10 ml aliquot of the slurry was then pipetted 
into the appropriate disposable plastic chromatography column (Bio-Rad 
Laboratories). The resin was held in the column by a glass wool plug placed 
in the bottom cap of the column. A second glass wool plug was placed on top 
of the resin in order to prevent distortion of the resin bed. Using this method 
produced a column 2 cm in height and 1. 6 cm in diameter. 
2. The one column ALA analysis 
It is now known that children do not excrete porphobilinogen (PBG) in 
their urine. Therefore, the principle of using an AG-l-X8 anion res ion to 
100 
retain and remove PBG, as an interfering substance to the ALA test, was no 
longer valid for determining lead exposure in children. 
A slurry of AG 50W-X4 resin, 100-200 mesh, hydrogen ionic form was 
made in distilled water using 5 grams of the resin and 7 ml of water for each 
batch of columns. A 1 ml aliquot of the slurry was pipetted into the disposable 
plastic chromatography column (Bio-Rad Laboratories) using a 5 ml Cornwall 
continuous syringe (Becton-Dickenson). The resin was held in the column 
by a small glass wool plug placed in the lower cap of the column. No glass 
wool plugs were used on top of the resin bed. This method produced a 
column 2 cm in height and 0. 6 cm in diameter. 
L. STABILITY OF THE COLOR DEVELOPED WITH MODIFIED EHRLICH'S 
REAGENT FOR DETERMINATION OF URINARY ALA 
Six aliquots of the ALA hydrochloride stock solution (O. 01, 0. 05, 0 .10, 
0.20, 0.30, and 0.50 ml) were placed in test tubes and after appropriate 
steps, color development was attained with modified Ehrlich's reagent. The 
optical density of each tube corrected for the blank was determined 15 minutes 
and 2 hours after the addition of the modified Ehrlich 1 s reagent. 
M. STABILITY OF THE COLOR DEVELOPED WITH EHRLICH'S REAGENT FOR 
DETERMINATION OF URINARY PBG 
Two random urine samples from a patient diagnosed as having acute 
intermittent porphyria were carefully pipetted to two separate AG-l-X8 
columns (2. 5 cm in height, 1. 6 cm in diameter). These urine samples were 
----------~--------·--™---·-,-· ---~·----------
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washed with 30 ml of water and eluted with 7. 0 ml of 1 N acetic acid. 
1. Standard Ehrlich's Reagent 
7. 0 ml of standard Ehrlich's reagent (2 grams DMAB dissolved in 100 ml 
of 6N HCl) was carefully added to the 7. 0 ml eluate. The optical density was 
determined at 5, 15, 30, 45, 60, 75, and 90 minutes at 555 mµ using a 
spectrophotometer. The sample was corrected for the reagent blank at each 
time reading. 
2. Modified Ehrlich's Reagent 
7. 0 ml of modified Ehrlich's reagent (2 grams DMAB dissolved in 84 ml 
acetic acid and 16 ml PCA) was carefully added to the 7. 0 ml eluate. The 
optical density of the sample corrected for the blank was determined at 5, 15, 
30, 45, 60, 75, and 90 minutes at 555 mµ using a spectrophotometer. 
N. PROCEDURE FOR THE DETERMINATION OF URINARY ALA BY MEANS OF 
TaE TWO COLUMN METHOD 
The procedure for the determination of urinary ALA is illustrated in 
Figure 4 and is as follows: 
1. Insert a dual disposable chromatographic column setup in the support 
rack with the column containing the anionic AG-1-XS resin on top and the 
column containing the cationic AG 50W-X4 resin on the bottom. 
2. Wash the top column with 10 ml of water and allow to drain through 
both columns into the drain tray. 
3. Apply 0. 5 ml of a random urine sample to the top column after having 
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determined that the pH of the urine is 6 or below. 
4. Wash the top column three times with 10 ml of water and allow the 
water to drain through both columns. 
5. Discard the top disposable column. 
6. Place the bottom column in a test tube (20 x 150 mm). Add 7. 0 ml of 
l. O M sodium acetate to the column and collect the eluted ALA. 
7. Discard the bottom disposable column and add O. 2 ml of acetylacetone 
to the tube and mix. 
8. Place the test tube in a boiling water bath for 10 minutes. 
9. Add 7. 0 ml of modified Ehrlich's reagent to the cooled test tube. 
10. Read the optical density, corrected for the reagent blank, after 15 
minutes at 553 mµ in a spectrophotometer and determine the concentration of 
ALA in the urine sample from the standard calibration curve. Normal values 
of urinary ALA produce a faint yellow color, while cibnormally elevated 
values produce a distinct red color. 
O. PROCEDURE FOR THE DETERMINATION OF URINARY ALA BY MEANS OF 
THE ONE COLUMN METHOD 
1. Remove numbered pip et guide from top of the support rack. Remove 
both the cap and tip cover from each column and place columns in the 
support rack. Apply 7 ml of distilled water to each column and allow to drain 
into the tray. 
2. Take a random urine sample having a pH of 6 or below, gently shake 
and apply 0. 5 ml of urine to each column by inserting a pipet through the 
correctly numbered hole in the pipet guide. 
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3. Remove numbered pipet guide. Apply 7 ml of dis tilled water to each 
column and allow to completely drain into the drain tray. Repeat four more 
times for a total water wash of 35 ml. 
4. Remove completely drained columns from the support rack and place 
in empty numbered 20 x 150 mm pyrex test tube rack. Add 7. 0 ml of 1. 0 M 
sodium acetate to each column and collect the eluate in the test tubes. 
5. Remove and discard the disposable column from the test tube. Add 
0. 2 ml of acetylacetone to the contents of the test tube and mix. 
6. Place the test tube rack containing the eluted ALA samples into a 
boiling water bath (90 C or greater) for 10 minutes, after which the rack should 
be removed from the bath and the test tubes allowed to cool to room temperature 
7. Add 7. 0 ml of fresh Ehrlich's reagent to the test tubes and mix. 
Allow to stand for 15 minutes for completion of color development. 
8. Read the optical density, corrected for the reagent blank, at 553 
mµ in a spectrophotometer and determine the concentration of ALA in the urine 
sample from the standard calibration curve. Normal values of urinary ALA 
produce a faint yellow color, while abnormally elevated values produce a 
distinct red color. It is therefore possible in a large screening program to 
immediately eliminate all non-red colors by visual inspection. A very accurate 
quantitation of the mg% ALA in the red sample can then be obtained by plotting 
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the optical density of the red samples against known concentrations of pure 
ALA standard carried through the identical procedure. 
P. PROCEDURE FOR THE DETERMINATION OF URINARY PBG 
1. Insert a dual disposable chromatographic column setup on the 
support rack with the column containing AG-1-XS resin on top and the column 
containing the cationic AG 50W-X4 resin on the bottom. The dual column 
setup is suggested only if one wishes to determine both urinary PBG and ALA.. 
If one wishes only to determine PBG, then the top column containing AG-1-XS 
resin should be used. 
2. Wash the column with 10 ml. of distilled water and allow to drain 
through both columns into a drain tray. 
3. Apply 0. 5 ml. of a random urine sample to the AG-1-XS column. 
The pH of this sample must be below 6. 
4. Wash the AG-1-XS column, or the total chromatographic column 
setup, with 30 ml. of distilled water, in 10 ml. batches, and allow the water 
to drain into the drain tray below. 
5. Separate the top AG-1-XS column from the column setup and place 
into an empty numbered 2 2 x 17 5 mm test tube held in a standard test tube rack 
If one has not elected to use the dual column setup then one just has to 
place the AG-1-XS column into the numbered test tube. 
6. Add 10 ml. of 1. 0 N acetic acid to each column and collect the 
eluted PBG in the numbered test tube. It is suggested that this procedure be 
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done in reduced light to prevent any photo reactions with the PBG. 
7. Remove and discard the AG-l-X8 column from the test tube. Add 
10 ml. of fresh Ehrlich's reagent to each test tube and mix. Allow the tube 
to stand for 15 minutes for completion of the color development. 
8. Read the optical density of the final reaction mixture, corrected 
for the reagent blank, at 555 mµ in a standard laboratory colorimeter. 
Q. DETERMINATION OF THE CORRECT VOLUME OF WATER TO WASH THE_ 
UREA OUT OF THE SINGLE COLUMN ALA TEST 
5 mg of pure, crystalline urea standard was added to 7 ml. of a normal, 
random urine sample. AO. 5 ml. aliquot of this urine solution was added to 
the single, disposable column for determining urinary ALA. The column was 
washed with 7. 0 ml. of distilled water five times. Each 7. 0 ml. eluate 
was collected in separate test tubes. 2.0 ml. of modified Ehrlich's reagent 
was added to each tube and the color was allowed to develop for a period 
of 15 minutes after which the optical density was determined, corrected for 
a reagent blank, at 415 mµ. 
R. PROCEDURE FOR PRESERVING RANDOM HUMAN URINE SAMPLES FOR 
THE ALA AND PBG ANALYSES 
60 ml. of fresh, normal urine, taken from a random urine sample was 
adjusted to pH 9 0 0 with lN NaOH. To this- urine sample was added ALA and 
PBG for purposes of recovery. 0. 2 ml. of 3M solutions of tartaric acid, 
oxalic acid, citric acid, and boric acid was added to the empty 15 ml. 
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glass screw capped bottles. The bottles were dried in a 7 5 C oven for one 
hour or until dry. After the bottles were cooled to room temperature 10 ml. 
of urine with the added ALA and PBG was added to each of the bottles and 
shaken well to dissolve the dried preservative. For control purposes one 
bottle had 0 .1 ml. of glacial acetic acid added as the only source of a urine 
preservative. The resulting pH of this urine sample (preserved as directed 
in the direction sheet from Bio-Rad Laboratories for the urinary ALA Test) 
was compared to the results using the dried preservatives. 
The pH of the urine sample, µg ALA, µg PBG, and percent recovery of 
these heme precursors as compared to day zero was determined throughout a 
28 day storage period at 4 C in the dark. The dual, disposable chromato-
graphic column setup was used in these studies. 
S. ANIMAL EXPERIMENTS 
1. Procedure for determining tissue levels of ALA in the lead-
poisoned rabbit 
Nine rabbits, three of which were controls, were used in this study. 
Each animal was given a single s. c. injection of a 5 percent solution of lead 
acetate in water (w/v) in the nape of the neck. The dose for each animal 
was 200 mg of lead acetate per Kg of body weight. Control animals were 
administered an equal volume of normal saline by the subcutaneous route in 
the nape of the neck. 
The following 21 control and lead poisoned tissues were removed and 
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analyzed for ALA: bone marrow, kidney, spleen, lung, cauda and caput 
epididymis, urinary bladder, seminal vesicles, heart, small and large 
intestines, testes, stomach, cerebrum and cerebellum, liver, lymph nodes, 
thymus, diaphragm, psoa sis muscle and adipose tis sue. 
Approximately one gram of tissue was removed (kidney, liver, bone 
marrow, etc.) at standard laboratory conditions of light and temperature and 
placed into 9 ml. of cold O. 001 N acetic acid. The well minced tissue (by , .. 
using a scissors) was homogenized in 9 ml. of 0. OOlN acetic acid in a 
Corning tissue homogenizer that was 19 x 150 mm in size. The ground glass 
tube and pestle insured adequate abrasive qualities yet produced a fine 
homologous sample. A Power-StirR stirrer (Eberback Corpora ti on, Ann Arbor, 
Michigan) with a controlled speed of 1000 RPM with a 1/10 H.P. motor supplied 
the power for the homogenization procedures. The torque that developed was 
16 in/lb through a 20 to l worm gear drive. The glass homogenizer was 
washed with O. OOlN acetic acid and the total homogenate and washing were 
combined, mixed well after the addition of 0 .10 ml. of 5% TCA and allowed 
to stand at room temperature for 10 minutes. The homogenate was centrifuged 
at 600 xg for 20 minutes at room temperature. 
To prevent excessive vibration during centrifuging every effort was 
made to distribute the weight evenly in all the tubes. This was done by 
pairing and numbering the shields and other rotating accessories in such a 
manner that opposing pieces were in balance. The centrifuge tubes that were 
..... ~----------------------·~--~--~---------
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chosen had approximately the same weight and shape and chipped glassware 
was never used. 
The supernatant was saved and combined with 0. 001 N acetic acid 
used to wash the pellet from the centrifugation step. The pH of the combined 
supernatants was adjusted to pH 5 with solid Na2C03 and was immediately 
frozen at (-) 7°C, in the dark, overnight. The frozen superna tan ts were 
defrosted in a 45C water bath and mixed well before being heated for 5 minutes 
in the 45C water bath. After removal from the water bath and cooling to 
room temperature the supernatants were centrifuged at 600 xg for 20 minutes. 
The supernatant was saved and combined with the 2 ml. of distilled water 
used in washing the pellet. 
The combined supernatants from the heating step was poured onto the 
top AG-1-XS column of a dual, disposable column chromatography unit. 
The columns were allowed to completely drain and then were washed three 
times with 10 ml. of dis tilled water. 
After the washing was completed the column chromatography unit 
was separated and ALA and PBG were eluted off the columns and quantitatively 
determined as previously described. 
2. Procedure for the isolation and determination of tissue amino-
acetone in the lead poisoned rabbit 
Ten adult rabbits, two of which were controls, were used in this study. 
Two of the animals received a single subcutaneous injection of a 30 percent 
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solution of lead acetate in water (w/v) in the nape of the neck. The dose 
for one animal was 400 mg of lead acetate per Kg of body weight and the 
other rabbit received a single subcutaneous dose of 800 mg/Kg body weight. 
A control rabbit was used for comparison. The six remaining rabbits were 
injected with a single subcutaneous injection of a 10 percent solution of 
lead acetate in water (w/v) in the nape of the neck. The dose for these 
animals was 200 mg of lead acetate per Kg of body weight. The controls 
in both series (2 rabbits) received an equal volume of normal saline adminis-
tered by the subcutaneous route in the nape of the neck. 
The following four tissues were isolated from each animal and analyzed 
for tissue levels of ALA, as described previously, and aminoacetone: 
bone marrow, kidney, liver, and spleen and whenever possible random 
urine. 
The bone marrow was removed from the right femur and was used for 
the determination of tissue levels of ALA. The bone marrow from the right 
and left tibia was used for the determination of aminoacetone (AA). The 
bone marrow from the left femur was fractionated for determining whether 
or not ALA was concentrated in the centrifuged pellet, in the supernatant, or 
in the floating adipose tissue. 
The fractionation was performed using approximately 1 to 1. 3 grams 
of bone marrow from the left femur. The bone marrow was carefully 
suspended in cold (4 C) Tyrode' s buffer that was made without calcium 
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ions (Goodman, 19 60). 0 .10 ml. of 5 percent EDTA was added to prevent 
deleterious effects to the suspended cells (Anderson, 19 65, and Harris, 19 66). 
The cells were gently mixed using a glass rod with a rubber policeman. 
The cell suspension was centrifuged at 10, 000 xg for 20 minutes at 4°c. 
The top adipose tissue was removed and treated as a separate tissue as 
was the supernatant and the centrifuged pellet. Each of these fractions was 
homogenized, washed, centrifuged and poured onto the top column of 
the dual column setup as previously described. 
The tissue ALA and AA (both are retained on the cation resin column) 
were eluted from the bottom AG-50W-X4 resin column with lM sodium 
acetate. 0. 2 ml. of acetylacetone was added to the 7 ml. eluate and mixed 
well. This solution was heated in a boiling water bath to form a pyrrole 
of ALA and M by a Knorr-type condensation (Mauzerall and Granick, 1956). 
After cooling to room temperature, the solution containing the ALA 
and AA pyrroles was poured onto an AG-1-XS column (same resin and size of 
column as used for the isolation of PBG). The aminoacetone pyrrole is 
then eluted with 10 ml of n-butanol containing 0. 01 m ammonium hydroxide. 
The eluate containing the AA pyrrole is carefully mixed with an equal volume 
of modified Ehrlich's reagent. The optical density of the color reaction is 
read, corrected for a reagent blank, at 55 6 mµ after exactly 10 minutes 
(Marver, Tschudy, Perlroth, Collins, and Hunter, 1966). 
The formula to determine aminoacetone mathematically is as follows: 
A556 = 
where A556 = 
E = 
c = 
l = 
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E x C x length (cm) of cuvette 
Optical density of the reaction 
mixture read at 55 6 mµ after exactly 
10 minutes of reaction time, and 
molecular extinction coefficient of an 
equal volume of AA pyrrole mixed with 
modified Ehrlich's reagent, under these 
conditions, using a l cm cuvette, the 
E of the color complex is equal to 7. 6 
x 104, and 
concentration expressed as moles/ 
liter, and 
length of the light pa th through the 
cuvette, in these experiments, l was 
always equal to l cm. 
Therefore the concentration (C) can be solved by dividing the optical 
density by the extinction coefficient to get moles/liter. 
c = b.5.5.6. 
7. 6 x 104 
c = moles/liter 
The grams of aminoacetone per liter is determined by multiplying the 
molecular weight of AA (73. 03) by moles/liter. 
grams/liter = (73. 03) (moles/liter) 
The grams of AA per liter is converted to milligrams per liter by 
multiplying grams by 1000. 
mg/liter = grams x 1000 
The milligrams of AA per liter is converted to micrograms per liter by 
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multiplying milligrams by 1000. 
µg/liter = milligrams x 1000 
The total reaction volume for determining the aminoacetone level of 
the tissue is 20 ml. (10 ml. eluate+ 10 ml. modified Ehrlich's). To convert 
µg AA/liter to µg AA/2 0 ml. reaction volume, the following ratio is utilized: 
µgM 
1000 ml = 
(x) µg M 
20 ml 
One therefore solves for the unknown quantity of µg M that is in the 
20 ml reaction volume. 
3. Procedure for Transplanting the Walker 256 Carcinosarcoma Tumor 
A 60 day old male, Sprague-Dawley rat bearing a 7 day old tumor was 
sacrificed by decapitation. The area of the surface of the abdomen (in the 
region of the external oblique muscles, either to the left or right of the 
anterior midline in the left or right lateral region) bearing the tumor was 
cleaned with 70 percent ethanol and pat dried with absorbant cotton. 
The subcutaneous tumor weighing approximately l. 5 - 2. 5 grams was 
surgically removed under semi-sterile conditions using sterile curved-on-
flat, 5 1/2 inch, scissors with sharp points. The tumor was handled with 
tissue forceps with 1 x 2 teeth and with forceps without teeth. 
The excised tumor was placed in a glass, sterile 100 mm dia, x 15 
mm deep petri dish and washed with 5 ml of sterile saline to remove tis sue 
debris and stray hairs from the surgical site. 
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The cleaned tumor was transferred to a second sterile petri dish and was 
carefully cut open and the center necrotic portions of the tumor were separated 
and removed. Areas of the tumor containing fatty tissue were also removed 
at this time. The prepared tumor was transferred to a third sterile petri 
dish and was weighed. The usual weight of the clean, prepared tumor was 
1.3 to 2.1 grams. 
The weighed tumor was then carefully cut into small pieces of tissue 
with a sterile curved-on-flat scissors. These pieces were finely minced by 
repeated cutting with the scissors. The minced tumor mass was carefully 
scrapped out of the petri dish and placed in a screw type stainless steel 
tissue press (Harvard Apparatus, Millis, Mass.) fitted with a fine sieve with 
holes measuring 1 mm in diameter. The method of Busch (1953) was used to 
further assure a clean cellular preparation free from connective tissue. The 
method was to use a 90-mesh stainless steel screen placed over the fine 
sieve. 
The tumor cells were forced through the screen and fine sieve by the 
pressure of the tissue press piston. The tumor cells thus produced were 
diluted with 5 ml of sterile saline. The sterile beaker was gently swirled to 
suspend the tumor cells which were then aspirated into a 2 1/2 cc sterile, 
disposable plastic syringe fitted with a 20-gauge sterile, disposable needle 
(Becton, Dickinson and Company, Rutherford, New Jersey) and injected into 
60 day old male, Sprague-Dawley recipient rats. 
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O. 50 ml of the tumor suspension was injected subcutaneously in the 
area of the external oblique muscles in the right or left lateral region of the 
abdomen. This total procedure was repeated every seven days. 
The Walker 256 Carcinosarcoma tumor used in these experiments has 
been propagated .in this laboratory for the past year (5 animals were used in 
one series of experiments). After 58 generations an infection of the tumor 
occurred necessitating starting a new series of Walker tumor propagations. 
The new tumor series had 2 experiments conducted several generations apart 
from each other (3 animals in each series). There was no difference in the 
results obtained with the old or the new tumors. The viability of these 
transplanted cells was established by tumor growth following injection. 
The growth of the tumor was determined by measuring, with calipers, 
the length, width, and height and multiplying these factors together to 
express the cubic millimeters of tumor growth. 
In order to be able to monitor the type of cells that were being injected, 
a sample of the tumor suspension from each transplant was submitted to the 
Cytology Laboratory of the Loyola University Hospital for non-gynecological 
staining. 
The cell suspension was applied to clean glass slides and was allowed 
to set up for two minutes before being placed into 9 5 percent ethyl alcohol 
for a period of 45 minutes. 
After removing the fixed slides from the 95 percent ethyl alcohol, the 
following modified Papanicolaou staining procedure was carried out: 
l. 80 percent ethyl alcohol - 30 seconds 
2. 70 percent ethyl alcohol - 30 seconds 
3. 5 0 percent ethyl alcohol - 3 0 seconds 
4. Dis tilled water - l minute 
5. Harris hematoxylin - l minute 
6. Dis tilled water - 3 0 seconds 
7. Distilled water - 30 seconds 
8. 7 0 percent ethyl alcohol/ammonium hydroxide -
until just blued - 2 0 seconds 
9. 80 percent ethyl alcohol - 30 seconds 
10 . 95 percent ethyl alcohol - 30 seconds 
ll • 9 5 percent e thy 1 alcohol - 3 0 seconds 
12 . OG6 - 60 seconds 
13 . 9 5 percent ethyl alcohol - 3 0 seconds 
14 • 9 5 percent ethyl alcohol - 3 0 seconds 
15 . EA65 - 60 seconds 
16. 95 percent ethyl alcohol - 30 seconds 
17 . 9 5 percent ethyl alcohol - 3 0 seconds 
18 • Absolute ethyl alcohol - 30 seconds 
19 • Absolute ethyl alcohol/xylol - 30 seconds 
20. Xylol - 30 seconds 
21. Xylol - 30 seconds 
2 2 . Xylol - 5 minutes 
4. Procedure for preparing ultracentrifuged, lyophilized tissue 
extracts 
a. Walker 2 5 6 Carcinosarcoma tumor extracts 
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Three different generations of the Walker tumor were used for these 
three separate studies. A 60 - 70 day old male, Sprague-Dawley rat bearing 
a 7 day old tumor that grew in at least 4 injection sites was sacrificed by 
decapitation. The site of tumor injection and growth was the same as was 
described under the section entitled, "Procedure for Transplanting the Walker 
256 Carcinosarcoma". 
The semi-sterile removal of the solid, subcutaneous growing Walker 
tumor, its washing to free from hairs etc., and its transfer to sterile petri 
dishes has been explained in detail under the section entitled, "Procedure 
for Transplanting the Walker 2 5 6 Carcinosarcoma". 
After proper cleaning, transfer, and removal of the center necrotic 
portions, the tumor was weighed. After weighing, the tumor was finely 
minced using sterile curved-on-flat scissors. 
The minced tumor mass was carefully scrapped out of the petri dish in 
approximately l - 2 gram amounts. This mass of tissue was placed into a 
19x150 mm Corning tissue homogenizer that had a ground glass tube and 
pestle. 10 ml of cold distilled water (4 C) was added to the tissue homo-
genizer and the tumor mass was carefully homogenized using a Power-StirR 
stirrer operating at 1000 RPM. 
This homogenization procedure was carried out until all of the tumor 
tis sue was homogenized. For every gram of tis sue homogenized 5 ml of 
distilled water was used, thus, a resulting 1:5 (w/v) homogenate resulted. 
The 1:5 (w/v) homogenate was swirled for 30 minutes at 4 C using a 
serological rota tor (Scientific Products, model R4140). After 3 0 minutes of 
swirling, the homogenate was centrifuged at 10, 000 x g for 30 minutes at 
4 C in a International High Speed Refrigerated Centrifuge, model HR-1. 
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The supernatant from this step was centrifuged at 600 x g for 10 minutes 
at room temperature. The resulting supernatant from this centrifugation was 
centrifuged at 105, 000 x g for l hour at 4 Cina Beckman Model L ultra-
centrifuge. 
The 105, 000 x g supernatant was carefully poured into a 600 ml 
VirTis freeze-drying glass flask with a filter-seal. This type of flask was 
choosen in order to eliminate using vacuum grease that could contaminate 
the lyophilized powder. The freeze-drying flask was placed into a shell-
free zer 9nd was mechanically rotated in a refrigerated bath with a temperature 
of (-) 60 C. Once the 105, 000 x g supernatant was frozen in the flask, the 
flask was attached to a VirTis auto ma tic, refrigerated freeze-dryer model 
D7024, outfitted with a Cenco heavy duty vacuum pump that could deliver an 
ultimate vacuum of 0.1 micron. The system delivered a maximum low conden-
ser temperature of (-) 65 F. The vacuum generated was read using a McLeod 
gauge. The lyophiliza ti on procedure usually took less than 24 hours using 
this instrument. 
b. Normal liver extracts 
Livers were removed from normal, non-tumor bearing, rats on two 
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different dates from different shipments of animals. 
The procedure and methods that were described above for preparing the 
ultracentrifuged, lyophilized tumor extract was followed for preparing the 
liver extracts. 
After lyophilization of the 105, 000 x g supernatant (Tumor or Liver) 
the lyophilized powder was carefully removed from the flask and placed into 
a clean glass vial. The vial was weighed and placed into a freezer at (-) 7 C, 
in the dark, until the appropriate experiment was conducted. 
The method of injection for the tissue extracts was by the cardiac 
puncture route. The lyophilized powder was reconstituted with sterile 
distilled water. The animals were lightly etherized and the cardiac punctures 
were easily carried out with minimal trauma to the animals. 
5. Effect of pretreatment with Walker tumor extracts on growth of 
solid tumors in the rat 
Normal, adult, 60 day old, male Sprague-Dawley rats were injected, 
by the cardiac puncture route, with Walker tumor extract or with normal 
liver extract prepared as described in the preceeding section. The dose was 
200 mg of tissue extract (lyophilized powder) per Kg of body weight. 
The animals were bled, via the tail vein, approximately 0. 25 - O. 30 
ml of whole blood on day 0, 1, 2, 4, 6, 8, 12, 14, 16, 18, and 20. This 
amount of blood was required for the enzyme and hematological studies to be 
described in a later section. 
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On the 20th day, after the blood was drawn from the rats, a solid 
Walker tumor was transplanted via the subcutaneous route (one site per animal) 
as previously described in the section entitled, "Procedure for Transplanting 
the Walker 256 Carcinosarcoma". 
The solid, subcutaneous tumor was allowed to grow until it became 
palpable at which time its total volume (1 x w x h = mm3) was determined by 
a non-biased person. The volume of the solid growing tumor was determined 
every other day until the solid tumor broke open or until the animal died. 
The rate of growth of the solid Walker tumor both in the tumor extract 
and normal liver extract pretreated animals was compared to the rate of 
growth of the same transplanted Walker tumor in normal, non-pretreated 
Sprague-Dawley rats. 
6. Procedure for determining ALA dehydra se levels in the solid tumor 
bearing and tissue extract injected rats 
The method of Weissberg (1971) was used which was a modification of 
the method of Bonsignore (19 65). This technic differs most notably from others 
in that who!~ blood rather than washed erythrocytes was employed, and only 
small volumes were required. 
In the experiments described in this dissertation, the tail of the exper-
imental rat was immersed in a 45 C water bath for 2 minutes prior to the 
cutting off of the end 2 - 4 mm with a sharp scissors exposing the tail vein. 
The first few drops of blood were wiped away using KimwipesR. 150 µL of 
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whole blood was drawn, by gravity, into a calibrated, heparinized (ammonium 
heparin) Natelson blood collecting pipet (Scientific Products, catalog no 
B-3092-2). Any blood that collected on the outside surface of the pipet tip 
was carefully wiped away before the blood was expelled into 1. 45 ml of 
dis tilled water. The pipet was flushed in the distilled water - hemolyzed 
blood cell mixture to remove any of the blood sample that adhered to the 
inner surface. 
The hemolysate was warmed to 37 C, and to this was added 1 ml of 
freshly prepared 0. 01 M ALA, pH 7. 0, also warmed to 3 7 C. The reaction 
was stopped after one hour of incubation at 37 C, in a constant temperature 
water bath, by the addition of 1 ml of 10 percent trichloroacetic acid and 0. 05 
ml of saturated copper sulfate solution. The mixture was centrifuged for five 
minutes in an International centrifuge, model V, at 600 x g. Two milliliters 
of the supernatant was added to 2 ml of modified Ehrlich's reagent. The 
optical density, corrected for a reagent blank, was determined in a spectra-
photometer at a wavelength of 555 mµ. 
A unit of ALAD activity was defined as the amount of enzyme necessary 
to convert lµ mole per milliliter per minute of ALA to PBG per milliliter of 
red blood cells. The molar extinction coefficient of PBG is 3. 6 x 104 
(Mauzerall and Granick, 1956, and Weissberg et al., 1971). The following 
formula was employed to determine ALAD units: 
OD6o - ODo x .J..Q_Q_ x 44. 61 = Units of ALAD 
ur+ 
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where OD 60 = Optical density after l hour at 37 C, and 
ODo = Optical density at 0 time (it was mea-
sured in samples to which trichloro-
acetic acid and copper sulfate were 
added to the incubation mixture before 
the addition of blood; it was consistent-
ly found to be O) . 
44 61 = Incubation Volume (3. 65ml) x 2 ( . ) l x 2 
• Blood Volume (0.15ml) 60 time x 0.036 (PBG ext. coeff) 
The following studies were carried out to arrive at the above conditions 
for the rat ALAD assay; it should be noted that the whole blood was hemolyzed 
in 1.45 ml distilled water for all experiments. 
a. Localization of enzyme activity 
Three volumes of fresh whole blood (50 µL, and 200 µL) were hemo-
lyzed and then incubated for one hour at 37 C with 1 ml of 0. OlM ALA (pH 7. O) 
as the substrate. The reaction was stopped with a TCA-Cuso4 mixture as 
previously described and the units of ALAD were determined. 
Three volumes of fresh plasma (50µL, lOOµL, and 200µL) were incubated 
as described above and the reaction was stopped and the ALAD units were 
determined to compare whole blood ALAD activity to that found in plasma. 
b. Effect of substrate pH 
Six whole blood samples (100 µL apiece) were added to individual 
test tubes and hemolyzed in distilled water. The six hemolysates were 
individually incubated with one of the solutions of 0. OlM ALA (1. 0 ml) 
brought to pH 5. 0, 5. 5, 6. 0, 6. 5, 7. 0, or 7. 5. The reactions were stopped 
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by using the TCA-Cuso4 mixture and the ALAD units were determined. 
c. Effect of temperature 
Two samples of 100µ1 of whole blood were hemolyzed in distilled 
water and incubated with 0. OlM ALA (pH 7. O) at 3 7 C. The enzymatic 
reaction was stopped using the TCA-CuS04 mixture and ALAD units were 
determined as previously described. Two samples of whole blood (100µ1 
each) were hemolyzed and treated as described above but were incubated 
at room temperature (approximately 25 C) and the results were compared. 
d. Effect of enzyme concentration 
Five samples of whole blood (50µ1, 100µ1, 150µ1, 200µ1, and 250µ1) 
were hemolyzed in individual test tubes. Each of these were incubated with 
l. 0 ml of 0. 01 ALA, pH 7. 0, at 37 C for one hour. The reactions were 
stopped and the optical density, corrected for a reagent blank, was deter-
mined for each test tube. 
e. Stability of the color developed with modified Ehrlich's 
Reagent 
In order to achieve an optical density greater than 0 .100 for the final 
color developed with the modified' Ehrlich's Reagent, a 400µ1 blood sample, 
from a normal rat, was hemolyzed in l. 4 5 ml of distilled water. The hemo-
lysate was warmed to 37 C and was incubated with 1. 0 ml of 0. OlM ALA, 
pH 7. 0, for 60 minutes at 37 Cina constant temperature water bath. The 
reaction was stopped as previously described and the optical density of 
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the color developed with modified Ehrlich's, corrected for a reagent blank, 
was determined at 2, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, and 60 min-
utes. 
7. Procedures for performing the hematological studies on control 
and experimental rats 
a. General princi];)le of electronic counters 
The Coulter counter (Coulter Electronics, Inc., Hialeah, Florida) 
model FN was used for counting all red and white cells in these s tu dies. 
The Coulter counter counts the individual red blood cells of a measured 
volume of diluted blood as it passes through a minute orifice guarded by an 
electric current flowing between platinum electrodes. The red blood cells, 
which are poor electrical conductors, passing through the orifice displace 
an electrically conductive 0. 9 percent saline solution (IsotonR, Coulter) in 
which the cells are suspended and thus modulate the electric current. The 
modulations are amplified and counted. They depend on the number and size 
of the cells pas sing through the orifice. The counter works with an accuracy 
and reproducibility of about 2 percent. The electronic counter enumerates 
red and white blood cells alike, and an error will be introduced if leukocytosis 
of over 3 0, 000 cells/mm3 exists. In this case, the results have to be correct-
ed. 
b. Procedure to count red blood cells using the Coulter counter 
2 OµL of whole blood, drawn from the tail of the experimental rat, is 
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diluted with IO ml of IsotonR to make a stock dilution of 1: 500. 100µ1 of this 
stock 1:500 solution is diluted 1:100 with 10 ml IsotonR using an automatic 
pipeting machine (Dade Industries, Cleveland, Ohio). The 1:100 solution is 
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expelled into AccuvetteR vials (Coulter) by the automatic pipet and the red 
blood cells are counted by the Coulter counter when the tip of the orifice and 
the external electrode are immersed in the red cell suspension. To correct 
for the coincidence effect one records the first three digits of the count on 
the digital counter and applies these to the conversion chart supplied with 
the instrument (figure nine ) to obtain the correct red blood cell count. The 
last two digits are ignored. One adds four zeros to the corrected red cell 
count and reports the result as the number of red cells/mm3. 
c. Procedure to count white blood cells using the Coulter 
counter 
The stock 1:500 solution prepared from whole blood used for the red 
blood cell counts was used for the white blood cell counts. 6 drops of Zap-
IsotonR lysing agent is added to lyse all the red cells. Within a period of 
20 - 3 0 seconds the red cells are completely lysed leaving a white cell 
suspension ready to be oounted. 
The white cell count is performed in the same manner as the red cell 
count except no correction is made for counts less than 10, 000. The result 
of this count is reported as the number of white cells/mm3. 
d. Procedure to determine the hematocrit 
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The hematocrit reading gives the number of millimeters of packed red 
cells/100 mm blood, indicating the volume (percent) of packed red cells/100 ml 
blood. Two heparinized capillary tubes (Sherwood Indus tries, St. Louis, Mo.) 
were filled about two-thirds full with tail blood by capillary attraction. The 
dry end of the tube was sealed with molding clay (Seal-EaseR, Clay-Adams, 
Inc., New York, New York) and the capillary tubes were centrifuged for three 
minutes at 12, 000 RPM in an Adams autocrit centrifuge (Clay-Adams, Inc.) 
provided with a special head for capillary tubes. 
After centrifugation, the volume of packed cells was determined from a 
scale on a hematocrit capillary tube reader (Scientific Products, catalog no. 
B-4397). The error of the microhematocrit method is less than 2 percent. 
e. Procedure to determine hemoglobin 
Hemoglobin is a conjugated protein (heme + globin). Heme contains 
iron in the ferrous state and can unite in a loose combination with oxygen to 
form oxyhemoglobin. About 55 percent of the red blood cell is hemoglobin. 
In 1964 the Technical Subcommittee on Haemoglobinometry of the Inter-
national Committee for Standardization in Haematology (published in 1965) 
recommended the cyanmethemoglobin method as the method of choice for 
determining hemoglobin. 
20µ1 of whole blood, from the tail, was added, by using 20µ1 micro 
Pipets (Scientific Products), to 5 ml of Drabkin solution (Van Kampen, 1965) 
which cons is ts of potassium ferricyanide, potassium cyanide, potassium 
--
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phosphate and Sterox SER, a polythiol compound added to increase the velocity 
of the overall reaction (Hartman-Ledden Co., Phil., Pa.). After 5 minutes the 
percent transmission, corrected for a reagent blank, was determined at 540 
mµ in a 13 x 100 mm cuvette in a Turner colorimeter. The grams percent of 
hemoglobin is determined by referring to the printed chart as shown in figure 
10. 
f. Procedure for staining and counting reticulocytes 
Reticulocytes are young red blood cells, some of which appear as 
macrocytic polychromatic cells (gray-blue) on smears stained with Wright 
stain, and if stained with supra vital dyes, they exhibit a blue-staining 
reticulum. 
The method used to stain the reticulocytes was to mix one full heparin-
ized micro-hema tocrit tube of peripheral tail vein blood with 3 drops of new 
methylene blue N (Harleco) in a 5 ml pyrex beaker. The reticulocytes were 
stained after 10 minutes of incubation at room temperature. After this 
staining time, the blood-dye mixture was gently mixed and thin smears were 
made on 3 x l inch, 1. 2 mm thick, micro slides. The slides were allowed to 
air dry. 
The reticulocyte count was performed using an oil-immersion lens and 
a 20x eye piece fitted with a Whipple eyepiece micrometer grid. The total 
magnification was 2000x. Ten fields of 100 red cells per field were counted 
so that the number of reticulated red cells per thousand red cells could be 
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expressed in a percentage, i.e., /100 RBC. 
It should be noted that all cells that contained a blue-staining 
reticulum or even just a fragment or granule of it were counted as reticulocytes. 
CHAPTER III 
RESULTS 
CHAPTER III 
RESULTS 
A. ONE-COLUMN ANALYSIS FOR URINARY ALA 
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The inappropriate use of lead has resulted in outbreaks of lead poisoning 
in humans from time to time since antiquity. 
At the level of cellular metabolism the best known adverse effect of lead 
is its inhibition of the activity of enzymes that are dependent on the presence 
of free sulfhydryl (SH) groups for their activity. The clearest manifestation 
of the inhibitory effect of lead on the activity of SH-dependent enzymes is 
the disturbance it causes in the biosynthesis of heme. 
Figure 1 is a presentation of the metabolic fate of ALA via the succinate-
glycine cycle. Shemin and Russell (1953) postulated a succinate-glycine 
cycle through which ALA can be oxidized to succinic acid and this oxidation 
would thus provide a pathway for glycine oxidation. The first step of this 
cycle is the deamination of ALA to a.-ketoglutaraldehyde which then releases 
the ALA-carbon derived from glycine to form succina te. The ALA-carbon 
derived from glycine provides the a-carbon atom to ureido groups of purines, 
the B-carbon atom of serine, the methyl group of methionine, and forms 
formic acid (Shemin et al., 1955). 
Figure 2 presents the mechanism of ALA accumulation in lead-poisoned 
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humans of animals using a simple reaction equation. It is noted that glycine 
plus succinyl-CoA with the rate limiting enzyme, ALA synthetase, form ALA. 
Normally 2 moles of ALA are condensed together by the enzyme ALA dehydrase 
to form one mole of porphobilinogen which is the second product in the heme 
biosynthetic pathway. This pathway then continues on to make the final 
product, heme. When lead is introduced into the host the enzyme ALA dehyd-
rase is inhibited. The end result of this inhibition is an accumulation of ALA 
which spills over into the urine of the host. This urinary ALA is determined 
quantitatively in the urinary ALA test as a means to detect early exposure to 
lead poisoning. 
The increased use of the commercially available ALA kit (Bio-Rad, 
Richmond, Ca.) for screening for lead poisoning in children has placed a 
financial strain on many budgets of local health departments. The reason for 
this expense has been due to the use of the dual piggyback unit which 
selectively removes PBG from the urine via the top anion AG-l-X8 resin 
column and ALA via the bottom cation AG-50 resin column (Abrahams, 1970). 
It has now been proven by many sources that children do not excrete 
PBG in their urine. The youngest recorded case of PBG in the urine of a child 
was that reported by Goldberg and Rimington (1962) of an ll year old girl. 
The ALA test kit, to date, has been primarily used to screen children for 
early detection of lead poisoning. 
It therefore became of interest to us to redesign the dual piggyback ALA 
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test kit into a one-column kit. This reduction in materials and cost of 
manufacture would then be passed along to the consumer and theoretically 
twice as many tests could be performed for the same price that one test did 
previously. 
The one-column test kit would be used only for screening a pediatric 
population while the original dual piggyback disposable column unit would 
remain the test kit for screening for lead exposure in an adult population. 
Table 1 presents the effect of varying the mesh size of the cation resin 
in the one-column ALA analysis. One column was filled with 100-200 mesh 
and another column was filled with 50-100 mesh, both resins were AG-50W-
x4, H-ionic form (Bio-Rad). For internal control purposes, a commercial 
dual piggyback column prefilled with 100-200 mesh size resin was used to 
compare the optical densities obtained from the eluted ALA of each of the one-
solumn experiments. Normal urines, normal urines with added ALA, as well 
as urines from industrial workers exposed to lead intoxication were used to 
compare the various mesh sizes of resin to the results of the dual piggyback 
column unit. It was found that 50-100 mesh resin gave a very fast flowing 
column but had little retention of the ALA. The 100-200 mesh resin gave the 
same results as the dual piggyback column unit. lt therefore became possible 
to obtain the same results with the one-column unit as was previously 
determined with the dual disposable chromatographic column (piggyback unit). 
Table 2 presents data comparing a dual piggyback column data to 
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that of the one-column. It also presents data on a one column that has had 
its bed height reduced from 4. 0 to 2. 0 cm keeping the column diameter 
constant. The bed volume was reduced to speed up the flow without sacrificing 
ALA retention of the cation resin bed. It can be noted that the 2. 0 x 0. 6 cm 
bed resin column matched the obtained optical densities from the dual piggy-
back unit while the 4. 0 x 0. 6 cm column consistently produced a reduced 
optical density. It was concluded to use 100-200 mesh size cation resin 
+ (AG-50W-X4, H ionic form) and to have the bed height no higher than 2. 0 cm. 
Table 3 presents the data on the recovery of ALA from aqueous solutions 
using the one-column method. The average percent recovery of ALA using the 
one-column method was 94. 25 percent. 
Table 4 compares the dual piggyback versus the one-column method for 
determination of urinary ALA. Normal urine had ALA added to it ranging from 
5 to 40 µg. Endogenous ALA was subtracted from the final determined ALA 
and it was found throughout the whole range of µg ALA determined, the one-
column averaged 94. 68 percent recovery while the dual piggyback column 
averaged 93. 58 percent. 
Table 5 once again compares the dual piggyback to the one-column unit 
but also compares the effect of storage for a 2 8 day period upon ALA remaining 
constant in tartaric acid preserved urine and its recovery using the one-
column unit. It can be observed that the difference between dual piggyback 
ALA values and one-column data is insignificant and may be considered to be 
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equal throughout the 28 day storage period. It was interesting to note the 
greater decrease in ALA values obtained with glacial acetic acid preserved 
urine than with tartaric acid preserved urine. It can be concluded from these 
data that: 1) a one-column unit is just as effective as a dual piggyback unit 
for urinary ALA analysis and 2) tartaric acid preserved urine does not affect 
the stability of urinary ALA or hamper its recovery from a random urine sample 
so preserved. 
Figure 3 illustrates the commercially available one-column unit for 
determination of urinary ALA as a method for screening children for early 
detection of lead poisoning. 
An interesting problem arose in the methodology related to the one-
column analysis for urinary ALA and that was washing the column free of 
urinary urea. The piggyback column unit is washed with 3 0 ml of water to 
free the columns from urea and other contaminants that do not adhere to 
the anion or cation columns. 
Table 6 summarizes the data obtained from the experiments involving 
washing the column free of urea. The table shows the effect of increasing the 
volume of water to remove the urea from the column. As an internal control, 
a dual piggyback unit was used to compare the optical density of the urea 
remaining on the cation column to the optical density of the urea that was 
on the one-column. Normal urine with Sµg ALA added to it was added to 
the dual piggyback and one-column units and analyzed for ALA in the usual 
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manner. The ALA-pyrrole-Ehrlich' s reaction product was analyzed using a 
Beckman DB-G spectrophotometer. Maximum absorption for urea plus Ehrlich's 
occurred at 415 nm and always served as the wavelength to determine urea. 
The data shows an optical density at 415 nm of 0. 025 for the dual piggyback 
column while an optical density of 0. 017 for the one-column at 3 0 ml of water 
wash. To be assured of complete washing, 35 ml of water has been suggested, 
by this laboratory, to be the most effective volume of water to use. It is 
to be noted that the percent recovery of ALA remains constant and comparable 
with the dual piggyback unit. 
Table 7 presents the data obtained when one prepares the ALA standard 
calibration curve according to the directions as described in Materials and 
Methods. The reproducibility of the data assures one of the realiability 
of the standard curve . 
Table 8 summarizes the data obtained whem one prepares an ALA standard 
curve in urine and applies this urine to a one-column unit. Endogenous ALA 
is subtracted from the recovered ALA and the values so obtained are plotted 
as a standard curve. 
Table 9 presents the data of an ALA standard curve that is prepared in 
water before being applied to the one-column unit for elution. Again the 
data reproducibility assures one of the realiability of the ALA standard curve 
and in particular the ALA test for early detection of lead poisoning. 
Chart l is a composite of the three standard curves presented in tables 
7, 8, and 9. It may be observed that any differences noted from one curve 
to the next is insignificant. One concludes that the ALA standard curve, 
prepared as directed in Materials and Methods, is accurate, reproducible, 
and easy to prepare. It is therefore the method of preparing a standard 
calibration curve that was followed throughout this dissertation. 
B. PRESERVATION OF RANDOM URINE SAMPLES FOR DETERMINATION OF 
URINARY DELTA-AMINOLEVULINIC ACID (ALA) 
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The simple problem of collecting random urine specimens from clinics, 
hospitals, or physicians' offices for urinary ALA determinations, whether done 
at the site of collection of the urine specimen or involving transportation of 
the specimen to a central laboratory for analysis at a later date, was compli-
cated by the fact that maximum recovery of ALA from the disposable ion exchange 
columns required a urine specimen having a pH of 6. 0 of below. 
Table 10 presents the effect of urine pH on the recovery of ALA from 
disposable ion-exchange columns. Urine samples having a pH from l. 0 to 
10. 0 were applied to piggyback columns (tandem units) and there was found to 
be an essentially identical recovery of ALA from these columns which received 
urine samples with a pH of 1. 0 to and including 6. 0. However, when the pH 
of the urine specimen was 7. 0 or above, a decrease in the recovery of ALA 
was noted. From these data it is suggested that the pH of all urine samples 
applied to the disposable column units be 6. 0 or below (Abrahams, 197 O). 
Chart 2 depicts the method of identification of ALA in urine and tissue 
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specimens. The ordinate is percent transmission and the abscissa is wave-
length in nm. The curve was made in a Beckman spectrophotometer, model 
DB-G, from urine and tis sue samples taken from lead intoxicated rabbits. 
The color curve was formed on heating pure ALA and ALA suspect samples 
with acetylacetone to form a pyrrole and subsequent reaction with DMAB in 
acid solution. The optimum wavelength to measure this color reaction is 
553 nm and all ALA determinations completed in this dissertation were measur-
ed at this wavelength. 
Chart 3 presents the stability of the color developed with modified 
Ehrlich's reagent. The optical densities of the ALA standards when read 
15 minutes and 2 hours after the addition of modified Ehrlich 1 s reagent are 
similar and thus the color formed with this reagent is stable for at least 2 houn . 
Chart 4 presents a typical ALA standard calibration curve obtained by 
following the procedure described in Materials and Methods entitled "Pre-
paration of an ALA Standard Calibration Curve". Urinary ALA concentrations 
up to 10 mg/100 ml (10 mg%) can be determined from this curve without 
dilution of the final red-colored reaction mixture. 
Figure 4 depicts the individual steps of the test procedure for the rapid 
analysis of urinary ALA. It should be noted that prefilled disposable chrom-
atography columns are illustrated and used in piggyback fashion. 
Table 11 summarizes the interpretation of urinary ALA values and the 
relationship of these values to lead exposure. It should be noted that the 
urinary ALA code is divided into six classifications ranging from normal to 
5+. Similarly, the relationship to lead exposure is graded from none to 
overwhelming. The terms in the column "re la ti on ship to lead exposure" 
were arbitrarily selected (Abrahams, 19 70). 
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It became of paramount importance to determine an alternative method 
to preserve random urine specimens. It had been suggested by this laboratory 
to add 10 ml of urine to a glass bottle containing 0 .10 ml glacial acetic acid. 
The problem arose when nursing personnel would dump out the preservative 
because of its offensive smell. The result was that urine samples were 
not adjusted to the proper pH while in transit to the lab. This resulted in 
serious errors in determining urinary ALA. Thus a new approach to urine 
preservation is described below. 
Table 12 shows the effect on pH of random urine preserved with 3M 
oxalic, boric, citric, and tartaric acid. Normal urine was adjusted to pH 
9. 0 with solid Na 2co 3 and then added to a 15 ml screw-capped glass bottle 
containing one of the above acids. The four bottles were gently shaken for 
5 seconds and the pH of each urine sample was determined. The urine was 
placed into a cold room at 4 C and stored in the dark. The pH of each sample 
was determined at 12 and 24 hours. It should be noted that citric acid and 
tartaric acid gave slightly cloudy and clear solutions, respectively, at 12 
hours and that tartaric-acid-preserved urine remained clear at 24 hours. 
The objective of having a urine sample preserved at a pH below 5. 0 was met 
with the oxalic, citric, and tartaric acid preserved specimens. Only the 
tartaric acid was chosen to preserve the random urine samples because in 
no instance did a precipitate form during the storage time. 
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Table 13 presents the effect of 3M tartaric acid on the pH of random 
urine specimens stored at 4 C, in the dark. The initial pH of the fresh voided 
urine was 6.0. This pH was adjusted to pH 8.30 with solid Na 2co 3 . The 
adjusted urine specimen was added to a screw-capped bottle containing either 
0.10 ml or 0.20 ml of a 3M tartaric acid solution that had been previously 
dried in an oven resulting in a fine even coat of tartaric acid crystals adhering 
to the bottle walls. The pH was determined after the initial mixing as well 
as 14 days and 28 days after storage. One sample of the original, normal 
random urine specimen was not adjusted with Na 2co3 . This sample's initial 
pH of 6. 0 rose to 7. 01 by the 28th day of storage. As an internal control, 
one urine specimen was preserved with glacial acetic acid (O .10 ml/10 ml 
urine) as is routinely done in the commercial ALA. test kit. 
It is of interest to note and compare the O. 20 ml-dried-down-tartaric-
acid-preserved urine specimen with the glacial acetic acid preserved 
specimen. The pH of the tartaric acid bottle remained stable throughout the 
28 day storage period while the acetic-acid-preserved specimen's pH rose 
from 4 . 5 0 to 4 . 6 0. 
Table 14 demonstrates the effect of various volumes of tartaric acid on 
the final pH of mid-afternoon voided urine. 12 ml of urine was adjusted with 
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lM Na 2co 3 solution to a final pH of 9. 0. Mid-afternoon voided urine was 
chosen because it presented an ideal, average test specimen to evaluate the 
acidifying property of 3M tartaric acid. The bottle to which the 0. 2 0 ml of 
tartaric acid was added, lowered the pH to 4. 4 which is safe for the proper 
preservation of urine specimens for the ALA analysis. Thus, O. 20 ml of the 
3M solution was judged to be the correct volume to use in the preservation 
of urine for ALA determinations. 
Table 15 presents the effect of storage on the recovery of ALA from 
random urine specimens preserved with 3M tartaric acid. Specimen number 
l and 2 had 8. 0 µg and 11. 0 µg ALA per 0. 5 ml urine, respectively, added 
before being added to the bottles containing the dried down tartaric acid. 
It can be observed that specimen l had a 95 percent recovery while specimen 
2 had a 98 percent recovery after a 28 day storage period at 4 C in the dark. 
Table 16 compares the pH of stored random urine specimens that have 
been preserved with tartaric or glacial acetic acid. The storage time was 
for a period of 28 days. The pH of the urine specimen was determined every 
7 days for both of the preserved specimens. It should be noted that no change 
in pH was observed with the tartaric-acid-preserved-specimen throughout 
the 28 day storage period. 
Chart 5 illustrates the recovery of ALA over a 28 day storage period. 
ALA was determined on day 0, 7, 14, 21, and 28 as well as was the urine pH. 
It should be noted that essentially no change in urinary ALA values or urine 
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pH was observed throughout the 2 8 day period. 
C. PRESERVATION OF RANDOM URINE SAMPLES FOR DETERMINATION OF 
URINARY PORPHOBILINOGEN (PBG) 
The interesting and complex nature of preserving urine for determining 
urinary porphobilinogen (PBG) was thrust upon us when it became of interest 
to determine PBG in uri~e samples obtained from industrial workers exposed to 
inorganic lead. 
Later, as further studies progressed, it became necessary to evaluate 
whether or not the lead poisoned animal excreted PBG in his urine or accum-
ulated PBG in his body tissues. 
Chart 6 illustrates the absorption curve obtained in a Beckman spectro-
photometer for PBG and PBG-like substances found in urine from lead-
intoxicated rabbits. The maximum absorption occurs at 555 nm after PBG 
is condensed with DMAB in acid solution. It should be recalled that PBG 
does not undergo pyrrole formation as ALA must, but rather directly reacts 
with DMAB in acid solution. 
Chart 7 compares the stability of the color developed with modified 
Ehrlich 1 s versus traditional Ehrlich 1 s reagent in chemical reaction with PBG. 
It can be noted that the color with modified Ehrlich's develops within 15 
minutes and remains stable over a period of 9 0 minutes. The color developed 
with unmodified Ehrlich's begins to loose absorbance within 10-15 minutes 
and continued on very rapidly until at 90 minutes the absorbance is less 
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than 50 percent of the original 0. D. measured at 5 minutes. It also should 
be noted that there is a difference in initial absorption obtained with modified 
Ehrlich's reagent over plain Ehrlich's. The initial increased color of PBG 
with modified Ehrlich's plus the stability of the color reaction directed us 
to use modified Ehrlich's reagent for all determinations of PBG. 
Chart 8 presents a typical standard calibration curve obtained with 
PBG and modified Ehrlich's reagent. The curve was constructed using the 
procedure described in Materials and Methods entitled "Preparation of a PBG 
Standard Calibration Curve". Urinary PBG concentrations up to 6 mg/100 ml 
(6 mg%) can be determined from this curve. 
Table 17 lists the expected results for the test for urinary PBG. The 
sensitivity of the test indicates its usefulness clinically. The high percent 
of recovery from the column indicates its reliability. 
Table 18 summarizes the data for interpretation of urinary PBG values 
and the relationship of these values to porphyria (acute intermittent). The 
urinary PBG code is divided into 7 classifications ranging from normal to 
5 plus and similarly the relationship to porphyria is graded from none to 
overwhelming. The terms in the column "relationship to porphyria" were 
arbitrarily selected. 
Chart 9 illustrates the stability of the color developed with PBG and 
modified Ehrlich's reagent. The initial graph was plotted after 15 minutes 
while the second curve was plotted 90 minutes after the reaction was started. 
The stability of the color assures one of a constant optical density for an 
extended period of time. 
Chart 10 illustrates the comparison of standard curves obtained from 
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PBG isolated from human urine versus synthetic PBG. It is of great satisfaction 
to obtain these identical curves because 1) it speaks highly for man's 
ability to synthesize organic compounds and 2) it encourages us to continue 
on isolating biological compounds. 
Table 19 presents the data on the stability of PBG in random urine 
preserved with tartaric acid while being stored at 4 C in the dark. The data 
represented is taken over a 7 day storage time and presents an interesting 
problem concerning the day by day loss, from control values, of PBG. Within 
24 hours of storage time, urinary PBG declined by 4 percent and by the 7th 
day of storage the PBG loss was 28 percent. The urine pH remained stable 
during this period. These data indicate the hazard in preserving urine samples, 
intended for PBG analysis, with tartaric acid - or any other acid media. 
Table 20 summarizes the effect of urine pH and storage time on stability 
of PBG stored at 4 C in the dark. Five urine samples were adjusted with 
acetic acid or sodium bicarbonate to the indicated pH. PBG was added to 
each urine sample and 0. 50 ml of this urine mixture was analyzed for PBG 
in the usual manner. The PBG eluted from the columns was considered to 
be equal to 100% on day 0 and served as the point of reference to determine 
percent loss. The experiment lasted for 7 days. It should be noted that 
143 
the percent loss of PBG from day 0 was considerably less at urine pH above 
7. O than that observed with random urine specimens preserved at pH below 
7. O. When the pH of the stored urine is 8. 0 the percent loss of PBG over 
a 48 hour period is 1. 0 percent. When one compares this 1 percent loss of 
PBG in alkaline urine with the ll percent loss of PBG in acid urine over the 
same 48 hour period, one appreciates that urine that is to be analyzed for 
PBG must be preserved differently than urine being stored for ALA analysis. 
Chart ll graphically illustrates the loss of PBG over a 28 day storage 
period when a random urine sample is preserved with tartaric acid. The 
random urine sample had PBG added to it before being added to the bottle 
containing the preservative. Urinary PBG was determined on days 0, 7, 14, 
21, and 28. It should be noted that PBG loss over a 28 day storage period 
approximates 50%. 
Table 21 in the form of a direction sheet, summarizes the recommended 
procedure for collection and storage of random urine samples for the detection 
of urinary ALA or urinary PBG. For the ALA analysis, one adds a random 
urine sample to a pre-packaged 15 ml screw-capped bottle containing a 
dried down film of tartaric acid. It is to be noted that if one refrigerates 
the preserved urine, the ALA remains constant up to a period of 4 months. 
Frozen urine samples preserved with tartaric acid will have constant values 
for ALA for a period up to a year. It should be noted that urine samples 
preserved with tartaric can only be analyzed for PBG within 24 hours of 
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collection time. 
To preserve a random urine sample for urinary PBG analysis one adjusts 
the pH of the random urine sample as summarized in table 21. By observing 
this procedure the refrigerated urinary PBG will remain constant for a period 
of 7 2 hours. If one elects to freeze the alkaline urine, the urinary PBG 
will remain constant, in the dark, for a period of 8 months. 
D. THE UTILIZATION OF THE ALA STANDARD CALIBRATION CURVE TO DETER-
MINE MILLIGRAM PERCENT URINARY PBG 
The great difficulties involved in isolating PBG prohibited its supply 
with each ALA-PBG analysis kit. It therefore became of prime interest to 
determine a method that would utilize the existing, readily available ALA 
standard to determine urinary PBG. 
Chart 12 illustrates a typical standard calibration curve of both ALA 
and PBG. It is seen that the ALA curve is approximately linear to 4. 0 mg 
percent while the PBG curve remains linear throughout the standard curve. 
To convert mg percent ALA to mg percent PBG one has to draw a horizon-
tal line from the optical density reading obtained with the PBG sample to 
the ALA standard calibration curve which was previously plotted and extend 
a line at right angles to the abscissa of the graph. This value of mg percent 
should then be multiplied by the conversion factor of 3. 53 in order to obtain 
the true value of mg percent PBG in the 0. 5 ml aliquot of urine applied to 
the column. 
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It should be noted that the conversion factor of 3. 53 (mg% PBG = mg% 
ALA x 3. 53) was obtained with authentic samples of PBG. It is therefore 
recommended that ALA hydrochloride be used to plot an ALA standard calibra-
tion curve which in conjunction with the conversion factor of 3. 53 can then 
be employed to calculate the mg percent concentration of PBG in the 0. 5 ml 
aliquot of urine applied to the column. 
Table 22 presents data for converting mg percent ALA to mg percent 
PBG with known optical densities. ALA and PBG were determined using the 
same batch of fresh Ehrlich's reagent. The two curves were constructed 
using the procedures outlines in Materials and Methods under the appropriate 
titles of preparing ALA and PBG standard calibration curves. 
E. DETERMINATION OF URINARY UREA 
The determination of urinary urea became of interest because it was 
a biological compound being passed through the piggyback column unit 
with the 30 ml of water used to wash the 0.5 ml of a random urine sample. 
The urea is not retained by the column unit but substances that would interfere 
with its determination, such as porphobilinogen, are. Thus relatively pure 
urea was obtained and determined along with the determination for urinary 
ALA and PBG. 
Table 23 presents, in flow sheet form, the determination of urinary 
urea. Random urine is applied to a piggyback unit and washed with 30 ml 
water as previously described in Materials and Methods under the section 
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entitled "procedure for the determination of urinary Af.A by means of the two 
column method". The entire 30 ml water eluate is collected and to it is 
added 4. 0 ml of fresh, modified Ehrlich's reagent. A lemon-yellow color 
develops maximally within 15 minutes after the Ehrlich 1 s is added. The 
optical density is determined at 415 nm in a standard laboratory colorimeter 
against a reagent blank. The mg of urea is determined by referring to a 
standard calibration curve. The method is simple and rapid and presents no 
complicated obstacle to its utilization. 
Chart 13 illustrates a typical urea standard calibration curve obtained 
by adding known amounts of urea to 30 ml of water, adding fresh Ehrlich 1 s 
reagent and determining the optical density at 415 nm after 15 minutes full 
color development. The curve is linear from 1 mg urea/30 ml water. We have 
determined up to 40 mg urea and have noted the curve remains linear to 
this point. 
Chart 14 shows the stability of the urea-Ehrlich's color reaction. 
The reaction was carried out over a 45 minute period with no significant loss 
of optical density at 415 nm. It may be concluded that the color developed 
is stable and will remain so for an extended period of time. 
Chart 15 and 16 illustrate the 95 percent confidence limits of human 
PBG, ALA and urea, pH respectively. 100 normal medical students donated 
mid-afternoon urine specimens to be analyzed for urinary ALA, PBG, Urea, 
and pH. The upper limit of normal for urinary ALA is 0. 54 mg percent, for 
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urinary PBG is 0. 205 mg percent, for urinary pH is 6. 88, and for urinary urea 
is 15.35 mg percent. 
F. POST-MORTEM DETERMINATION OF TISSUE LEVELS OF DELTA-AMINO-
LEVULINIC ACID (ALA) IN LEAD-POISONED RABBITS 
Previous results from this laboratory (Davis, 1970) have indicated a 
positive correlation, in children, between lead poisoning and an increase in 
urinary ALA excretion. It became of interest to attempt to answer the question 
of whether an accumulation of ALA might also occur in various tissues of 
the animal poisoned with lead. 
The unique idea of determining tissue levels of ALA using dual dispos-
able column chromatography units became of great interest because it afforded 
an opportunity to easily quantitate ALA in a manner never achieved before. 
To those investigators charged with the responsibility of determining the 
cause of death of an individual, the advantage of having a means to quantitate 
a product of a specific poisoning process presented itself favorably for 
medical-legal purposes. 
The utilization of tissue specimens was dictated by the fact that the 
post-mortem examination of bodies usually begin some four to six hours 
after the death of the deceased. The bladder urine, by this time, contains 
bacteria, products of enzymatic ca tabolism, and general waste products 
and debris associated with death. All of these have the potential to interfere 
with the ALA analysis. 
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Chart 17 presents the effect of a single injection of lead acetate on 
the excretion of ALA over a period of 58 days. The random urine samples 
were collected from the clean excreta service trays and adjusted with glacial 
acetic acid to a pH of 5. 0 (Abrahams, 19 70). The upper limit of normal 
for urinary ALA values, in control rabbits, was found to be 0. 05 mg percent 
as indicated by the dashed line. An essentially linear increase in urinary 
ALA was observed following the single subcutaneous injection of 200 mg/kg 
lead acetate. The urinary ALA reached a level of approximately 3. 0 mg 
percent at 58 days after injection. These data indicated that the adult rabbit 
exposed to a single injection of lead acetate would constitute a useful model 
for investigating any changes in tissue levels of ALA that might occur during 
the course of lead poisoning. 
Table 24 presents, in flow sheet form, the method for determination 
of tissue levels of ALA. The time for analysis of one gram of tissue from the 
time the tissue specimen is brought to the lab to the time the supernatant 
pH is adjusted to pH 5. 0 and frozen is approximately one hour. The freezing 
step takes about one hour to an indefinite period depending upon the laboratory 
concerned and when they wish to analyze for tissue ALA. It takes another 
hour to complete the analysis after the supernatant is defrosted. It therefore 
becomes very easy and rapid to determine levels of ALA in tissues of animals 
poisoned with lead. 
Table 2 5 presents, in flow sheet form, the method for the determination 
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of a tissue blank in the ALA analysis. The purpose of this tissue blank was 
to detect any possible substances present in the tissues that might interfere 
with the analysis of ALA by reacting with Ehrlich's reagent alone. The optical 
density of the tissue blank was so small that it was concluded that no inter-
fering substances were coming through the column to hinder or hamper the 
ALA analysis. 
Table 2 6 shows the recovery of various quantities of added ALA to liver 
homogenates. One gram of tissue was used in each of these experiments 
to which ALA was added ranging from 2. 5 to 2 0. 00 µg. The total experiment 
for tissue extraction was carried out and an average of 92 percent of ALA 
was recovered indicating an accurate method for recovery was found. 
Chart 18 graphically presents the mean control levels of ALA found in 
21 tissues of non-treated adult rabbits. Control levels of tissue ALA ranged 
between 0. 02 microgram per gm for adipose tis sue to 0. 53 microgram per 
gm for the tail of the epididymis. 
Chart 19 illustrates the effect of a single subcutaneous injection of 
200 mg per kg of lead acetate on the tissue levels of ALA found in the bone 
marrow, kidney, spleen, and liver of the adult rabbit. A marked progressive 
increase in the ALA content of both bone marrow and kidney was observed 
throughout the time period studied. In contrast, very little ALA accumulation 
was noted in samples of both the spleen and liver. 
Because of the extremely large amounts of ALA found in samples of the 
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bone marrow and kidney 58 days after injection of lead acetate, an attempt 
was made to investigate whether other tissues might not exhibit an increase 
in ALA content at a similar time following exposure to lead acetate. 
Chart 20 indicates the levels of ALA found in 21 tissues of the adult 
rabbit 58 days after the single subcutaneous injection of 200 mg per kg of 
lead acetate. The bone marrow was found to have the highest content of 
ALA of all the tissues studied averaging 24. 6 micrograms per gram wet weight 
of tissue. The level of ALA found in the kidney was 10. 9 micrograms per 
gram while corresponding values for the spleen, lung, and tail of the epididy-
mis were 1.50, 1.25, and 1.05, respectively. All of the remaining tissues 
studied were found to have an ALA content below O. 7 microgram per gm wet 
weight. 
Chart 21 presents a comparison of the degree of lead induced ALA 
accumulation in tissues 58 days after lead acetate injection. The height of 
each bar represents the ratio of tis sue ALA found in lead-poisoned rabbits over 
the control levels of ALA found in non-treated rabbits. The greatest accumula-
tion of ALA occurred in the bone marrow which approximated a 100 fold increase 
in ALA over control values. The kidney and lung displayed an accumulation 
of ALA amounting to a 27 and a 20-fold increase, respectively. ALA accumula-
tion in all the other tissues studied was found to range from an 8-fold increase 
to essentially no change. 
Tables 27 and 2 8 indicate the effect of a subcutaneous injection of 
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lead acetate on the accumulation of ALA or PBG in the bone marrow and kidney 
of the adult male rabbit. It is observed that ALA increases almost 100 fold 
over control in the bone marrow while the kidney increases 27 fold over 
control, both at 58 days after the single injection of lead acetate. The bone 
marrow PBG increases to 40 fold over control while the kidney increases 85 
fold 58 days after the single injection of lead acetate. 
Chart 22 demonstrates the effect of increasing the dose of lead acetate 
for the single subcutaneous injection. Animals were injected once either with 
200, 400, or 800 mg lead acetate/kg body weight and were sacrificed 20 
days latter. The bone marrow, kidney, spleen, and liver were analyzed 
for ALA accumulation. It was observed that the bone marrow consistently 
had a higher quantity of ALA accumulating per dose of lead acetate administ-
ered followed very closely by the kidney. The spleen and liver essentially 
showed no change in ALA accumulation over the entire dose range of lead 
acetate administered. It can be concluded from this chart that 1) ALA 
accumulation is dose dependent, 2) the bone marrow accumulates the most 
ALA per gram of tis sue, and 3) the kidney serves as an excellent second choice 
for a tissue to study that accumulates ALA. 
G. DETERMINATION OF AMINOACETONE IN URINE AND TISSUES OF THE 
LEAD-POISONED RABBIT 
Aminoacetone (AA) is an aminoketone of physiological significance 
produced enzymically by the condensation of glycine and acetyl coenzyme A 
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or by the oxidation of threonine. 
Since both ALA and AA occur in urine, are produced in mitochondria, 
form pyrroles by condensation with acetylacetone, anr:! form a color complex 
with Ehrlich's reagent measured at 553 nm (ALA) and 556 nm (AA), respectively, 
the measurement of these substances in both urine and tissues requires their 
separation. The objective of this separation was to determine whether or 
not aminoacetone was being synthesized and, if so, in what quantity in the 
lead-poisoned animal. 
The question that had to be answered by this study was how much 
color does the AA-pyrrole plus Ehrlich's reagent add to the overall optical 
density in the ALA analysis. 
Table 29 presents, in flow sheet form, the method to fractionate AA 
from ALA contained in tissues from a lead poisoned animal. The procedure 
is carefully described in Materials and Methods under the section entitled 
"procedure for the isolation and determination of tissue aminoacetone in 
the lead-poisoned rabbit". The tissue submitted to the laboratory for 
analysis of ALA and AA is processed and homogenized in the same manner as 
previously described for the tissue ALA analysis. The fractionation procedure 
begins after the ALA and AA pyrroles have been formed. The pyrroles are 
added to the anion AG-1-XS column and AA pyrrole is eluted from the column 
as indicated by the flow sheet. The remaining ALA pyrrole is eluted from the 
anion column by first washing the column with acetic acid and then eluting 
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the ALA pyrrole. Thus by this frac tiona ti on procedure, one can readily 
separate and identify the two pyrroles. Once the AA and ALA pyrroles have 
been separated, they then can be individually reacted with modified Ehrlich's 
reagent. The color complex optical density formed from this reaction is 
determined in a laboratory colorimeter and the quantitation of ALA is completed 
by referring to an ALA standard calibration curve. Aminoacetone is determined 
mathematically as described in Materials and Methods. 
Table 30 indicates the data for the total percent of final color due to 
aminoacetone in a urine specimen from a lead-poisoned rabbit. The table 
compares the two methods of Marver (19 6 6) and Davis (19 68) for determining 
ALA. Marver uses Ehrlich's reagent that contains l gm DMAB dissolved in 
3 O ml glacial acetic acid to which is added 8. 0 ml of 7 0 percent perchloric 
acid. After mixing, the solution is diluted to 50 ml with acetic acid. Davis 
uses Ehrlich's reagent that contains 2 gm DMAB dissolved in 84 ml glacial 
acetic acid to which is added 16 ml of 70 percent perchloric acid. The only 
difference, in essence, between the two formulas is the method of mixing 
the components together. The proportions are almost identical". It can be 
seen that the total percent of color due to aminoacetone averages 2. 0 
percent between the two methods. It can be concluded from this data that 98 
percent of the observed optical density obtained in the urinary ALA analysis 
is due to ALA and that the amount of aminoacetone present is there in only 
insignificant amounts. 
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Table 31 presents the percent of final color due to aminoacetone in 
tissue samples from lead-poisoned rabbits. The percent of color developed 
from the AA for the kidney, bone marrow, spleen, and liver averaged 0. 39 
percent. The kidney and bone marrow each averaged 0. 01 percent. These 
data indicate that the aminoacetone pyrrole does not add any increased color 
to the two tissues we are suggesting for post-mortem analysis for lead 
poisoning -- namely the bone marrow and the kidney. These data also 
suggest that ALA was determined accurately in these tissue samples and 
that a minoacetone can be ruled out as an interfering biological compound. 
H. DELTA-AMINOLEVULINIC ACID DEHYDRASE (ALAD) LEVELS IN THE 
SPRAGUE-DAWLEY RAT BEARING THE WALKER 256 CARCINOSARCOMA 
The purpose of this investigation was to study the enzyme delta-
aminolevulinic acid dehydrase (ALAD) in rats bearing the Walker tumor. We 
investigated this enzyme because its inhibition in the lead-poisoned animal 
results in severe anemia. The anemia of cancer was observed in the rats 
bearing the Walker tumor and the question arose as to whether or not ALAD 
was inhibited, in some manner as in the lead-poisoned animal, by the action 
of the growing, malignant tumor. 
Chart 23 illustrates the inhibition of ALAD in the lead-poisoned rat. 
One observes two important items on this chart: one -- the immediate fall 
in ALAD units within one day of the single intraperitoneal injection of lead 
acetate, with the slow return to 50 percent of original activity by day 10, 
and two -- the immediate rise in urinary ALA levels to a maximum 1. 86 mg 
percent within 24 hours after the initial injection. ALA levels slowly fall 
back to control levels by day 18. The inhibition of this enzyme in lead-
poisoned humans and animals accounts for the spill-over of its substrate, 
ALA, in to the urine • 
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The concept of studying an hematopoietic enzyme such as ALA dehydrase 
appeared to be unique and warranted further investigation. In preliminary 
studies evaluating the anemia observed in these malignant tumor bearing 
rats, a survey of peripheral blood smears revealed a marked reticulocytosis. 
It therefore became of interest to us to answer the following questions: 
1) can ALAD be detected in rats bearing the Walker tumor, 2) is there any 
relationship to the ALAD enzyme activity and the appearance of reticulocytes, 
3) what occurs hematologically in these tumor bearing animals over the span 
of time the tumor is growing, and 4) is this enzyme inhibited when extracts 
from the tumor are injected into control animals. 
Table 3 2 presents, in flow sheet form, the method for transplanting 
the Walker 2 56 Carcinosarcoma. A 60 day old Sprague-Dawley rat bearing 
a 7 day old subcutaneous growing tumor was sacrificed and the tumor was 
removed. It was washed and trimmed to remove debris and fatty tissue, 
while the center necrotic area was carefully cut away and discarded. The 
tumor was finely minced and this minced preparation was added to a tissue 
press fitted with a fine sieve covered with a 90-mesh stainless steel screen. 
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Under pressure, the tumor cells were forced through the sieve and screen 
and were suspended in saline and mixed well. 0. 50 ml of this cell suspension 
was injected subcutaneously in the lower abdomen of an untreated, 60 day 
old Sprague-Dawley rat. This procedure was carried out every seven days 
to propagate the tumor. Samples of the suspension were sent to pathology 
for staining and for careful microscopic examination. 
Table 33 presents, in flow sheet form, the method for determination of 
IALAD activity (modification of the method of Weissberg, 1971). Whole blood, 
drawn from the tail, is added to distilled water and the resulting hemolysate 
has added to it fresh 0. 01 molar ALA. After incubation for 60 minutes, the 
enzymatic reaction is stopped, centrifuged, and the supernatant is added to 
an equal volume of modified Ehrlich's reagent. The color is allowed to 
develop for 2 minutes after which the absorbance is measured in a standard 
laboratory coloimeter at 555 mµ against a reagent blank. Therefore, within 
a period of 80 minutes one could determine ALAD activity in a peripheral 
blood specimen. 
Table 34 illustrates the formula for determining ALAD activity in peripher-
al blood. The formula is optical density at 60 minutes times 100 divided by the 
lhematocrit times 44. 61. The value 44. 61 is derived from the formula as shown 
!in the table. The incubation volume of 3. 65 ml represents the total volume of 
the incubation (1. 45 ml distilled water, 0 .150 ml whole blood, 1 ml of ALA, 
1 ml 10% TCA, and 0. 05 ml copper sulfate). The answer is multiplied by 2 
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because one ml aliquot of this incubation mixture is mixed with an equal 
part of Ehrlich's reagent. The final answer is multiplied by 2 to represent 
the fact that the enzyme activity is defined "as amount of enzyme necessary 
to convert lµ mole of ALA to PBG" and that 2µ moles of ALA are utilized to 
synthesize one µmole of PBG (Oski, 1973). 
Blood was drawn from the tail vein on alternate days, up to and including 
day 20 after transplantation of the tumor, and was assayed for ALAD using 
whole blood by a modification of the procedure of Weissberg (1971) 
Table 35 summarizes the data on the determination of ALAD activity 
in whole blood and plasma. It was determined that the activity of the 
enzyme was always found in the whole blood rather than the plasma, in fact 
the plasma had no enzymatic activity. 
Table 3 6 represents the data on the stability of the color reaction 
developed in the analysis of ALAD in peripheral blood of the 60 day old rat. 
It can be observed that the optical density, measured at 555 nm, begins to 
decrease within the first 5 minutes of the reaction by 1. 55 percent, reaching 
10 percent by 3 5 minutes. At 60 minutes of reaction time the optical density 
decreased by 17. 83 percent indicating a steady decline and loss of optical 
density. It was therefore concluded to determine the optical density exactly 
at 2. 0 minutes after the color reaction began. 
Chart 24 illustrates the effect of the growing Walker tumor on the 
reticulocyte count and ALAD activity of the host. The left ordinate represents 
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cubic millimeters tumor volume while the two right ordinates represent ALAD 
units and percent reticulocytes respectively, while the abscissa represents 
days after transplantation of the tumor. The growing tumor becomes slightly 
palpable at 4 days and increases up to a maximum of lll, 000 cubic millimeters 
at 16 days, after which the size of the tumor could not be measured accurately. 
The upper limit of normal for ALAD uni ts in control rats was found to be 4. 0. 
It is to be noted that the increase in ALAD activity begins immediately after 
transplantation, and on day 4, the first day of palpable tumor growth, the units 
were 16 and on day 16, the day of maximum growth of the solid tumor, the 
units were 35 to continue onto a maximum of 47 units on day 20. 
The reticulocyte count followed the same pattern as the enzyme 
activity. The upper limit of normal for percent reticulocytes in control rats 
was found to be 4. 2. The percentage rose to 13 percent on day 4, to 43 
percent on day 16 continuing onto a maximum of 62 percent on day 20. 
It is of interest to note two things about this graph: 1) the similarity 
and parallelism of the ALAD units curve with the percent reticulocyte curve, 
and 2) the immediate and rapid elevation of these two parameters before any 
growth of the tumor could be detected as well as their persistence throughout 
the time of the growth of the tumor. 
Chart 25 demonstrates the percent increase in reticulocyte count and 
ALAD activity over control. ALAD activity increased ll7 percent over control 
within 24 hours after transplantation and rose to 619 percent by day 4, to 
1440 percent by day 16, rising to two thousand percent over control on day 
20. The reticulocyte count increased 70 percent within 24 hours and rose 
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to 387 percent by day 4, to 1822 percent by day 16 rising to 2300 percent over 
control on day 20 after transplantation. 
Chart 26 is a composite chart presenting the e.ffect of a growing 
subcutaneous tumor on the host. The abscissa in all 4 graphs is days after 
transplantation while the right and left ordinate change per individual chart. 
The top chart summarizes the growth of the tumor as compared to total body 
weight. The next chart summarizes the units of ALAD compared to percent 
reticulocytes - again it is important to note the ever increasing and immediate 
response both of these parameters have as a result of the growing transplanted 
tumor. The third graph presents data on the red and white blood cell counts 
compared to each other. Both of these counts were done electronically and 
it should be noted that the red cell count consistently decreased per unit of 
time starting with an initial value of 5. 8 million per cubic millimeter and 
ending up with 2 million per cubic millimeter on day 20. The bottom graph 
shows the data obtained when one compares hemoglobin grams percent to 
hematocrit percent. Both curves decrease per unit of time in parallel with 
the decreasing red cell count. Therefore, these data suggest that there is 
no accumulation of red cells but rather a severe distruction of them. 
Figure 5 is a composite of one of a series of photomicrographs depicting 
the reticulocyte response to the growing, subcutaneous Walker tumor. 
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The freshly drawn peripheral blood was stained with the vital dye New Methyl-
ene Blue - N. The photograph on the left is a control blood obtained from 
a rat before transplantation of the tumor. One reticulocyte can be identified 
in this field. The photograph on the right shows the response to tumor 
growth 16 days after transplantation. In this particular field 40 percent of 
the cells are reticulocytes. The photograph below the above two depicts 
the reticulocyte response obtained on day 20 after transplantation. The pre-
ponderance of reticulocytes -- approximately 65 percent in this field --
demonstrates the reticulocytosis that is occuring in response to malignant 
tumor growth. 
Because of these results indicating a positive correlation in the tumor 
host between ALAD activity and reticulocytosis we then turned our attention 
to cell-free water extracts of the Walker tumor and compared these data 
with that obtained from a normal liver cell-free water extract. 
Table 3 7 presents, in flow sheet form, the method of preparing a 
lyophilized cell-free water extract of the Walker tumor. A number of 7 day old 
tumors from several 60 day old rats were combined together, homogenized, 
gently swirled in the cold and centrifuged. The supernatant from this 
centrifugation was centrifuged twice, the last being at 105, 000 x g. The 
resulting supernatant was lyophilized for 24 hours producing a lyophilized 
cell-free water extract of the Walker tumor. 
Chart 27 presents the effect of a single intra-cardiac injection of a 
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lyophilized cell-free water soluble tumor extract. It should be noted that 
the reticulocyte count reaches the highest percentage at day 2 while ALAD 
activity reaches its highest level at day 8. Both of these parameters return 
to normal values by day 20. 
Chart 28 is a composite chart showing the effect of a single intra-
cardiac injection of the lyophilized cell-free water soluble tumor extract. 
The ordinates and abscissa is the same as previously described. The body 
weight, red and white cell count as well as the hemoglobin and hematocrit 
remain relatively stable and constant with a slight depression in the red cell 
count. The increase in ALAD units and reticulocyte percent remain the 
only significant parameters affected by the tumor extract. 
Figure 6 is a composite summarizing the tumor extract experiments. 
The photograph on the left is a control blood smear stained with New Methyl-
ene Blue-N. The photograph on the right is taken from a blood smear two 
days after injection of the tumor extract. The reticulocyte count reaches its 
highest percentage on this day. The photograph below the above photographs 
depicts the reticulocyte response obtained on day 20 after injection of the 
tumor supernatant. It should be observed that the reticulocyte count has 
returned to control values -- in marked contrast to the reticulocytosis obtained 
when there is a growing malignant tumor. 
Table 3 8 presents, in flow sheet form, the method for preparing a 
lyophilized cell-free water extract of normal rat liver. This flow sheet is 
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identical to the method used to prepare a water extract of the Walker tumor. 
The end product is a lyophilized cell-free liver extract that can be utilized in 
the experiments comparing extracts of the tumor to extracts of normal liver. 
Chart 29 presents a composite graph showing the data obtained with a 
single intra-cardiac injection of a lyophilized cell-free water soluble extract 
of normal liver. The ordinates and abscissa are the same as previously 
described. It is to be noted that there is no change in any of the parameters 
measured during the 2 0 day period. 
Figure 7 is a composite summarizing the liver extract experiments. The 
photograph on the -left is a control blood smears tained with New Methylene 
Blue-N. The photograph on the right is taken from a blood smear 2 days after 
injection of the liver extract and essentially shows no change over 
controls. The photograph below the above photographs depicts the results 
20 days after injection and once again demonstrates the lack of reticulocyte 
response characteristic of the liver extract experiments. 
Chart 30 presents a comparison of the effect of a single intra-cardiac 
injection of the lyophilized cell-free protein from the Walker tumor extract 
and from normal liver extract. The upper 2 curves represents the data 
obtained from the tumor extract injection while the lower 2 curves represent 
the data obtained from the normal liver extract injection. Essentially all 
the change is noted with the animals given the tumor extract while no change 
is observed with the liver extract injected animals. 
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It is therefore concluded that the growing Walker tumor produces a 
stimulating substance that initiates a great increase in ALAD activity with a 
concomitant increase in reticulocytosis. A water soluble lyophilized cell-
free extract of the tumor will cause similar but smaller increases in ALAD 
activity and reticulocytosis for a short period of time while normal liver 
extracts will not. 
It should once again be pointed out that the immediate and unique 
elevation of ALAD activity in parallel with reticulocyte formation before 
tumor growth becomes palpable suggests an early tumor-host relationship 
that may be unique in the early detection of neoplastic disease. 
I. STUDY OF THE EFFECT OF PRE-TREATMENT WITH EXTRACTS OF THE 
WALKER TUMOR ON FACILITATION OF GROWTH OF THE WALKER 2 56 CARCINO-
SARCOMA IN SPRAGUE-DAWLEY RATS 
The fascinating subject of manipulating conditions of tumor growth 
have been and will continue to be of prime research interest to investigators. 
The purpose of this preliminary study was to determine if pretreatment 
of rats with 100 mg/kg body weight of the lyophilized cell-free water soluble 
tumor extract would in some way facilitate or inhibit growth of the subcut-
aneous growing transplated Walker tumor. 
The animals were pretreated with one intra-cardiac injection of the 
tumor extract. For control and comparison purposes an injection of a 
lyophilized cell-free water soluble extract of normal rat liver was employed. 
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The animals were bled, via the tail vein, for 20 days to determine ALAD 
activity, reticulocyte counts, and basic hematology studies as previously 
described. 
On the 20th day each pretreated animal, whether tumor or liver extract, 
was inoculated with a O. 5 ml subcutaneous injection of a Walker tumor cell 
suspension from a 7 day old growing tumor. Control, untreated litter mates 
of the pretreated group were injected with a 0. 5 ml of the same Walker tumor 
cell suspension, as previously described. 
Each animal was housed in a separate cage during the pretreatment 
period as well as during the growth or the Walker tumor. 
The volume of the growing subcutaneous tumor was measured, as 
previously described, by an unbiased observer on alternate days until the 
tumor could not be accurately measured or until the animal died. 
Chart 31 illustrates the percent increase in tumor volume in animals 
pretreated with water soluble extracts of the Walker tumor or normal liver. 
It is to be noted that the water extracts of the Walker tumor facilitated the 
growth of the subcutaneous growing tumor. On the sixth day after transplant-
ation, the tumor extract pretreated animals had a 200 percent increase in 
tumor volume over the control tumor bearing rats. This percentage increased 
to 295 percent by day 12. 
In contrast, the liver extract pretreated animals showed very minimal 
percent increase in tumor volume over control untreated rats. The maximum 
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percent of increase in tumor volume was observed on day 10 with a 73 percent 
increase but this peak in tumor volume was lost by day 12 when the control 
tumor volume approached the liver extract pretreated animals. 
CHAPTER IV 
DISCUSSION 
CHAPTER IV 
DISCUSSION 
A. ONE COLUMN ALA ANALYSIS 
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One of the cardinal manifestations of lead intoxication in man is the 
disturbance in the synthesis of heme. Indeed, this biosynthetic pathway is 
so sensitive to the toxic effects of lead, that one of its metabolites - delta-
aminolevulinic acid - can be consistently demonstrated in great excess in the 
urine even in the absence of clinical symptoms. 
Porphyrinuria was first demonstrated in human cases of plumbism by 
Garrod in 189 2 so its appearance is nothing new to the scientific community. 
In a series of papers published chiefly during the past twenty years, 
Shemin and his collaborators have shown that prophyrins are formed from 
glycine and succinyl-CoA & that ALA and PBG are early intermediates in this 
biosynthesis. 
When methods for quantitative determination of ALA in urine became 
available (Granick and Vanden Schrieck, 19 55; Shuster, 19 5 6; and Mauzerall 
and Granick, 1956) a study of the excretory pattern of these metabolites in 
various diseases with disturbed porphyrin metabolism was started. 
Using the method of Mauzerall and Granick (1956) the concentration of 
an ALA-like substance was found to be markedly raised in urine from men 
exposed to lead (Haeger, 1957). Later, it could be stated that this substance 
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consisted of ALA (Haeger, 1958). 
The findings of Haeger-Arons en (19 60) prompted Davis et al (19 67, 19 68) 
to modify the method of Mauzerall and Granick (1956) to utilize disposable ion-
exchange chromatography columns for the determination of urinary ALA levels 
in the lead poisoned pediatric population. 
Abrahams (1970) completed a Ph.D. dissertation on "Urinary Delta-
Aminolevulinic Acid (ALA) Levels in Childhood Lead Poisoning", under the dir-
ection of Davis, using the disposable dual piggyback ion-exchange columns. 
The Ph.D. dissertation was based on utilization of urinary ALA as a possible 
indicator for early lead poisoning in children, which until that time had never 
been carried out. The studies had three objectives - first, the modification 
and simplification of the method described by Mauzerall and Granick; second, 
making the urinary ALA test readily available for use throughout the country; 
and third, the initial correlation of the urinary ALA test with the clinical inci-
dence of childhood lead intoxication. Recently Davis (197 0) published a paper 
on the "Reliability of Urinary ALA as a Mass Screening Technic for Childhood 
Exposure to Lead" • 
This dissertation (Abrahams, 197 O) plus the many excellent papers on 
the validity of urinary ALA for determining the degree of lead absorption has 
allowed us to move one step further in the pursuit of a means to detect early 
exposure to childhood lead poisoning. 
We agree with Vincent (1970) and others that there are no known condi-
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tions in children which might cause an accumulation of PBG in the urine. For 
this reason it is not necessary to use a top anionic column for the removal of 
PBG as an interfering substance in this age group. 
It therefore became of interest to modify the dual piggyback unit to a 
simplified, disposable ion-exchange one-column determination of urinary 
ALA for children only. The objective was to obtain identical results with those 
obtained by the originally-modified dual piggyback column described by Davis 
(1967, 1968). 
It should be emphasized that the use of urinary ALA as a mass screen-
ing procedure for the detection of childhood exposure to lead was never intend-
ed to replace the determination of blood lead levels. Davis (1970) has 
always recommended that 11 all children found to have elevated urinary ALA 
excretion should be followed up with a careful history and physical examination 
together with a blood lead determination 11 • 
The data of the present experiments indicate that the mesh size of the 
cation resin is critical for obtaining exactly similar results with the one-
column ALA analysis as was obtained with the dual piggyback unit. It was 
found that a coarse mesh would increase the flow rate greatly but the retention 
of ALA on the column was lost. Therefore, the 100-200 mesh of the AG-50W-
X4 analytical grade cation exchange resin in the hydrogen ionic form was 
determined to be best suited for our requirements. 
An interesting part of the study to obtain optimum conditions for 
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retention of ALA on the one-column unit as well as ease of eluting the sample 
from the column was the discovery that ~s one reduced the resin bed height 
by 50 percent while keeping the resin bed width the same, one could match, 
identically, the results obtained with the dual piggyback unit. Apparently, 
with the increased bed height the urinary ALA was being tenaciously retained 
and not being completely eluted by the 7. 0 ml of IM sodium acetate. The 
reduced height gave the surface area required for proper retention but also gave 
the proper physical conditions resulting in ease of elution of the ALA with the 
sodium acetate. 
The experiments involving the percent recovery of ALA were most re-
warding because, on the average, they resulted in a 94 percent overall recovery 
versus a 93 percent recovery from the dual piggyback unit. 
The storage of urine that was preserved with tartaric acid presented no 
obstacle to the recovery of ALA. In fact, the data that is presented in Table 
17 indicates that tartaric acid preserved random urine safeguarded the total 
ALA content better the longer the urine was stored as compared to acetic acid 
preserved urine. 
The data obtained from the experiments determining the elution of 
urinary urea demonstrated that the one-column unit retained less urea than 
the dual piggyback unit. It is fortunate that in both cases the absorbance at 
415 nm does not interfer, as small as it maybe, with the determination of the 
ALA chromophore at 553 nm. 
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The present data indicate that the one-column unit is just as effective 
as the dual piggyback unit for urinary ALA analysis. The data also indicates 
that the tartaric acid preserved urine does not affect the excellent recovery of 
ALA even upon prolonged storage at 4 C, in the dark. 
MEDICAL-LEGAL AND CLINICAL IMPLICATIONS OF THE ONE-COLUMN ALA 
ANALYSIS 
The primary aim of treatment for plumbism in children is the prevention 
of injury to the nervous system. In practice today, therapeutic intervention at 
the subclinical stage of lead poisoning and close follow-up observation during 
the toddler and preschool years can do much to prevent the severe forms of 
residual nervous-system injury. At least 25 percent of young children with 
acute lead encephalopathy or recurrent but less severe clinical bouts of 
plumbism sustain permanent injury to the nervous system (Byers and Lord, 1943; 
Perlstein and Attala, 1966; and Smith, 19 64). Treatment instituted before the 
onset of symptoms may be far more effective. Under this concept, any child 
with > 80µg of lead per 100 ml of whole blood (2-4 mg% urinary ALA) should 
be handled as a pediatric emergency, hospitalized and treated with calcium 
disodium edetate, even if he has no symptoms (Silver, 1971). The rationale 
for this approach is as follows: children with > 80µg of lead per 100 ml of 
whole blood (2-4 mg% urinary ALA) generally show marked derangements in 
heme synthesis due to lead (National Research Council - National Academy of 
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Sciences, 1972) that can be demonstrated by appropriate tests (urinary ALA); 
at levels ) 80µg, neither blood lead concentration nor any other clinical 
laboratory test is predictive of the onset or severity of symptoms, which may 
appear without warning. 
Under this concept, children having 40 to 80µg of lead per 100 ml of 
whole blood (O. 6-2. 0 mg% urinary ALA) may also require at least brief chela-
tion therapy to reduce soft-tissue lead levels, if they show derangements in 
heme synthesis. This precaution is considered prudent, although there is 
as yet no clear evidence whether this lower level of increased lead absorption 
is associated with subtle neurologic impairment. The available evidence in 
this area is scanty, but provocative (Lin-Fu, 197 2). 
The utilization of the one-column ALA test for screening the pediatric 
population for early exposure to lead was summarized by Cramer and Selander 
(1966) when they wrote "By far the closest correlation between clinical findings 
and a biochemical test for lead poisoning was between the amount of ALA in 
the urine and the symptom score". The one-column urinary ALA test has the 
unique value of indicating individual overexposure to lead before symptoms 
become obvious. 
As stated in the introduction, the ALA test indicates high body burdens 
of lead from previous exposures to lead. In such cases, blood lead values 
could be found acceptable whereas the accumulated reserves of lead in the 
body may be exerting a pathological effect. This pathological effect could 
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go undetected when based on the blood lead level alone. Thus, a case of 
lead poisoning could go undetected when diagnosis is based solely upon the 
observed blood lead level. 
The utilization of the one-column ALA analysis will shift the focus 
from treatment of lead poisoning to prevention through early detection and 
termination of undue exposure. 
The tragic problem today is that there is an erroneous concept regard-
ing "normal" levels of lead. It is obvious that Davis (1967, 1968, 1970) has 
determined correct limits for urinary ALA in its relationship to lead exposure 
(table 11). The upper limit of "normal" blood lead has been variously set at 
80, 60, 40, 36 and 20µg per 100 ml of whole blood (Amer. Academy Pediatrics, 
1961; Blanksma, et al., 1968; Berman, 1966; Rennert et al., 1970). The inter-
esting point about these papers is that they imply that values not diagnostic 
of lead poisoning are normal. In fact, most papers written on the subject 
equate the lowest blood lead level diagnostic of lead poisoning with the upper 
limit of normal. A level not associated with overt clinical evidence of toxicity 
is not necessarily normal; however, most children with increased and therefore 
"abnormal" blood lead levels are reported as "asymptomatic" (Sachs et al., 
1970; Greengard et al., 1968; Berman, 1966; and Rennert et al., 1970). But 
symptoms from low-level lead intake may have been overlooked because no one 
knows what to look for, and children are considered asymptomatic when classic 
symptoms and signs of lead poisoning are absent. 
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The problem is quite simple - blood lead concentration is the result of 
several equilibria and should thus be interpreted with caution. Thus, a low 
blood lead level value does not necessarily exclude a high bone burden of 
lead. In fact, there is evidence that different laboratories use different 
methods of blood lead determination, and some of these laboratories vary con-
siderably in accuracy (Keppler et al., 1970). 
In summary, undue absorption of lead is a health problem of alarming 
proportions among young children living in old dilapidated neighborhoods. 
Its magnitude is many times that of lead poisoning, an illness already labeled 
as "epidemic" in many areas (Rothschild, 1971). At present, it remains uncer-
tain whether or not lead causes permanent damage in humans at a low level of 
absorption and in the absence of clinical symptoms. But there is in vitro 
evidence of metabolic disturbance at such low levels, and some reports sugges 
that permanent neurologic damage can occur in the absence of overt clinical 
symptoms. 
One certainty is that if exposure is not terminated in children with 
early evidence of undue absorption of lead, many will become poisoned. 
Early detection via urinary ALA levels and termination of the exposure at this 
stage is therefore an essential step foreward in the prevention of childhood 
lead poisoning. 
B. PRESERVATION OF URINE SPECIMENS FOR ALA AND PBG ANALYSIS. 
URINARY UREA ANALYSIS COMPLEMENTING ALA AND PBG DETERMINATIONS 
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ALA Data. The question of stability of the porphyrin precursors delta-
aminolevulinic acid (ALA) and porphobilinogen (PBG) in human urine is of 
great importance from the standpoint of analysis in the clinical laboratory. 
The qualitative Ehrlich reaction for PBG may change from strongly positive to 
negative in a few hours if the urine is kept at room temperature. This may 
result either from the formation of an inhibitor of the reaction and/or simple 
disappearance of PBG through conversion to porphyrin, or other unidentified 
substances. When analysis of the freshly voided urine is not possible it is 
important to know the optimum conditions under which the urine can be 
preserved. 
Previous data from this laboratory have indicated that a small amount 
of glacial acetic acid (O .1 ml/10 ml urine) satisfactorily preserves urine speci-
mens for the ALA analysis (Davis, 1970). At the time this method of preserving 
urine was introduced no concern was given for PBG determinations. Subsequent 
to these investigations an analysis for urinary PBG has been worked out (re-
ported in Materials and Methods chapter) utilizing disposable ion-exchange 
column chromatography. 
Thus, the present study was undertaken to provide more definite infor-
mation about preserving the urine specimen prior to determination of ALA and/or 
PBG. 
It was found by Abrahams (1970) that ALA recovery from the disposable 
ion-exchange columns was found to be essentially identical if the urine 
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samples had a pH of 1. 0 to and including 6. 0. However, when the pH of the 
urine specimen rose to 7. 0 or above, a decrease in the recovery of ALA was 
noted. 
A comparison was initiated to study the effect of 3M oxalic, boric, 
citric, and tartaric acid upon the recovery of ALA from urine specimens. Fresh 
voided urine was made alkaline (pH 9. O) to ensure that the studied acid would 
be capable of lowering the urine pH to below 6. 0 and to maintain this pH 
for a reasonable period of storage. The data indicated in table 12 shows tar-
taric acid lowered the pH of the urine to proper levels, maintained a correct 
pH during storage, and at no time did a precipitate form during the storage time. 
It was found that if 0. 2 ml of a 3M tartaric acid solution was added 
to a 15 ml screw-capped bottle, and heated to 75 C for 60 minutes a clear, 
crystalline film would result firmly adhering to the bottom and sides of the 
bottle. This thin film is readily soluble in urine and became the basis for 
future preservation of urine. 
The data of the present studies indicate greater than 94 percent recovery 
of ALA from urine samples preserved with 3M tartaric acid - even if the urine 
is stored for a period of 2 8 days at 4 C. 
The data also shows that no change in pH of the urine sample was 
observed throughout the 28 day storage period. It was later determined that 
ALA will remain constant up to a period of 4 months if the urine is stored at 
4 C in the dark. Frozen urinary ALA samples will remain constant up to a year, 
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as long as they are in the dark. 
PBG Data: The introduction of disposable ion exchange column chromato 
graphy in the analysis of ALA in lead poisoning opened a new area - that of 
detection of PBG. Use of the disposable column facilitated the rapid identifi-
cation and quantitative determination of PBG from a random urine sample. 
Up until a few years ago, before the drug culture came into vague, 
acute intermittent porphyria (AIP) had its most frequent age of onset in the 
late second decade for females and the fourth decade for males. Today AIP 
must be suspected in all age groups over ll years old. 
The most serious consequence of the administration of a porphyrogenic 
drug is the precipitation of an acute attack in cases of latent porphyria. It 
is difficult to estimate what proportion of the total number of porphyries will 
develop attacks after taking barbiturates, steroid oral contraceptives and other 
drugs. It is also impossible to predict whether or not an acute infection 
(Heroin addict) will precipitate an attack. Since the attacks can be extremely 
dangerous and even fatal and, once they have been precipitated, very little 
can be done to improve the outcome, the prevention of this dangerous reaction 
is of the greatest importance. 
Acute intermittent porphyria has been named "the simulator" because 
abdominal pain is frequently the presenting complaint. The pains are easily 
mistaken for manifestations of renal colic, acute appendicitis, cholelithiasis, 
or pancrea titis. It is not uncommon for patients with AIP to have multiple 
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surgical scars on the abdomen due to misdiagnosed AIP. 
A summary of the characteristic features of lead poisoning compared 
with several types of porphyrias is presented in table 39. This table could 
serve as a ready reference when the emergency laboratory is called upon to 
determine urinary ALA and PBG. 
The significant point of these experiments based on urinary PBG lies 
in the fact that this is the first report of the utilization of disposable ion-
exchange columns in conjunction with the ALA standard calibration curve. 
This unique combination results in a rapid, accurate, and quantitative deter-
mination of urinary PBG that, to date, has been absent from the clinical 
laboratories armamentarium. 
THEORETICAL CONSIDERATIONS OF AIP: IN REGARDS TO STEROID 
HORMONES: The primary lesion in acute intermittent porphyria has been post-
ulated to reside in an operator gene defect (Watson, 1964) that ultimately finds 
expression in the 11 over-production 11 of the mitochondrial enzyme delta-amino-
levulinic acid synthetase (ALAS) (Nakao, 19 66; Tschudy, 19 65). This enzyme, 
as previously discussed in the introduction, controls the rate-limiting step 
in porphyrin-heme formation (Granick and Urata, 1963). Hepatic ALAS, however 
is inducible experimentally by a variety of drugs and foreign chemicals (De 
Matteis, 1967; Granick, 1966; Marver, 1966) and recent studies from the lab-
oratories of Kappas have demonstrated that many 5 13-steroid metabolites 
derived from hormones natural to man are also potent inducers of ALAS 
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(Granick and Kappas, 1967; Kappas and Granick, 1968; Kappas, 1971). Kappas 
postulated that AIP patients might have abnormalities in steroid hormone 
biotransformation that lead to the disproportionate formation of 5 S-metabolites 
from precursor compounds. The Kappas data indicates that individuals carrying 
the genetic lesion of AIP do have an abnormality of steroid hormone metabolism 
that results in the disproportionate generation of 5 S-steroid metabolites from 
precursor hormones such as all neutral steroid hormones secreted by the 
adrenals and the gonads. These hormones have one common structural feature--
the basic steroid nucleus characteristic of 5 S-H compounds --they are all 
derivatives in which the junction of the A & B rings is of the cis, or highly 
angulated configuration. Trans configurations have no porphyrin-inducing 
activity (Kappas, 1971). This abnormality is due to a relative deficiency in 
4 
activity of the steroid hormone metabolizing enzyme D -5 o:-reductase in such 
individuals (Kappas, 1971). 
As a result of this deficiency, reductive transformation of endogenous 
steroids of appropriate structure is shunted away from the 5 a: toward the 5 S 
pathway through which metabolites having potent ability to induce ALAS are 
generated. 
These findings of Kappas define a new biochemical lesion involving 
steroid hormone metabolism in AIP and support the view that there is significant 
interplay of endocrine and genetic factors in the pathogenesis of this hereditary 
disorder. 
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Table 40 is taken from the data of Granick (1966) and lists some of 
known inducers of porphyrins that were detected in primary cultures of chick 
embryo liver cells. 
It is for these reasons that the procedure for the proper determination 
of PBG as well as the correct method to preserve its stability in urine was 
undertaken. 
The data from the present experiments indicated that urine preserved 
with tartaric acid enhanced the loss of PBG. Within 24 hours of storage, the 
urinary PBG decreased by 4 percent from control and that by the seventh day 
the loss was 28 percent. Further experiments confirmed these results. 
The percent loss of PBG from stored urine decreased as the pH of the 
urine increased above pH 7. O. It was observed that when the pH of the urine 
was 8. 0 the percent loss of PBG over a 48 hour period was 1. 0 percent. The 
data indicated that urine to be analyzed for PBG must be preserved differently 
than urine being preserved for future ALA analysis. 
The experimental evidence presented in this series of experiments 
allowed us to conclude that the random urine specimen pH must be adjusted 
to approximately 8. 0 and that it must be refrigerated, in the dark, as soon as 
pas sible after the collection. 
The present studies have indicated to us that refrigerated urinary PBG 
will remain constant up to 7 2 hours, while frozen PBG in alkaline urine will 
remain constant, in the dark, up to 8 months. 
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Previous to the advent of the use of ion-exchange column chromato-
graphy the nonspecific nature of the Ehrlich aldehyde reaction made the evalu-
ation of qualitative and quantitative urinary PBG determinations very difficult 
and very often meaningless. In a very fortunate way, PBG is distinguished 
in having a strong absorption peak at 555 nm with a weaker peak at 525 nm 
(Mauzerall and Granick, 19 5 6), the ratio of the optical densities being 0. 82. 
The Ehrlich-positive metabolites which have caused confusing results in the 
qualitative tests, are effectively removed by the anion AG-l-X8 resin. 
The possibility of obtaining false-positive results in the qualitative 
PBG tests have been reported (Ludwig and Epstein, 1961). The false results 
have resulted from indole compounds in the urine. The passage of the 0. 5 ml 
of urine through the anion column effectively eliminated all interference due 
to indole and 5-hydroxy-indoleacetic acid (Taddeini, 19 62). 
It is with anticipatory optimism that the author wishes to see the PBG 
test utilized in the clinical practice of medicine. The test should be used to 
evaluate whether a woman, placed on steroid contraceptives, is indeed a 
latent carrier of the gene. This should be done at the one, six and twelve 
month office visits after starting on the "pill". PBG should also be routinely 
determined in all patients placed on barbiturates for one medical reason or 
another and the results of such determinations should become part of the 
patients permanent medical record. 
Urinary Urea Data: Urea is the principal end product of protein 
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metabolism in the human, it usually represents 80 to 90 percent of the total 
urinary nitrogen. 
The excretion of urea is decreased in certain liver diseases, such as 
cirrhosis, in which the capacity to form urea is decreased. In cases of 
severe acidosis the amount of urea excreted maybe considerably reduced be-
cause of diversion of amino nitrogen to ammonia formation, Excretion of 
urea also maybe decreased in nephritis when the ability of the kidneys to 
excrete it is severely impaired. 
As discussed previously, the introduction of disposable, dual piggy-
back ion-exchange chromatography columns for determining urinary ALA and 
PBG allowed us to collect urea free from interfering substances. 
The quantitative determination of urinary urea would be practical, 
rapid, and inexpensive as well as being very convenient in regards to the 
patient (0. 5 ml of urine required) and to the clinical laboratory. 
The data of the present experiments is based upon the color reaction 
of modified Ehrlich 1 s reagent with urea producing a lemon-yellow color. The 
optical density is determined at 415 nm in a standard laboratory colorimeter. 
The ease of collecting the 30 ml of water washed through the column 
to remove the urinary urea from the 0. 5 0 ml urine sample afforrl ed us the 
opportunity to produce a linear calibration curve for urea. 
The average adult excretes 12 grams of urinary urea in 24 hours in an 
average volume of 2, 000 ml. For the data on 95 percent confidence limits, the 
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present studies indicated a mean of 6. 9 6 mg of urea in a 0. 5 ml urine .sample 
while the data showed 15. 3 5 mg of urinary urea as being the upper limit of 
normal. There was no difference noted in the age of the adult nor his sex. 
The experiments determining the 95 percent confidence limits of ALA, 
PBG, urinary pH, and urinary urea showed the upper limit of normal to be 
0.54 and 0.20 mg percent, respectively, for ALA and PBG and 6.88and15.35 
for pH and mg urinary urea. 
The present studies indicate that disposable ion-exchange chromato-
graphic columns can be employed for the isolation of urea from the urine in a 
manner which permits a rapid, accurate, and quantitative test procedure to 
be performed. 
An advantage of the colorimetric determination is in the visible spec-
trum with regard to a large-scale screening program dealing with a vast number 
of samples. Normal values of urinary urea produce a light lemon-yellow color 
while abnormally high urea produce a definite and distinct bright lemon-yellow 
color. It is therefore possible to immediately eliminate all non bright yellow 
colors as being of normal urea values. 
If kidney disease or urinary obstruction causing decreased amounts 
of urinary urea are detected, or if acute nephritis, pyelonephritis, renal tuber-
culosis, renal cortical necrosis, malignancy or chronic gout are suspected, 
then it becomes critical to have an accurate, rapid, quantitative test procedure 
to determine urinary urea. The goal, in this case, is the detection of 
184 
potentially toxic manifestations of kidney disease in asymptomatic individuals. 
Another use for quantitating urinary urea would be to reflect the level 
of dietary protein intake or to reflect the degree of adherence to a specific 
protein-restricted diet. Another use would be for determining the presence of 
unrecognized catabolic stress. 
Finally, one must remember the urinary urea value is affected by the 
level of renal function and the rate or urine flow. It is also affected by the 
net breakdown of body protein. 
C. DELTA-AMINOLEVULINIC ACID TISSUE LEVELS FOR POST-MORTEM 
ANALYSIS 
Lead is absorbed into the human organism by respiratory and digestive 
routes and is distributed to organs and tissues by the bloodstream. As a 
result of growing industrial use and the introduction of alkyl lead compounds 
such as gasoline additives, exposure to lead is substantially above the back-
ground of absorption from food and drinking water. Experimental and epidem-
iological data point to a logarithmic correlation between the concentration of 
lead in the air and that in the blood of exposed individuals suggesting that, 
· in man, lead can accumulate as a result of increasing environmental contam-
ination. Needless to say that childhood lead poisoning with true ingestion of 
lead-containing paints presents an environmental problem that must be con-
stantly searched out and eradicated. 
To date, there is no data correlating tissue ALA levels with lead 
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ingestion. This unique finding is missing from the literature because there is 
a lack of a rapid and practical laboratory method for quantitative determination 
of ALA levels in post-mortem tissue specimens. One can determine lead levels 
in tissue but the analysis is so very cumbersome that for manpower reasons 
alone, most laboratories avoid determining lead. 
There is no literature on ALA tissue levels as a means to diagnosis lead 
poisoning in the post-mortem period. In fact, ALA tissue levels for any diseasE 
or toxicology related mishap is non-existent in the literature. 
The data of the present experiments shows that urinary ALA increases 
with time after a single subcutaneous dose of lead acetate had been administer-
ed. It should be pointed out once again that the urinary ALA increased after 
one exposure to lead - and the ALA remained elevated. If blood lead was 
determined it probably would show normal due to the deposition within the bone 
The time required to complete the total tis sue analysis, excluding 
the freezing time, is under 2 hours. It therefore became, for the first time, 
a very easy and rapid determination of ALA. The urinary ALA standard calibra-
tion curve served as the reference for these tissue ALA level determinations. 
The method, as the data indicates, gave over a 92 percent recovery of added 
ALA to control tissues, indicating an accurate method. 
The control levels of tissue ALA ranged from 0. 02 microgram/gram for 
adipose tissue to a maximum of 0. 53 microgram/gram for the tail of the epidi-
dymis. After a single subcutaneous injection of 200 mg/kg of lead acetate, 
the bone marrow averaged 24. 6 microgram/gram while the kidney averaged 
10. 9 micrograms/gram 58 days after the one-time injection. 
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The greatest accumulation of ALA occurred in the bone marrow which 
approximated a 100 fold increase in ALA over control values. The kidney showed 
an average of a 27 fold increase over control. In all of the experiments the 
bone marrow consistently had a higher quantity of ALA accumulating per dose 
of lead acetate administered followed very closely by the kidney -- one must 
keep in mind the fact that this data is based upon a single subcutaneous dose 
of lead acetate. 
It is always of interest to compare the dose of lead that was administer-
ed to the rabbit to that dose a child may be exposed to in a 3 month period 
(the average time required for a child, with pica, to demonstrate signs and 
symptoms of lead intoxication). As has been discussed in the Introduction, 
a chip of paint about the size of an adult's thumbnail can contain between 50 
and 100 milligrams of lead. If the child only eats 3 chips of paint per day for 
a period of 9 0 days and if the lead content of those paint chips averages 7 5 
milligrams (225 mg/day dose) he will ingest 20, 250 milligrams of lead~ 
He absorbs 10 percent of this dose or approximately 2000 milligrams of lead. 
If the child weights 10 killiograms, he will have given himself a dose of 2 00 
mg/kg - the same dose used in the animal experiments -- except the dose is 
being administered over a 90 day period. 
The accumulation of ALA in the bone marrow and kidney and its physio-
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logical effects have not been studied to date. This avenue of research appears 
to be most needed and most rewarding if we are to understand the full meaning 
of lead intoxication. 
D. DELTA-AMINOLEVULINIC ACID DEHYDRASE (ALAD) LEVELS IN THE RAT 
BEARING THE WALKER 256 CARCINOSARCOMA 
I would like to begin this section with a quote from J.B. Sumner (1950) 
who said "One way of defining life is as an orderly functioning of enzymes. 
Disease manifests as a disorder, inhibition, or hyperfunction of enzymes". 
The unique finding of greatly increased ALAD activity in parallel with reticulo-
cyte formation in the rat bearing the Walker tumor certainly fits the last part 
of Sumner's quote - hyperfunction of an enzyme. 
The general concept behind most chemical studies of tumors is that 
there must be, at the origin of neoplasia, some fundamental change(s) in 
cell chemistry. If such change(s) were revealed, therapeutic means could be 
attempted, probably with much greater chances of success. The change is 
believed by many to occur in the enzymes which regulate cell metabolism 
and cell function. It is not known whether the cause of cancer resides in 
abnormal cell metabolism or, more specifically, in altered enzymatic proper-
ties and whether it represents a gain or a loss of a given substance(s). 
The bulk of the data accumulated on enzymatic properties of tumors 
has been obtained by biochemical analyses of tissue homogenates or tissue 
slices. Such methods, which include a great number of precise quantitative 
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procedures, have contributed greatly to a better knowledge of many processes 
in living organisms. 
Recently biochemists have become progressively aware of the limit-
ations of chemical assays on homogenates or tissue slices. Their conclusion 
was that enzyme activities present in homogenates represent, in a majority 
of cases, the mean of the activities of several cell types and that of extra-
cellular elements. In such cases, variations in mean activities may reflect 
not only the changes in the enzyme activities of several tissue elements, 
but also those resulting from changes in the relative proportions of various 
structural elements. 
The methods utilized in the present studies assured us of pure Walker 
tumor cells in the proportion of 9 8 percent tumor cells to 2 percent extra-
cellular elements. This data was obtained by careful microscopic examination 
of the growing tumor as well as cell suspensions from it. 
Previous studies on ALAD have focused on lead-poisoning and the effect 
of lead upon the inhibition of the enzyme. Many authors have discussed ALAD 
but always in relation to lead poisoning, some of these authors besides those 
mentioned in the Introduction include: Granick and Mauzerall (1958), Lichtman 
and Feldman (1963), Bonsignore {1966), de Bruin and Hoolboom (1967), de Bruin 
(19 68), Nakao et al (19 68), Chisolm (1970), Hemberg et al (1970), Hernberg and 
Nikkanen (1970), Millar et al (1970), Deutsch (1971), Burch and Siegel (1971), 
Haeger-Aronsen et al (1971), Esham and Avent (1972), Moore (1972), Padmanaban 
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and Malathi (1972), Goldberg (1972), Granick and Sassa (1972), Hernberg et 
al (1972), Morgan and Burch (1972), Kao and Forbes (1973), Tola et al (1973), 
Mcintire et al (1973), and Oski (1973). 
The unique feature of this study, outside of the fact that ALAD has never 
been studied as an indicator of the neoplastic process, was that we did not 
study slices or homogenates from the Walker tumor. The experimental data 
was based on the hemopoietic effects of the in vivo tumor or homogenates 
from it. The biological effects we studied were two in number: 1) increased 
degree of reticulocytosis and 2) elevation of ALAD activity. As has been 
discussed in the Results chapter other hemopoietic factors were also studied 
but they served only to highlight the unique biological activity of the enzyme. 
It is hoped that the control of enzyme levels in normal and pathological tissues 
may be a field of enzymology which will flourish in the coming years. 
Of great interest to neoplastic studies is the fact that with the growth 
of the Walker tumor there is an alteration of the enzyme pattern of cells (re-
ticulocytes) coming from the bone marrow of the tumor host. This elaboration 
of cells into the circulation with concomitant enzyme activity appears to be a 
documentation of such an enzyme-tumor interaction that Bodansky began 
searching for in 19 60. 
Another point of interest to the clinical laboratory is the fact that the 
enzyme activity was always found in whole blood and never in the serum or 
plasma. 
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Chart 24 illustrates the effect of the growing Walker tumor on the 
increased degree of reticulocytosis and increased ALAD activity. It is of 
interest to note two things about this chart: 1) the similarity and parallelism 
of the ALAD activity curve with the percent reticulocyte curve and 2) the 
immediate and rapid elevation of these two parameters before any growth of 
the tumor could be detected, as well as their persistence throughout the time 
of the growth of the tumor. 
ALAD activity increased 117 percent over control within 24 hours after 
transplantation of the tumor and rose to 619 percent by day 4, the first day of 
palpable tumor growth, rising to 2, 000 percent over control on day 20, the day 
of termination of the experiment. The reticulocyte count increased 70 percent 
within 24 hours and rose to 3 87 percent by day 4, rising to 2, 3 00 percent 
over control on day 20. 
The fact that the ALAD activity rose to 619 percent over control by day 4 
after transplantation of the tumor makes one want to speculate about the avail-
ability of any other enzyme systems that respond so quickly to a beginning 
neoplastic process in the host. To date, no literature data can supply this 
information with which to compare ALAD activity. 
The fact that reticulocytosis was occuring in such magnitude lead us 
to believe that the Walker tumor was excreting erythropoietin. We also thought 
we may have an excellent model for the control of tissue development within 
the tumor with an endogenous indication - ALAD activity. 
191 
We determined erythrocyte counts to evaluate if there was, in fact, 
a process of erythropoiesis occurring. By definition, the process is one of 
production of erythrocytes with concomitant increases in red cell count, hemo-
globin, and hematocrit. If erythropoietin was being excreted by the Walker 
tumor it would take an interval of five days before the appearance of an increas-
ed blood reticulocyte count would occur. Five days is the length of time re-
quired for maturation of erythroblasts from the earliest cell to the reticulocyte 
{Yoffey, 1957). 
Chart 2 6 is a composite chart showing the effect of a growing sub-
cutaneous tumor on the host. It is of interest to note several items from this 
chart: 1) the immediate response of reticulocytosis and increased ALAD activity, 
2) the red cell count consistently decreased per unit of time, starting with 
an initial value of 5. 8 million per cubic millimeter and finishing with 2 million 
per cubic millimeter on day 20, and 3) the hemoglobin and hema tocrit decreased 
in parallel with the decreasing red cell count. The data indicates a severe 
destruction of red cells from the moment the Walker tumor is transplanted. 
The data indicates there is no process of erythropoiesis occuring 
because of the immediate response of reticulocytosis to the transplanting 
of the tumor and most important of all, the immediate destruction of red cells 
with a parallel decrease in hemoglobin and hematocrit. 
To date there is insufficient evidence to be certain that the bone 
marrow is the principal site for the inactivation or degradation of erythropoietin 
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but one would like to speculate on the induction of factor(s) caused by the 
Walker tumor which may be responsible for the apparent shut-down of the bone 
marrow in the tumor host. 
The data indicates that the primitive bone marrow cells are being in-
hibited, by the growing Walker tumor, from the day of transplantation to the 
day the animal dies. It would be interesting to investigate the effect the 
growing tumor has on the development of the erythron (i.e. the red cells and 
the erythroblasts in the marrow or spleen) and the development of the stem 
cells (i.e. those cells which reproduce themselves and give rise to the ery-
thron). The question of selectivity of the factor(s) from the tumor would have 
to be investigated. 
The question arises how does the growing Walker tumor affect the 
kidney, the major site controlling the production of erythropoietin. Would 
this effect of the tumor affect the basic cellular integrity of the renal tubules 
etc? Could one detect these changes using a light microscope? 
It would be of interest to determine if the tumor excretes anti-erythro-
poietin antibody. 
It should be pointed out that no attempt was made to isolate the factor(s 
from the Walker tumor which produced the reticulocytosis and increased ALAD 
activity. 
The extreme immaturity of the reticulocyte was noted in the peripheral 
smears stained with New Methylene Blue-N. It normally takes 24 hours for 
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a reticulocyte to mature once in the circulation (Finch, 1959) - that is a loss 
of reticulum. In the preparations from these experiments the reticular network 
filled the cells in an evenly distributed pattern indicating very immature 
reticulocytes. 
The preponderance of reticulocytes in blood smears, studied throughout 
the total experiment, demonstrated up to 65 percent of the total cell count 
consisted of reticulocytes, indicating the biological response to malignant 
tumor growth. 
We turned our attention to water soluble cell free extracts of the 
Walker tumor when it became clear that the results of these experiments 
indicated a positive correlation in the tumor-host between ALAD activity 
and reticulocytosis. The objective of the water extract experiments was to 
determine whether or not cell-free homogenates could produce the same effect 
on increased ALAD activity and reticulocytosis. The control in these exper-
iments was soluble cell free water extracts of normal rat liver. 
Malignant Tumor Extracts: The concept of studying the effect of tumor 
extracts was originated in 1947 with the work of Gross (1947) who reported 
that hemolysis occurs when centrifuged or filtered extracts prepared from 
spontaneous mouse mammary carcinomas were mixed with mouse erythrocytes. 
He found that the hemolysis was specifically directed against mouse red blood 
cells and no hemolysis occurred when these extracts were mixed with other 
species blood cells including human. 
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In 1948 Gross showed that extracts made in a weight to normal saline 
ratio of 1:20 could be heated up to 68 C for over 30 minutes without any loss 
of hemolysis activity. Heating the extracts over 68 C destroyed the hemolytic 
potency. 
Experiments were conducted using the transplantable mouse sarcoma 
180 extracts. These results matched the original data of the mammary carcinoma. 
Gross studied extracts from normal, healthy mouse organs on mouse 
erythrocytes in vitro. Extracts were prepared from mammary glands, liver, 
kidneys, spleen, and lungs. The technic of these experiments was identical 
with that used for the tumor extracts and the results were all negative --
neither hemolysis, nor agglutination resulted from these tests (Gross, 1948). 
Reynolds and Friedell (1963) studied extracts of hamster sarcomas. 
They use separate saline extracts of the necrotic and viable portions of the 
tumor for their studies. The active material in the tumors that caused hemo-
lysis was localized to the viable tumor tissue. 
The evidence presented in the paper suggests that the hemolytic agent 
is a protein or that it is bound to a protein. It does not pass through a dialyzin<~ 
membrane. The factor is soluble in ether and this implies a lipid-protein 
complex. 
Sohier et al (19 57) have shown by repeated determinations of red cell 
survival how the onset of hemolysis correlates closely with the beginning of 
rapid host deterioration. 
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Knowledge of what causes a progressive decrease in the viability of 
the erythrocytes at the time of rapid clinical deterioration might help us under-
stand how the last barriers of host resistance are destroyed. 
In the natural history of neoplastic disease, decreased red cell pro-
duction has been ascribed to a tumor toxin, to replacement of bone marrow 
cells by tumor, to disturbances in protein synthesis including globin, to 
inadequate intake or storage of hematinic factors such as vitamin s12, iron, 
or folic acid due to malnutrition or extensive liver metastases (Hyman, 1954). 
In the many patients dying of cancer where massive hemorrhage, in-
fection, or destruction of vital organs does not take place, the direct cause 
of death still remains unknown, so it still remains a valid research question 
to answer. 
Normal Liver Extracts: Soergel and Friedel! (19 64) investigated the 
concept that chronic, progressive liver disease is perpetuated by production 
of autoantibodies. The extracts were prepared in saline from normal rat livers. 
The investigation studied single versus multiple (subcutaneous) injections, 
serum e.lectrophoresis, agar double diffusion, and hemagglutina ti on tests to 
detect any appearance of antibodies. 
The results of this study were that liver extracts did not give rise to 
specific liver lesions, serum protein changes, or the appearance of antibodies 
to the water soluble components of liver tissue. Repeated injections and 
variations in the age of the experimental animals did not alter these negative 
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results. 
Soergel and Friedell conclude that the search for an experimental 
model for the production of autoantibodies to liver tissue and autoimmune liver 
disease has, so far, not met with success. They also proved how innoxious 
water soluble liver extracts are on the experimental animal so injected. 
The data of experiments indicated that cell-free homogenates of the 
Walker tumor did cause an increase in ALAD activity with concomitant increase! 
in reticulocytosis. After a single cardiac injection of 100 mg/kg of 105, 000 x g 
unheated, lyophilized tumor extract two things were noted: 1) the reticulocyte 
count reached the highest percentage at day 2 and 2) ALAD activity reached 
its highest activity at day 8. It is of interest to note that both of these 
parameters return to normal values by day 20. 
Chart 28 illustrates the effect of a single intra-cardiac injection of the 
water-soluble tumor extract. The body weight, red and white cell count as 
well as the hemoglobin and hematocrit remain relatively stable and constant 
with a slight depression in the red cell count. The increase in ALAD units 
and reticulocyte percent remain the only significant parameters affected by 
the tumor extract. 
These water extract experiments held the potential, in the cell-free 
aquoeus solution of the lyophilized tumor, to reveal any erythropoietin or 
erythropoietin-like activity that may have been masked by the great destruction 
of red blood cells that occurs with the growing tumor in vivo. It is obvious, 
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from the data, that no such activity could be elicited. 
It should be observed in Chart 27 that the reticulocyte count has 
returned to control levels ---- in marked contrast to the reticulocytosis 
obtained when there if an in vivo malignant tumor. 
The potential arguement that the simple procedure of injecting an 
aqueous protein solution, via the intra-cardiac route, was the cause of the 
release of reticulocytes from the bone marrow with concomitant increase in 
ALAD activity was rejected by the normal liver extract data. As shown in 
Chart 28, there was no change in any of the parameters measured during the 
20 day period. 
Essentially, all the change is noted with the animals given the tumor 
extract while no change is observed with the liver extract injected animals. 
As stated in the Results section, the data indicates that the growing 
Walker tumor produces a stimulating substance (s) that initiates a great increase 
in ALAD activity with a concomitant increase in reticulocytosis. 
The immediate and unique elevation of ALAD activity in parallel with 
reticulocyte formation before tumor growth becomes detectable suggests an 
' 
early tumor-host relationship that may be unique in the early detection of 
neoplastic disease. 
Recently, Emmanuel Farber (1973), the president of the American Assoc-
iation for Cancer Research said in his presidential address that work in his 
laboratory has shown the rise in serum a-fetoprotein coincides with the 
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early appearance of nodular hyperplasia. 
One of Farber's collegues, Dr. Oki ta, has now found that the reappear-
ance of a-fetoprotein often occurs before any recognizable malignant 
neoplasia appears. Farber is very excited about this property of malignant 
neopla sia appearing well before cancer can be detected. 
The data from the current experiments suggests that the unique elevatio 
of ALAD activity, in every experiment, before tumor detection may serve, in 
conjunction with the a-fetoprotein, as a dual means of detecting a neoplastic 
cell population at the molecular level. 
As data is gained in the field of enzymes in cancer, one hopes that soon 
an order in which certain events occur prior to the actual appearance of overt 
neoplasia will be discovered. This discovery will allow the pharmacologist 
to turn off the sequence of events leading to neoplasia by pharmacological 
inhibition of the rate limiting enzymes. The key question to be answered in 
the future is - when in the cellular evolution of a neoplastic process do the 
rate limiting enzymes begin to be expressed. Then we must answer the obvious 
question of what might the mechanisms be for the encouragement of growth 
of selected populations of cells that have the enzymes of the neoplastic 
process without involving the whole organ or tissue population. 
Farber (1973) states "If we are to understand the essential nature of 
neoplastic development, we must begin to identify, isolate, and study the 
different cell types that seem to be the key precursors from which the malignant 
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neoplasm is ultimately derived". We believe the discovery and study of en-
zymes such as ALAD will contribute to a small part of the understanding process 
Farber speaks about. 
It is obvious that researchers are attempting to discover the one 
mechanism that triggers the neoplastic process to begin. We have studied the 
result of a growing neoplastic tumor - but somehow, someway the two processeE 
must be related. We realize the severe limitations imposed upon the specula-
tions discussed. 
Some other speculations the current studies have generated include 
the possibility that many zymogens that are not normally detected in whole 
blood are activated at the time of transplantation. Could there be cleavage 
of peptide bonds to open up cyclic peptide structures, or the cleavage of 
portions of the enzyme proteins with loss of these portions as peptides result-
ing in increased ALAD activity? 
Could there be an induction of a coenzyme which associated with ALAD 
facilitates the enzyme reaction more efficiently and maybe improves the 
enzyme activity? 
Could such ions as Ca, Fe, K, Mg, Mn, Na, or Zn become activators 
of the ALAD as a result of the transplantation process? These ions were 
chosen because they are known to be loosely bound to enzymes versus Mo, 
Cu and Co which have been found to be non-dissociable (Bray and Harrap, 
19 59). 
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E. FACILITATION OF GROWTH OF THE WALKER TUMOR AFTER PRE-TREATMENT 
WITH WATER EXTRACTS OF THE TUMOR 
The data reported in the current investigation is the result of the exposure 
of the author to cancer research. 
The original objective of pre-treating a future receipent of a Walker 
tumor with water soluble cell-free tumor extracts was to cause rapid rejection 
of the transplanted tumor. It was obvious that if facilitation of tumor growth 
occurred as a result of such manipulations of the tumor-host then the data so 
received would be treated as a bonus. 
The data of the present experiments indicates a phenomen occurring 
that is similar to the production of antilymphocytic serum (ALS). The data 
also is completely opposite to that which ALS is founded - that is ALS is 
raised in one species against the lymphoid tissues of another, e.g. rabbit, 
goat or horse anti-mouse. In general ALS is specific to the species against 
which it is raised. The most widely used animals for raising sera are rabbits, 
goats and horses. Usually the antigen is derived from spleen, lymph nodes 
or thymus lymphocytes. Normally ALS is raised by injecting 109 mouse 
thymus lymphocytes intravenously into each rabbit; the injection is repeated 
14 days later and after a further week the rabbits are bled out. The serum is 
separated, decomplemented, absorbed with mouse erythrocytes to remove 
hemeagglutinins and sterilized by filtration; it can be stored indefinitely 
at -20 C. 
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The present experiments were opposite to ALS in the following manner: 
1) No lymphocytes or cells from the tumor host were used: 2) No injections of 
any cells were made into the host-to-be or into another species of animal, 
and 3) No collection of serum was attempted nor was there any interaction with 
rat erythrocytes. 
The method of pre-treatment is fully explained in the Materials and 
Methods chapter under the section "Effect of pretreatment with Walker tumor 
extracts on growth of solid tumors in the rat". It is enough to say that cell-
free, lyophilized tumor and normal liver water extracts were used in these 
studies. 
The results obtained were identical to those one would expect if he had 
used ALS - that is a facilitation of growth of the transplanted subcutaneous 
growing tumor. In fact, by the sixth day after transplantation, the tumor 
extract pre-treated animals had a 200 percent increase in tumor volume over 
the control litter mate tumor bearing rats. This percentage increased to 
approximately 3 00 percent by day 12. 
To date ALS has proved to be one of the most useful laboratory tools for 
elucidating the basic physiology of the immunological processes - such as that 
ALS coats the lymphocyte surface, preventing contact with antigens. It is now 
established that ALS acts by eliminating from the circulation that pool of lym-
phocytes which is long-lived and derived from the thymus (T-cells) (Taub and 
Lance, 19 68). ALS was first used by Starzl (19 68) and his colleagues in Denver 
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in renal and liver transplantation studies as a powerful immunosuppressant 
which worked very effectively. 
The current studies do not indicate we have anything approaching an ALS 
type of activity. It does, however, allow us the opportunity to speculate 
on many subjects using the ALS experiments of Starzl (19 68) as a reference. 
Would the pretreatment of the tumor receipent with tumor extracts inhibit 
the rat's cellular immune processes? Could this method be used to prolong 
the survival of homografts in the rat? Is this pretreatment applicable to 
transplantation research? 
An interesting question is does the water extract treatment prevent the 
action of host antigens against the growing tumor. The data comparing the 
growth of the tumor in pretreated rats to their brother ~itter mates indicates 
the treated animals offered little resistance to tumor growth. For example, 
on day 6, after transplantation, the control, untreated rats, had a tumor volume 
of l, 650 cubic centimeters while the treated animals had a tumor volume of 
4, 9 28. On day 12, the data became even more impressive: control tumor 
volume equaled 18, 682 while the pre-treated group measured 73, 360 cubic 
centimeters. We could ask if the host's immunological memory had been 
erased. 
Another interesting question would be based on the use of several doses 
of the cell-free tumor extract. First what would happen to the host -- would 
tumors be established that normally the body rejects? 
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Finally, one would like to think there may be a very small possibility 
that cell-free water extracts of the tumor could be used as a test to give a 
rapid indication of tumorigenic potential of experimental protocols in rat 
tissue culture cells. Today the use of newborn hamsters with inoculation into 
cheek pouches are the biological tool of research. This process could take up 
to several months. 
CHAPTER V 
SUMMARY 
I ) 
CHAPTER V 
SUMMARY 
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1. The method for the isolation of urinary ALA from random urine specimens 
has been modified utilizing a one-column disposable chromatographic 
unit prefilled with resin that can be conveniently held in a support rack 
over a drain tray. 
2. The screening for lead poisoning is divided into two routes utilizing the 
one-column or the dual piggyback column unit. It is suggested that the 
pediatric population be screened utilizing the one-column unit because 
PBG is not excreted in this age group while the dual piggyback column 
unit is to be used for screening an adult population. 
3. It was determined that the cation resin bed height of the one-column unit 
had to be reduced to half of its expected bed height -- from 4 cm to 2 cm 
keeping the diameter constant at O. 6 cm -- for maximum elution of ALA. 
4. The recovery of ALA in the range of 5 to 40 µg when added to normal random 
urine averaged 94. 68 percent for the one-column unit as compared with a 
93. 58 percent recovery from the dual piggyback unit. 
5. The recovery of ALA using the one-column method was not affected in 
urines preserved with tartaric acid, even if the urine was stored in the 
dark at 4 C for a period of 28 days or longer. 
6. The amount of urinary urea remaining on the one-column unit after washing 
the column with distilled water was determined by eluting the urinary 
ALA and urea with lM sodium acetate, forming an ALA pyrrole with acetyl-
acetone and then adding modified Ehrlich's reagent. After 15 minutes 
reaction time, the color absorbance of urinary urea was determined at 
an optical density of 415 nm. Theoretically, urea should be completely 
wa.shed through the cation resin column but in reality a minute amount 
may adhere to the column (less than 0. 50%). It was determined that 
35 ml of distilled water would give an O.D. of 0.013 at 415 nm in compar-
ison to an O.D. of 0.025 obtained from the dual piggyback commercial 
column unit, washed with 30 ml of water as directed in the ALA test kit. 
7. The ALA standard calibration curve can be accurately produced in sodium 
acetate, normal urine, or in distilled water with essentially similar 
I 
results. The method utilizing lM sodium acetate is rapid, accurate, 
and reproducible and is utilized throughout this dissertation. 
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8. Recovery of ALA from random urine is critically dependent upon the pH 
of the urine sample. It was found that recovery of ALA was reduced 
when the pH of the urine specimen was 7. 0 or above. It is suggested 
that the pH of all urine samples applied to the one and dual piggyback 
column uni ts be 6. 0 or below. 
9. The color formed with the ALA-pyrrole and modified Ehrlich's reagent pro-
duces a maximum absorption at 553 nm. A Beckman spectrophotometer, 
model DB-G, was utilized throughout this study to determine the 
absorption spectra of the urine or tissue sample being studied. 
10. 3M tartaric acid was found to be an excellent preservative for urine 
being analyzed for ALA. It was found that 0. 20 ml of a 3M solution of 
tartaric acid, in water, would lower the urine pH to 4-5 and that this 
pH would remain constant, even upon storage of the urine sample for 
28 days at 4 C in the dark. It was also determined that tartaric acid did 
not affect the recovery of urinary ALA from one or dual piggyback column 
units. The recovery of urinary ALA, from one-column units, after being 
preserved for a period of 28 days at 4 C in the dark averaged 95 percent. 
11. The maximum absorption of PBG when condensed with DMAB in acid 
solution occurs at 555 nm with a shoulder at 525 nm. If pure PBG is 
present in a sample, a ratio of A525/ASSS will be approximately O. 83. 
In all studies carried out in this dissertation the determined PBG always 
had a ratio of 0.80-0.83. 
12. Pure crystalline PBG was isolated from the urine of a 21 year old female 
patient with acute intermittent porphyria. The standard quantitative 
curve obtained with the human PBG matched identically the standard 
calibration curve obtained with synthetic PBG supplied through the 
cooperation of Bio-Rad Laboratories, Richmond, California. 
13. The color reaction that develops with PBG and modified Ehrlich's reagent 
is stable for a period beyond one hour while the color developed with 
unmodified Ehrlich's begins to fade within the first 15 minutes of the 
reaction. The reaction with modified Ehrlich's assures one of a constant 
optical density for an extended period of time. 
14. Guidelines for the quantitative interpretation of urinary PBG values were 
-----establsihed. The urinary PBG code is divided into 7 classifications 
ranging from normal to 5 plus. The similarity to porphyria is graded 
from none to overwhelming. 
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15. The data on preserving urine with tartaric acid for later PBG analysis 
indicated that urinary PBG decreased 4 percent within 24 hours of storage 
and by the 7th day the PBG loss was over 25 percent. The data indicates 
the hazard in preserving urine samples, intended for PBG analysis, 
with tartaric acid -- or any other acid media. 
16. It was found that the urine intended for PBG analysis must be adjusted 
to pH 8. 0 with sodium carbonate. If the urine is so adjusted then the 
PBG loss in 48 hours of storage is approximately l. 0 percent. By 
observing this procedure, refrigerated urinary PBG will remain constant 
for a period of 72 hours. If one elects to freeze the alkaline urine, the 
PBG will remain constant, in the dark, for a period of 8 months. 
17. A method was devised to convert mg percent ALA to mg percent PBG 
utilizing the ALA standard calibration curve. One plots the ALA curve 
and determines the optical density of the PBG sample in modified Ehrlich's. 
By drawing a horizontal line from the 0 . D. ordinate to the ALA curve 
and then drawing a line at a right angle to the abscissa will give one the 
mg% ALA. The value of mg% ALA is then multiplied by the conversion 
factor of 3. 53 in order to obtain the mg% PBG in O. 5 ml aliquot bf urine. 
Therefore, mg% PBG = mg% ALA x 3 . 53. It should be noted that this is 
a rapid, quantitative method to determine urinary PBG. 
18. The utilization of the dual piggyback column unit to remove all interfering 
substances from a 0. 50 ml urine sample allowed pure urinary urea to be 
washed from the unit with distilled water. Modified Ehrlich's reagent 
was added to the urea-water solution and the resulting lemon-yellow 
color absorption was determined at 415 nm against a reagent blank. The 
color developed is stable and will remain so for an extended period of 
time. 
19. The 9 5 percent confidence limits were determined for human urinary ALA, 
PBG, pH, and urea. The upper limit of normal for urinary ALA and PBG 
is O. 54 and 0. 205 mg percent, respectively. For urinary pH the value 
is 6.88 and for urinary urea it is 15.35 mg percent. 
20. Post-mortem determination of tissue levels of ALA in lead-poisoned 
rabbits utilized the unique idea of using dual piggyback disposable 
column chromatography units. This method afforded an opportunity to 
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easily quantitate ALA in a manner never achieved before. 
21. A single subcutaneous injection of lead acetate steadily increased the 
excretion of ALA in the lead-poisoned rabbit over a period of 58 days. 
The upper limit of normal for urinary ALA in rabbits was found to be 0. 05 
mg percent. After the single injection of 200 mg/kg of lead acetate the 
urinary ALA reached a level of approximately 3. 0 mg percent at 58 days 
post injection. 
2 2. One gram of tissue was considered to be sufficient for the analysis of 
tissue ALA levels. 
23. The time required for complete analysis for tissue ALA, excluding the 
freezing step, was approximately two hours. 
24. The recovery of ALA added to normal liver homogenates from one gram of 
tissue averaged 92 percent. The amount of ALA added ranged from 2. 5 
to 20 µg per gram of tissue being analyzed. 
25. Control levels of tissue ALA in 21 tis.sues of non-treated adult rabbits 
ranged bet~. 02 microgram per gram for adipose tissue to 0. 53 
microgram per gram for the tail of the epididymis. 
26. It was observed that after a single subcutaneous injection of lead acetat~, 
a marked progressive increase in the levels of ALA was noted in the bone 
marrow and kidney of the lead-poisoned rabbit. 
27. 21 tissues of the lead-poisoned rabbit were studied for accumulation of 
ALA and it was found that the bone marrow had the highest content of ALA 
of all the tissues studied averaging 24. 6 micrograms per gram wet weight 
of tissue. The level of ALA found in the kidney was 10.9 micrograms per 
gram, while corresponding values for the spleen, lung, and tail of the 
epididymis were 1. 50, 1. 25, and 1. 05, respectively. All of the remaining 
tissues studied were found to have an MA content below 0. 7 microgram 
per gram wet weight. 
28. The greatest accumulation of ALA occurred in the bone marrow which 
approximated a 100 fold increase in ALA over control. The kidney displayec 
an accumulation of ALA amounting to a 27 fold increase over control. 
29. Studies were completed showing that ALA accumulation in the bone marrow 
and kidney were dose dependent on the lead acetate injected. 
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30. It was concluded that the bone marrow and kidney served as excellent 
tissues to determine ALA levels in the post-mortem diagnosis of lead 
poisoning. 
31. Aminoacetone £) was determined because there was a doubt whether or 
not AA was pro uced in the lead-poisoned animal. Both ALA and AA 
pyrroles are dete mined at an absorption of 553-555 nm, consequently, 
AA could influence the final result of the ALA determination by adding to 
the total color reaction. 
32. AA pyrrole and ALA pyrrole, both formed by the condensation with acetyl-
acetone, are separated from each other by means of an anion AG-1-XS 
column. Once the pyrroles have been separated they can be individually 
reacted with modified Ehrlich's reagent and ALA can be quantitated by 
referring to the ALA standard calibration curve. Aminoacetone is deter-
mined mathematically. 
33. Urinary AA averages about 2 percent of the total final color of the two 
pyrroles added together when reacted with modified Ehrlich's reagent. 
It can be concluded that 98 percent of the observed optical density 
obtained in the urinary ALA analysis is due to pure ALA and that the 
amount of aminoacetone present is there only in insignificant amounts. 
34. The percent of final color due to aminoacetone in tissue samples from 
lead-poisoned rabbits was determined. The average percent of color 
due to AA in the kidney, bone marrow, spleen, and liver averaged 0. 39 
percent. The kidney and bone marrow each averaged 0. 01 percent. 
The data suggests that the aminoacetone pyrrole does not add any increasec 
color to the two tissues suggested for post-mortem analysis of ALA for 
lead-poisoning -- namely the bone marrow and the kidney. Aminoacetone, 
therefore, can be ruled out as an interfering biological compound. 
35. The study of an enzyme of the heme biosynthetic pathway -- namely delta-
aminolevulinic acid dehydrase (ALAD) was undertaken in the Sprague-
Dawley rat bearing the Walker 256 Carcinosarcoma. This study was 
originated to find some clue to the anemia of cancer and in particular 
to determine if ALAD was being inhibited by the growing tumor resulting 
in host anemia. The concept of studying a hematopoietic enzyme such as 
ALAD appeared to be unique and warranted further investigation. 
36. At the time the ALAD studies were initiated in tumor bearing rats a study 
of other hematology factors was also begun -- namely determining red 
and white cell counts, hemoglobin, hema tocrit, body weight, tumor 
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volume and percent reticulocytes. The most significant factor determined 
from these other studies was the reticulocyte count. 
37. A method was devised for the transplantation of the Walker 256 Carcino-
sarcoma. 
3 8. ALAD enzyme activity was localized to the red blood cell. 
39. The growing tumor becomes slightly palpable at 4 days after transplant-
ation and increases to a maximum of 111, 000 cubic millimeters at 16 
days after which the tumor becomes inaccurate to measure. 
40. Immediately after trij.'rtsplantation and 4 days before the transplanted 
tumor becomes palpabl\, ALAD activity increases over control values 
as well as does the reticulocyte count. 
41. ALAD activity increased 117 percent over control within 24 hours after 
transplantation and rose to 619 percent by day 4, the first day of palpable 
tumor growth, to l, 440 percent by day 16, the last day to measure the 
tumor accurately, rising to 2, 000 percent over control on day 20, the final 
day of the experiment. 
42. The reticulocyte count increased 70 percent over control within 24 hours 
and rose to 387 percent by day 4, to l, 822 percent by day 16 rising to 2, 30) 
percent over control on day 20 after transplantation. 
43. Two things are noted about the growth of the Walker tumor in vivo: 
1) the similarity and parallelism of the ALAD units curve with the percent 
reticulocyte curve, and 2) the immediate and rapid elevation of these 
two parameters before any growth of the tumor could be detected as 
well as their persistance throughout the time of the growth of the tumor. 
44. The concept of the Walker tumor excreting erythropoietin was ruled out 
by the fact that at no time, from the moment of transplantation to the 
time of death of the tumor host, did the red cell count increase nor did 
the hemoglobin or hematocrit levels. All of these factors decreased with 
onset of tumor growth and continued to decrease until the animal died. 
45. The interesting point is with the onset of increased ALAD activity with 
concomitant reticulocytosis correlates closely with the beginning of 
rapid host deterioration. An inquiry into the immediate ca,use of this 
elevated enzyme and reticulocyte activity might lead to a better under-
standing of host responses to tumor growth. 
46. The growing tumor studies indicate a positive correlation in the tumor 
host between ALAD activity and reticulocytosis. 
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4 7. A method was developed to isolate cell-free water extracts of the Walker 
tumor and of normal liver of the rat. These cell-free extracts were 
lyophilized and stored in a dark freezer. 
48. A single intra-cardiac injection of 100 mg/kg of the lyophilized Walker 
tumor extract resulted in the reticulocyte count being elevated, reaching 
the highest value of 12 percent on day 2 after injection while ALAD 
activity reached its highest level at day 8 with 13 units of activity. 
Both of thes·e parameters returned to normal values by the 20th day of 
the experiment. 
49. In the lyophilized cell-free tumor extract experiments the body weight, 
red and white cell counts as well as the hemoglobin and hematocrit 
remain relatively stable and constant with a slight depression in the red 
cell count. The increase in ALAD units and reticulocyte percent remain 
the only significant parameters affected by the tumor extract. 
50. Data from the experiments utilizing lyophilized cell-free water extracts 
of normal rat liver indicate there is no change in any of the seven 
parameters studied for the 20 days of the experiment. 
51. The immediate and unique elevation of ALAD activity in parallel with 
reticulocyte formation before tumor growth becomes palpable suggests an 
early tumor- host relationship that may be unique in the early detection 
of neoplastic disease. 
52. A study to determine if pre-treatment of rats with 100 mg/kg of the lyo-
philized cell-free water soluble tumor extract would in some way facilitate 
or inhibit growth of a transplanted subcutaneous growing Walker tumor 
was undertaken. For control purposes a lyophilized cell-free water 
soluble extract of normal rat liver was employed. After transplantation, 
the volume of the growing subcutaneous tumor was determined on alter-
nate days until the tumor could not be accurately measured or until the 
animal died. 
53. The data indicates that pre-treatment of the animals with lyophilized 
cell-free extracts of the Walker tumor does facilitate the growth of the 
subcutaneous growing tumor. On the sixth day after transplantation, 
the tumor extract pre-treated animals had a 200 percent increase in tumor 
54. 
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votme over control. This percentage increased to 29 5 percent by day 12, 
In contrast, the liver extract pre-treated animals showed very minimal 
percent increase in tumor volume over control untreated rats. The 
maximum percent of increase in tumor volume was observed on day 10 
with a 73 percent increase but this peak in tumor volume was lost by 
day 12 when the control tumor volume almost equaled the liver extract 
pre-treated animals. 
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CHAPTER VI 
FIGURES 
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Figure l 
Metabolic fate of ALA: Shemin and Russell (1953) postulated a succinate-
glycine cycle through which ALA can be oxidized back to succinic acid and 
this oxidation would thus provide a pathway for glycine oxidation. The 
first step of this cycle is the deamination of ALA to a-ketoglutaraldehyde 
which then releases the ALA-carbon derived from glycine to form succinate. 
The ALA-carbon derived from glycine provides the a-carbon a tom to ureido 
groups of purines, the a-carbon atom of serine, the methyl group of methion-
ine, and forms formic acid (She min et al., 195 5). 
&-carbon atom to 
Tricarboxyfic 
Acid Cycle 
Succinyl CoA"' 
( ~-Ketoglutarate 
Succinate 
+Glycine 
Succinate-glycine 
Cycle 
a-Amino-J3-ketoadipic acid·, 
fHOOC-CH2-CH2-ri-cHol . J L o J -~ 
J<etoglutaraldehyde HOOC ~ . -~u .~ -CH2-CH2-C-CH2 NH.,. 
j , .... II -(0) .... , _____ .... - 0 . 6-Aminolcvulinic acid 
HOOC-CH2-CH2 -C-COciH I II 
0 
cx-Ketoglutaric acid Porphyrin 
SUCCINA TE-GLYCINE CYCLE 
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Source: Sshmid, R. 1966 The Porphyrias. In "The Metabolic Basis of 
Inherited Disease, Second Edition" (J.B. Stanbury, J.B. vVyngaarden, and 
D.S. Fredrickson, eds.), pp. 813-870. McGraw-Hill, New York; Shemin, 
D. 1955 The Succinate-Glycine Cycle; The Role of ,f-Aminolevulinic Acid 
in Porphyrin Synthesis. h1 Ciba Foundation Symposium on "Porphyrin 
Biosynthesis and Metabolism" (G. E.W. Wolstenholme and E. C. P. Millar, 
eds.), pp. 4-26. J. and A. Churchill Ltd., London. 
Figure 1 
Figure 2 
Mechanism of delta-aminolevulinic acid (ALA) accumulation in lead 
poisoning: This figure presents, in diagrammatic form, the synthesis of 
216 
ALA from glycine plus succinyl-CoAcatalyzed by the rate limiting enzyme of 
heme synthesis, ALA synthetase. The diagram shows the inhibition, by lead, 
of ALA dehydrase with the accumulation of ALA resulting from such an 
inhibition. Under normal circumstances, ALA dehydrase catalyzes the 
con de nsa ti on of two molecules of ALA to form one molecule of PBG which 
then goes on to complete the heme synthetic pathway. 
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MECHANISM OF DELTA-AMINOLEVULINIC ACID !ALAI ACCUMULATION IN LEAD POISONING 
\ I 
. I 
syn~~~ase AL A \\Jeh~~~0(: F\++ 
+ -------?>- ~~ Porphobilinogen ~ -7----?- Protoporphyrin IX ~HEME 
GLYCINE 
SUCCINYL-CoA 
Source: Davis, J.R. 1968. 
Assoc., 204: 29. 
/, \ 
Blocked' by 
I lead \ 
I \ 
\ 
Lead poisoning test simple, rapid. I. Amer. 
Figure 2 
Figure 3 
Commercially available one-column urinary ALA test for screening 
children suspected of being exposed to lead. 
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Figure 3 
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Fi;ure 4 
Individual steps of the test procedure for the rapid analysis of urinary 
ALA employing prefilled, dual disposable plastic chromatography columns 
arranged in piggyback fashion. 
I STEP 1 I 
CATION 
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Read optical density ol final 
•ill:ture at 553 mp in a 
atudard laboratory colorimeter. 
Source: Abrahams, R.H. 
Levels in Childhood Lead 
of Chicago, Pg. 111. 
197 0. Urinary Delta-Aminolevulinic Acid (ALA) 
Poisoning. Ph.D. Dissertation, Loyola University 
Figure 4 
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EFFECT OF SINGLE INTRA-CARDIAC INJECTION OF A WATER-
SOLUBLE NORMAL LIVER EXTRACT ON THE PERIPHERAL RETICULOCYTE SMEAR* 
' 
Control Animal 
Day 0 
Depicting 1 Reticulocyte 
in the Field (640 X) 
Water-Soluble-Normal-Liver-
Extract- Injected Animal 
Day 2 
Depicting 2 Reticulocytes 
in the Field (640 X) 
Water-Soluble-Normal-Liver-
Extract- Injected Animal 
Day 20 
Depicting 1 Reticulocyte 
in the Field (640 X) 
*Reticulocytes stained with New Methylene Blue-N 
Figure 7 
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Figure 8 
Biosynthesis of Heme: The general scheme of the biosynthesis of heme 
whereby Ac =acetate, Pr = propionic acid, and Vi = vinyl. Two moles of ALA 
are required to form one mole of PBG. Four moles of PBG are required to form 
uroporphyrinogen. In this figure the acetic and prop ionic acid side chains on 
uroporphyrinogen III are shown as Ac and Pr. Coproporphyrinogen III results 
when the four Ac side chains of uroporphyrinogen III are decarboxyla ted to 
yield methyl (CH 3) groups. Oxidation and decarboxylation of two of the Pr 
groups of coproporphyrinogen III to vinyl groups yields protoporphyrin-9. 
Glycine+ pyPidoxal-P + succinyl-CoA 
i dAL synthetase 
COOH-CH2-CH2 - CO-CH2NH2 
o-omino levulinic acid (dAL) 
COOH 
COOH CH2 
CH2 CH2 dAL-ase )Ii(. 
ZoAL -~N-H~"){'H 
H 
nnG~i::~r::)NH, r n-1 J 
1'oly-pyrf'y1 methane 
vsomePase + PBG ? 
'Pr H2 Ac Ac~c~Pr ~NHHN.Z_ 
~2~c~:c 
Pr H2 'Pr 
U!'opoPphyrinogen Ill (UROGEN) i UROG:E.NASE 
Pr> H2 CH3 tt3C~C~Pr> _)-NttttN~. 
H2C NHHN CH2 tt3C~C~CH3 
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cop roporphyr>i nogen Ill (COPROGIN) i COPROGEN oxidose + 02 
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Source: Chisolm, J.J. Jr. 1970. Poisoningduetoheavymetals. Pediat. 
Clin. N. Amer., l.Z_: 591-615. 
Figure 8 
Pa11• 1 at 2 
Coulter Counter Coincidence Correction Chart 
Count loss due to coincident passage of cells is a function of aperture volume and 
:cell concentration • This chart is for use with a 100 micron aperture only and covers 
. cell concentrations from 10,300 per ~l to 109,600 per ~1. Only the first three sig-
·nificant numbers are shown. 
! Example: If the counters record a count of 26,000, locate 260 on the chart, read the 
. number in the adjacent column and r-ecord the true count as 27,800 cells per 12rol • 
: 100 103 150 156 200 210 250 267 300 323 350 382 400 441 450 503 
01 104 51 157 01 211 51 268 01 324 51 383 01 442 51 504 
02 105 52 158 02 212 52 269 02 326 52 384 02 444 52 505 
03 106 53 160 03 213 53 270 03 327 53 386 03 445 53 507 
04 107 54 161 04 214 54 272 04 328 54 387 04 446 54 508 
05 108 55 162 05 216 55 273 05 329 55 388 05 448 55 509 
06 109 56 163 06 217 56 274 06 330 56 389 06 449 56 510 
07 110 57 164 07 218 57 275 07 331 57 390 07 450 57 512 
08 111 58 165 08 219 58 276 08 333 58 392 08 451 58 513 
09 112 59 166 09 220 59 277 09 334 59 393 09 453 59 514 
: 110 113 160 167 210 222 260 278 310 335 360 394 410 454 460 515 
11 114 61 168 11 223 61 279 11 336 61 395 11 455 61 516 
12 115 62 169 12 224 62 281 12 337 62 396 12 456 62 518 
13 116 63 170 13 225 63 282 13 338 63 398 13 457 63 519 
14 117 64 171 14 226 64 283 14 340 64 399 14 459 64 520 
15 118 65 172 15 227 65 284 15 341 65 400 15 460 65 521 
16 119 66 173 16 228 66 285 16 342 66 401 16 461 66 523 
17 121 67 175 17 230 67 286 17 343 67 402 17 462 67 524 
18 122 68 176 18 231 68 287 18 345 68 403 18 464 68 525 
19 123 69 177 19 232 69 289 19 346 69 405 19 465 69 526 
: 120 124 170 178 220 233 270 290 320 347 370 406 420 466 470 527 
21 125 71 179 21 234 71 291 21 348 71 407 21 467 71 529 
22 126 72 180 22 235 72 292 22 349 72 408 22 469 72 530 
23 127 73 181 23 236 73 293 23 350 73 409 23 470 73 531 
24 128 74 182 24 237 74 294 24 352 74 410 24 471 74 532 
25 129 75 183 25 239 75 295 25 353 75 412 25 472 75 534 
26 130 76 184 26 240 76 296 26 354 76 413 26 474 76 535 
27 131 77 185 27 241 77 298 27 355 77 414 27 475 77 536 
28 ·132 78 186 28 242 78 299 28 356 78 415 28 476 78 537 
29 133 79 187 29 243 79 300 29 358 79 416 29 477 79 538 
:130 134 180 188 230 244 280 301 330 359 380 418 430 478 480 540 
31 136 81 190 31 245 81 302 31 360 81 419 31 480 81 541 
32 137 82 191 32 246 82 303 32 361 82 420 32 481 82 542 
33 138 83 192 33 248 83 304 '33 362 83 421 33 482 83 543 
34 139 84 193 34 249 84 305 34 363 84 422 34 483 84 544 
35 140 85 194 35 250 85 307 35 365 85 424 35 484 85 546 
36 141 86 195 36 251 86 308 36 366 86 425 36 486 86 547 
37 142 87 196 37 252 87 309 37 367 87 426 37 487 87 548 
38 143 88 197 38 253 88 310 38 368 88 427 38 488 88 549 
39 144 89 198 39 254 89 311 39 369 89 428 39 489 89 550 
: 140 146 190 199 240 256 290 312 340 370 390 429 440 491 490 552 
41 147 91 200 41 257 91 313 41 372 91 430 41 492 91 553 
42 148 92 201 42 258 92 314 42 373 92 432 42 493 92 554 
43 149 93 202 43 259 93 315 43 374 93 433 43 494 93 555 
44 150 94 204 44 260 94 316 44 375 94 434 44 496 94 556 
45 151 95 205 45 261 95 317 45 376 95 435 45 497 95 558 
46 152 96 206 46 262 96 319 46 377 96 436 46 498 96 559 
47 153 97 207 47 263 97 320 47 379 97 438 47 499 97 .'j60 
48 154 98 208 48 265 98 321 48 380 98 439 48 501 98 561 
49 155 99 209 49 266 99 322 49 381 99 440 49 502 99 563 
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Conversion Chart for Percent Transmission into Grams Percent Hemoglobin 
by the Method of Drabkins: To use this chart one determines the percent 
transmission of the reaction mixture at 540 nm using a 13 x 100 cuvette. One 
reads the percent transmission down and across to obtain the grams percent 
hemoglobin in the appropriate box. For example: 35% T = 15 gm% Hgb. 
HETH OD flrabkins WAVELE~N~GT~~.:....-~_5_4_o~~~~~-
INSTRUMENT Turner CUVETTE 13 x 100 
curve checke<I 10/11/7~ 
Read% T down and across and obtain value in appropriate box 
0 I 2 3 4 5 6 7 8 I 9 
90 1.4 
80 3.0 2.R 2.7 2.5 2.4 2.1 2.0 l.R 1.6 1.5 
70 5.0 4.R 4.6 4.5 4.3 4.0 3.R ~.7 3.5 3.1 I 
60 7.3 7.21 6.8 ".5 6.3 6 .1 5.9 5,R 5.5 5.1 
i 
~ -···-·· 
' I 
50 '.10.0 9J 9.4 9.2 R.R 8.7 8.3 R. l 7.R 7.6 
40 3.2 12 .R 12.5 12.2 11 .R 11.5 11 .2 10.R nn.6 f'.2 
30 7.5 17 .0 16.51 lfi.O 15.5 15.0 14.8 14.4 n4.o 
3.7 
20 b3.5 22.2 22 .o l 21 .5 21.0 20.0 19.5 19 .0 ~ B.5 8.0 I 
---'---
_II I I '5.0 d.~ 10 I ~ 
-· 
Source: Hematology laboratory, Loyola University Hospital, Maywood, 
Ill. 60153. 
Figure 10 
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CHAPTER VII 
CHARTS AND LEGENDS 
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Chart 1 
Composite chart of three standard calibration curves based on the one-
column ALA analysis. The ALA standard curve was prepared in lM sodium 
acetate as described in chapter II. The ALA standard curve prepared in 
normal urine used urine, at pH 5. 0, in place of sodium acetate. An 
aliquot of the urine representing 1, 5, 10, 20, 30 and 50µg ALA, respectively, 
was pipetteted onto individual one-column units. The ALA was eluted off 
with IM sodium acetate and analysis for ALA minus the endogenous urinary 
" ALA proceeded as described in Chapter II. The ALA standard curve prepared 
in water substituted 7.0 ml of pH 4.5 water for the sodium acetate normally 
utilized in the pre para ti on of the ALA standard calibration curve. Aliquots 
representing l, 5, 10, 20, 3 0 and 50µg ALA, respectively, were pipetted 
onto one-column units and the elution of the ALA and analysis for it 
proceeded as described in Chapter II. 
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Chart 2 
Visible spectrum of chromophore resulting from colorimetric analysis 
of delta-aminolevulinic acid (ALA): The color curve was formed on heating, 
separately, 20µg ALA· HCl and ca ti on-exchange column eluates from urine 
and tissue samples of lead-poisoned rabbits with acetylacetone to form a 
pyrrole. After coolL1g to room temperature, the color complex was developed 
by reacting the pyrroles with DMAB in acid solution. The reaction conditions 
were as follows - The ALA· HCl curve: 20µg ALA ·HCl in 7. 0 ml lM sodium 
acetate plus 0. 20 ml. acetylacetone. The mixture was heated for 10 minutes 
at 95 C, afterwhich the mixture was cooled to room temperature. The 
pyrrole was reacted with 7. 0 ml. of fresh, modified Ehrlich's reagent and 
full color development was obtained in 15 minutes. The absorption curve 
was made in a Beckman DB-G spectrophotometer and the maximum wave-
length of 553 nm was determined. The column - eluate curve: The ion-
exchange columns were eluted with 7. 0 ml. of lM sodium acetate and the 
procedure outlined above was followed. 
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Chart 3 
Stability of the color developed with modified Ehrlich's reagent for 
urinary ALA: Six aliquots of the ALA · HCl stock solution were placed in 
test tubes and after appropriate steps, color development was attained 
235 
with modified Ehrlich's reagent. The optical density of each tube, corrected 
for the reagent blank, was determined 15 minutes and 2 hours after the addition 
of the modified Ehrlich's reagent. 
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Chart 4 
ALA standard calibration curve: Six aliquots of the ALA· HCl stock 
solution (12.5 mg ALA·HCl dissolved in 100 ml. acetate buffer, pH 4.6) 
corresponding to l, 5, 10, 20, 30, and 50µg - were pipetted into test tubes 
and diluted to 7. 0 ml. with lM sodium acetate. 0. 20 ml. of acetylacetone 
was added to each tube and the tubes were placed into a boiling water 
bath for 10 minutes. After cooling to room temperature, 7. 0 ml. of fresh, 
modified Ehrlich 1 s reagent was added to each tube. The color developed 
fully within 15 minutes. The optical density of the color reaction was 
determined, after correction for the reagent blank, at 553 nm in a spectro-
photometer using a l. 0 cm cuvette. 
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Chart 5 
Recovery of exogenous ALA from 3M tartaric acid preserved urine: 
27 Sµg ALA· HCl were added to 12. 5 ml. random urine resulting in a final 
concentration of llµg ALA·HCl/O. 5 ml. urine applied to the column. Endo-
genous ALA was subtracted in determining the amount of ALA recovered. 
The preserved urine-ALA mixture was stored, in the dark, at 4 C for a period 
of 28 days. The pH was determined and analysis for urinary ALA was com-
pleted on day 0, 7, 14, 21, and 28 using dual disposable ion-exchange 
column chromatography units. 
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Chart 6 
Visible spectrum of chromophore resulting from colorimetric analysis 
of porphobilinogen (PBG): The color curve was produced by adding, separately, 
30µg PBG and anion-exchange column eluates from urine and tissue samples 
of lead-poisoned rabbits to DMAB in acid solution. The reaction conditions 
were as follows - the PBG curve: 30µg PBG added to 10 ml. of lN acetic 
acid. After mixing, the solution was reacted with 10 ml. of fresh, modified 
Ehrlich's reagent and full color development was obtained in 15 minutes. 
The absorption curve was made in a Beckman DB-G spectrophotometer and 
the maximum wavelength of 555 nm was determined. The column-eluate 
curve: The ion-exchange columns were eluted with 10 ml. of lN acetic acid 
and the procedure outlined above was followed. 
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Chart 7 
Compa-rison of the stability of modified versus unmodified Ehrlich's 
reagent in PBG analysis: Two 0. 5 ml. samples from the same random urine 
sample received from a patient diagnosed as having acute intermittent 
porphyria were carefully pipetted onto two separate anion-exchange columns. 
These urine samples were washed with 30 ml. of water and eluted with 10 ml. 
of lN acetic acid. 10 \1. of modified Ehrlich's (DMAB, PCA, acetic acid) 
was added to one of the~olumn eluates while unmodified Ehrlich's (DMAB, 
HCl) was added to the other eluate. The optical density of each of the 
reactions, corrected for the reagent blank, was determined at 5, 15, 30, 45, 
60, 75, and 90 minutes at 555 nm using a spectrophotometer. 
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Chart 8 
PBG standard calibration curve: Four aliquots of the PBG stock solution 
(O. 05 ml., 0. JO tl., 0. 2 0 ml., and 0. 3 0 ml.) were pipetted into separate 
test tubes. Each was diluted to 10 ml. with lN acetic acid. 10 ml. of 
modified Ehrlich's reagent was added to each tube and full color developed 
in 15 minutes. The optical density, corrected for the reagent blank, was 
determined at 555 nm in a spectrophotometer. 
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Chart 9 
Stability of color developed with PBG and modified Ehrlich's reagent: 
Four aliquots of the PBG stock solution corresponding to 5, 10, 20 and 30µg 
PBG were diluted to 10 ml. with IN acetic acid. 10 ml. of modified Ehrlich's 
reagent was added and full color developed in 15 minutes. The optical 
density, corrected for the reagent blank, was determined at 15 minutes and 
at 90 minutes at 555 nm in a spectrophotometer. 
STABILITY OF COLOR DEVELOPED WITH 
PBG AND MODIFIED EHRLICH'S REAGENT 
E 
c 
IO 
IO 
0,300 
IO 0.200 
>-
~ 
en 
z 
w 
c 
...J 0.100 
<t 
u 
~ 
a.. 
0 
0 
e e 15 MINUTES 
0-----0 90 MINUTES 
0 5 10 15 20 25 30 
JJg PBG I 20 ml REACTION VOLUME 
Chart 9 
248 
Chart 10 
Comparison of standard curves obtained from human-extracted PBG 
versus synthetic PBG: For the human-extracted PBG curve, four aliquots 
of the PBG solution equaling 5, 10, 20, and 25µg were pipetted into 4 
separate test tubes and were diluted to 7. 0 ml. with lN acetic acid. 7. 0 
249 
ml. of fresh, modified Ehrlich's reagent was added to each tube and full 
color developed in 15 minutes. The optical density, corrected for the reagent 
blank, was determined at 5 5 5 nm using a s pee trophotometer. For the 
synthetic PBG curve aliquots from the PBG standard were analyzed as 
described above and the results were compared. 
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Chart 11 
Effect on the stability of PBG in urine preserved with tartaric acid: 
378µg PBG were added to 10 m~. of a random urine sample resulting in a 
251 
final concentration of 18. 94µg/0. 5 ml. placed on the column. The preserved 
urine - P BG mixture was stored for 2 8 days in the dark at 4 C . The pH 
was determined and analysis for PBG was completed using disposable ion-
exchange column chromatography units on day 0, 7, 14, 21, and 28. 
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Chart 12 
Typical standard calibration curves for ALA and PBG: The ALA and PBG 
curves are based on Mg% ALA and PBG in 0. SO ml. of a random urine sample. 
The two curves are combined on one chart to study the interrelationships of 
the two in reference to the optical denslt( Each point on these charts 
represents an average of five ALA and PBG standard calibration curve deter-
minations. 
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-~ Chart 13 
Urea standard calibration curve: Crystalline urea was added to 30 ml. 
water to make-up standard concentrations ranging from 4 to 15 mg/30 ml. 
A yellow-lemon color developed after adding 4 ml. of fresh, modified 
Ehrlich's reagent to each tube containing a water-urea solution. The 
optical density was determined, corrected for a reagent blank, at 415 nm 
and was plotted against mg urea to produce the standard calibration curve. 
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Chart 14 
Stability of color developed with urea and modified Ehrlich's reagent: 
5 mg crystalline urea was dissolved in 7 .O ml. water and to this was added 
2 ml. fresh, modified Ehrlich's reagent. After thorough mixing the optical 
density, corrected for a reagent blank, was determined every 5 minutes up 
to and including 50 minutes after adding the Ehrlich's reagent. 
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Chart 15 
9 5 percent confidence limits of human urinary ALA and PBG values: 100 
normal medical students each donated a mid-afternoon random urine specimen 
for these studies. 0. 5 ml. aliquot of the urine specimen was utilized for 
these studies. The PBG and ALA. were separated from each other by using 
dual piggyback, disposable ion-exchange column chromatography units. 
PBG was eluted from the anion column by 10 ml. of lN acetic acid. After 
addition of 10 ml. of fresh, modified Ehrlich's reagent the PBG color chromo-
phore' s optical density, corrected for a reagent blank, was determined at 
555 nm. The ALA was eluted from the cation column with lM sodium acetate, 
heated with acetylacetone to form a pyrrole, and then had added to it 
fresh, modified Ehrlich's reagent to form a color chromophore which had 
its optical density determined, corrected for a reagent blank, at 553 nm. 
The mean for urinary ALA WAS 0.25_±0.14 mg. percent (95% C.L. =0.54 mg%); 
n = 100* anrl the mean for urinary PBG was 0 .11_±0.04 mg. percent (95% C. L. 
* = 0.21mg%);n=100 . 
*Figure depicts values obtainerl from forty of the 100 samples. 
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Chart 16 
9 5 percent confidence limits of human urinary pH and urea values: 
100 normal medical students each donated a mid-afternoon random urine 
specimen for these studies. 0. 5 ml. aliquot of the urine specimen was 
utilized for the urinary urea studies. The dual piggyback, disposable ion-
exchange column chromatography units were washed with 30 ml. of water •. 
The water eluate was collected and to this was added 4 ml. of fresh, 
modified Ehrlich's reagent. After 15 minutes the optical density, corrected 
for a reagent blank, of the lemon-yellow colored urea solution was determined 
at 415 nm. The pH was determined electronically after the urine specimen 
reached room temperature (25 C) and was mixed thoroughly. The mean for 
urinary pH was 6.00 .± 0.44 (95% C.L. = 6.88); n = 100* ano the mean for 
* urinaryureawas 6.97_±4.19 (95%C.L. =15.35);n=l00. 
*Figure depicts values obtained from forty of the 100 samples. 
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Chart 17 
.Excretion of urinary ALA after injection of 200 mg/kg lead acetate via 
single subcutaneous dose in adult rabbits: Random urine specimens were 
collected, adjust to pH 5 with glacial acetic acid, and O. 5 ml. was analyzed 
for ALA using dual disposable ion-exchange column chromatography units 
(piggyback columns). Each point on the chart represents urine specimens 
from six lead-poisoned, adult New Zealand white rabbits. Urine samples 
were preserved with acetic acid by the method of Abrahams (1970). 
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Chart 18 
Control levels of tissue ALA: 21 tissues from control, adult rabbits 
were analyzed for tissue ALA. The cauda epididymis had the highest 
concentration of tis sue ALA with 0. 53µg ALA/gm wet weight tissue. The 
least concentration was found in adipose tissue with less than 0. 03µg 
ALA/gm. Each point on the chart represents six control adult New Zealand 
white rabbits. The average concentration of tis sue ALA was 0. 2 0 .± 0. 0 6 µ 
gram/gram wet weight. 
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Chart 19 
µg ALA/gm wet weight tissue in adult lead-poisoned rabbits given single 
subcutaneous injection of 200 mg/kg lead acetate: Four tissues were 
studied at 20 and 58 days post-injection - the bone marrow, kidney, spleen, 
and liver - to determine the effect of lead poisoning. The tissue ALA 
4 
concentration was determined utilizing dual piggyback disposable ion-
exchange column chromatography units. Each point on the graph represents 
an average of six adult lead-poisoned New Zealand white rabbits. 
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Chart 20 
Levels of ALA in tissues 58 days after a single subcutaneous injection 
of 200 mg/kg lead acetate into adult rabbits: 21 tissues were analyzed for 
ALA 58 days post-injection of lead acetate. The bone marrow accumulated 
25µg ALA/gm wet weight while the kidney accumulated 10. 8µg ALA. The 
other 19 tissues ranged from an ALA level of 1. 8µg ALA for the spleen down 
to 0. 02µg ALA/gm wet weight tissue for adipose tissue. Each point on the 
graph represents an average of six lead-poisoned adult New Zealand white 
rabbits. The average concentration of tis sue ALA for the bone marrow and 
kidney was 17. 78 ..± 1. 43 µ gram/gram wet weight. The average concentration 
of tissue ALA for all other tis sues was 0. 5 2 .± 0. 06 µ gram/gram wet weight. 
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ADULT RABBIT 
levels of ALA in tissues 58 days after a single 
subcutaneous Injection of 200 mg/kg lead acetate 
average S.D. for bone marrow and kidney • 1.43 
average S.D. for all remaining t111ue1 • 0.06 
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Chart 21 
Comparison of lead induced ALA accumulation in tis sues 58 days after 
a single subcutaneous injection of 200 mg/kg lead acetate into adult rabbits. 
21 tissues were studied for lead induced accumulation of ALA. The ordinate 
represents a ratio of the µg ALA/gm wet weight of lead-poisoned animal over 
µg ALA/gm wet weight of control animal. The highest ratio, approaching 100 
occurred with the bone marrow followed by the kidney and the lung at 2 8 and 
22, respectively. The other 18 tissues ranged from less than 8 (heart) 
down to l (adipose tissue). The ALA concentration was determined by using 
dual disposable, ion-exchange column chromatography units (piggyback 
columns). Each point on the chart represents an average of six lead-
poisoned adult, New Zealand white rabbits. 
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ADULT RABBIT 
comparison of lead induced ALA accumulation in tissues 58 days 
after a single subcutaneous injection of 200 mg/kg lead acetate 
average S.D. for bone marrow. kidney and lung• 2.71 
average S.D. for all other tl11ut1 • 0.35 
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Chart 22 
Tissue ALA levels 20 days after single subcutaneous injection of lead 
acetate into adult rabbits. Four tissues - bone marrow, kidney, spleen, and 
liver - were analyzed for ALA in rabbits injected with either 200, 400, or 
800 mg/kg lead acetate. The µg ALA/gm wet weight of tissue increased as 
the dose of lead acetate increased in the bone marrow and the kidney while 
there was no effect on the spleen or liver. Each point on the chart represents 
an average of six animals for the 200 mg dose and an average of three lead-
poisoned adult, New Zealand white rabbits for the 400 and 800 mg/kg dose. 
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Chart 23 
Single intraperitoneal injection of 15 mg/kg lead acetate into adult 
rats: Two parameters -- ALAD enzyme activity and excretion of urinary 
ALA -- represented by the left and right ordinates, respectively, were studied. 
150µL of whole blood was utilized for the enzyme experiments while 0. 50 
ml. of a random urine sample, adjusted to pH 5 with acetic acid, was 
used for the ALA determinations. Each point on the chart represents an 
I 
average of three adult, male Sprague-~ley rats. 
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Chart 24 
Effect of tumor growth on reticulocyte count and ALAD activity in adult 
rats bearing the Walker 256 Carcinosarcoma: Cell suspensions of the Walker 
tumor were transplanted into adult, male Sprague-Dawley rats. The growth 
of the tumor was determined by measuring it in 3 dimensions. This data is 
recorded by the left ordinat;or the enzyme assay 150µ1 of whole blood 
was drawn from the tail vein on alternate days up to and including day 20 
and is represented by the right ordinate. The reticulocytes were stained 
with New Methylene Blue N and 10 fields of 100 red cells per field were 
counted so that the number of reticulated red cells per thousand red cells 
could be expressed in a percentage. This data is recorded on the second 
ordinate on the right. The abscissa represents days after transplantation 
of the Walker tumor. Each point on the chart represents an average of six 
tumor bearing Sprague-Dawley rats. 
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Chart 25 
Percent increase in reticulocyte count and ALAD activity over control 
in rats bearing the Walker tumor: ALAD enzyme activity and reticulocyte 
counts were determined as previously described. The percent increase in 
reticulocyte count is represented by the left ordinate and the percent 
increase in enzyme activity is shown by the right ordinate. The abscissa 
is days after transplantation of the Walker tumor. Each point on the chart 
represents an average of six tumor bearing Sprague-Dawley rats. 
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Chart 26 
Effect of a growing subcutaneous tumor on the host: This chart is 
divided into 4 smaller charts -- all with the same abscissa -- days after 
transplantation of the Walker tumor. The top graph compares tumor volume 
to body weight; the next chart shows the parallel relationship of ALAD 
enzyme activity to percent reticulocytes. The third chart demonstrates the 
falling red cell count with the increased white blood cell count and the 
bottom chart shows the parallel decline in hemoglobin and hematocrit in 
rel a ti on ship to the gro·;ving subcutaneous Walker tumor. 
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Chart 27 
Effect of a single cardiac injection of 100 mg/kg of 105, 000 x g unheated 
cell-free, lyophilized protein from a water-soluble extract of the Walker 
tumor: Reticulocyte counts and enzyme activity were determined as previously 
described. The left ordinate represents enzyme activity while the right 
ordinate represents percent reticulocytes. The abscissa is days after 
injection of the lyophilized protein. Each point on the chart represents 
an average of six animals injected with the water-soluble extract of the 
tumor. 
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Chart 28 
Effect of 105, 000 x g unheated cell-free, lyophilized protein from a 
water-soluble extract of the Walker tumor: This chart is divided into 4 
charts -- all with the same abscissa -- days after injection of the water-
soluble extract of the Walker tumor. The top chart records the body weight 
of the animal while the next chart depicts the parallel rise and fall of ALAD 
enzyme activity and percent reticulocytes. The third chart represents the 
effect the water-soluble injection had upon the red and white blood cell 
counts while the bottom chart demonstrates the slight effect the tumor 
extract had upon the hemoglobin and hematocrit. Each point on the chart 
represents six animals injected with the water-soluble extract of the Walker 
tumor. 
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Chart 29 
Effect of 100 mg/kg single cardiac injection of 105, 000 x g unheated 
cell-free lyophilized protein from water-soluble extracts of normal rat 
287 
liver: This chart is divided into 4, each chart having the same abscissa --
days after injection of the water-soluble liver extract. The top chart 
shows the body weight of the injected rat while the next chart shows the 
relationship of enzyme activity to percent reticulocytes. The third chart 
demonstrates the effect on red and white blood cell counts while the bottom 
chart represents the effect the normal liver extract had upon hemoglobin 
and hematocrit. Each point on the chart represents an average of six 
animals injected with the normal liver extract. 
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Chart 30 
Comparison of the effect of a single cardiac injection of 100 mg/kg of 
105, 000 x g unheated cell-free lyophilized protein from the Walker tumor 
extract and from normal liver extract: ALAD enzyme activity and reticulocyte 
counts were determined in animals injected with tumor extracts or liver 
extracts and the data is compared on this chart. The enzyme activity is 
represented by the left ordinate and reticulocyte percent is represented by 
the right ordinate while the abscissa is days after injection of the tumor 
or liver extract. 
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Chart 31 
Percent increase in tumor volume in animals pre-treated with water 
soluble extracts of the Walker tumor or normal liver: Each point on the chart 
represents an average of three animals that were pretreated with either water 
extracts of the tumor or normal liver. The animals were given the water-
soluble extracts and for a period of 20 days after injection had enzyme, 
reticulocyte counts, and basic hematology studies performed upon them. 
At the conclusion of this experiment, 0. 5 ml. cell suspension of a fresh 
7 day old Walker tumor was transplanted to the experimental pretreated 
rats. For control, litter mates of the experimental animals were transplanted 
with the same tumor cell suspension. The growth of the tumor was determined 
by measuring its volume. The difference in size of the tumor in animals 
pretreated was observed and serves as the ordinate on the chart -- percent 
increase in tumor volume -- while the abscissa is days after transplantation 
of the Walker tumor. 
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PERCENT INCREASE IN TUMOR VOLUME IN 
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CHAPTER VIII 
TABLES 
Specimen 
R.A. 
G. L. 
R.B. 
R.B. 
12791 
12785 
12774 
12916 
pH 
6.0 
5.0 
4.5 
4.5 
5.0 
6.0 
6.3 
6.0 
Table 1 
EFFECT OF VARYING THE MESH SIZE OF THE CATION 
RESIN IN THE ONE-COLUMN URINARY ALA ANALYSIS 
Type Of 
Specimen 
Normal 
Normal 
Norma 1 
Normal + 
10 µg ALA.HCl 
Industrialb 
Low ALA 
Industrialb 
Medium Low ALA 
Industrialb 
Medium High ALA 
Industrialb 
Very High ALA 
Dual Pigqyback Column Control 
Optical Density 553 nm 
AG50W-X4~ 100-200 Mesh 
0.009 
0.030 
0.010 
0.270 
0. 061 
0.170 
0.429 
0.660 
One-Column 
Optical Density 553 nm 
AG50W-X4~ 100-200 Mesh 
0.008 
0. 031 
0.009 
o. 271 
0.058 
0. 169 
0.425 
0.657 
One-Column 
Optical Density 553 nm 
AG50W-X4~ 50-100 Mesh 
0.000 
0.010 
0.000 
0. 120 
0.020 
0.079 
0. 105 
0.270 
a. Analytical grade cation exchanqe resin, hydrogen ionic form, Bio-Rad Corp., Richmond, California. 
b. Industrial urines supplied through courtesy of automotive industry. N 
<.D 
~ 
Table 2 
COMPARISON OF THE DUAL PIGGYBACK COLUMN AND ONE-COLUMN 
METHODS FOR DETERMINATION OF URINARY ALA 
Piggyback Columna One-Columnb One-ColumnC 
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Optical Density 
Sample 553 nm 
(4.0 x 0.6 cm bed resin) 
Optical Density 553 nm 
(2.0 x 0.6 cm bed resin) 
Optical Density 553 nm 
Norma 1 Uri ned 
(No ALA Added) 0.044 0.041 0.044 
Normal Urine 
1 µg ALA Addede 0.052 0.043 0.050 
Normal Urine 
5 µg ALA Addede 0.185 o. 169 o. 186 
Normal Urine 
10 µg ALA Addede 0.379 0.349 0.380 
Normal Urine 
20 µg ALA Addede 0.660 0.659 0.660 
Normal Urine 
30 µg ALA Addede 0.990 0.845 0.980 
Normal Urine 
50 µg ALA Addede 1. 490 1. 500 1. 500 
a. Commercial dual piggyback column, AG50W-X4 analytical grade resin, 100-200 
mesh, H+ ionic form, Bio-Rad Corp., Richmond, California. 
b. One-column unit, 4.0 x 0.6 cm bed resin, AG50W-X4, 100-200 mesh, H+ ionic 
form. 
c. One-column unit, ~O x 0.6 cm bed resin, AG50W-X4, 100-200 mesh, H+ ionic 
form. 
d. Normal random urine, pH adjusted to 5.0. 
e. ALA.HCl added to urine specimen so that 0.50 ml urine would contain l, 5, 
10, 20, 30 or 50 µg ALA. 

Table 4 
COMPARISON OF DUAL PIGGYBACK COLUMN VERSUS ONE-COLUMN METHOD 
FOR ~ETERMINATION OF ALA ADDED TO NORMAL URINE 
A. B. ALA Recovered ALA Recovered 
ALA Added Endogenous ALA To Be One-Column Methoda Pigqyback Methodb 
{µg) ALA {µq) Recovered (A-B) µg % Recovered µg % Recovered 
5.20 0.20 5 4.9 98 5 100 
5.20 0.20 5 4.8 96 4.5 90 
10.20 0.20 10 10.0 100 10. 3 103 
10.20 0.20 10 9.8 98 9. 1 91 
20.20 0.20 20 18.8 94 19 95 
20.20 0.20 20 19.0 95 18. 5 93 
30.20 0.20 30 27.4 91 27.7 92 
30.20 0.20 30 28.0 93 27.4 91 
40.20 0.20 40 36.5 91 36 90 
40.20 0.20 40 36.0 90 36.3 90 
a. Column size 2.0 x 0.6 cm bed resin, AG50W-X4, 100-200 mesh, H+ ionic form. 
N 
b. Commercially available piggyback column. c.o 
'1 
Table 5 
EFFECT OF STORAGE OF RANDOM URINE SPECIMENS PRESERVED 
WITH TARTARIC ACID ON THE STABILITY OF URINARY ALA 
COMPARISON OF DUAL PIGGYBACK COLUMN TO ONE-COLUMN ALA METHOD 
DAY 0 
OpticJl Density 
DAY 7 DAY 14 DAY 21 DAY 28 
Optical Density 
553 nm 553 nm 0. D. 0. D. 0. D. 0. D. 0. D. O.D. 0. D. 0 
Piggyback Column (P.BJC One Column (O.C.)d (P.B:) (0. c.) (P. B.) (0. c.) (P. B.) (0. c.) ( p. B. ) (0 
Jri ne Preserved 0.460 0.459 0.445 0.450 0.450 0.449 0.440 0.443 0.430 0. 
lith 3 M Tartarica ( 11. 85) . (11.81) ( 11. 53) ( 11. 60) ( 11. 60) ( 11. 59) ( 11. 35) ( 11. 50) (11.10) (11 
Jri ne Preserved 0.462 0.460 0.450 0.452 0.425 0.430 0.435 0.425 0.410 o. 
lith Glacial Acetica,b ( 11. 87) ( 11. 85) (11. 60) (11.63) ( 10. 90) ( 11 . 1 0) (11.25) (10.90) ( 10. 50) ( 10 
) = µg ALA recovered. 
t. 10 ml of fresh random urine, 260 µg ALA.HCl added to 10 ml urine, final concentration = 13 µg ALA/0.50 ml, adjusted to 
pH 8.3 before being added to preservative. 
>. 0.10 ml glacial acetic added to 10 ml random urine. 
Commercial piggyback column. 
L 2.0 x 0.6 cm bed resin column, AG50W-X4, 100-200 mesh, H+ ionic form. 
N 
c.o 
co 
Table 6 
EFFECT OF INCREASING THE VOLUME OF WATER TO WASH NORMAL 
URINARY UREA THROUGH THE ONE-COLUMN IN THE ALA DETERMINATION 
UREA DATA ALA COLUMN DATA 
Volume of Water Op ti cal Density 
Passed Throuqh Urea+ Ehrlich's 0.D. ALA Pyrrole µg ALA 
Th2 Column (~ 415 nmC 553 nm Recovered 
Pigg~back Columna: 
5 µg ALA in 0.5 ml urine 30 0.025 0. 161 4.50 
One-Columnb: 
5 µg ALA in 0.5 ml urine 21 0.085 0.167 4.75 
5 µg ALA in 0.5 ml urine 28 0.037 0.158 4.45 
5 µg ALA in 0.5 ml urine 30 0.017 o. 158 4.45 
5 µg ALA in 0.5 ml urine 35 0.013 o. 157 4.45 
a. Commercial piggyback column, washed with 30 ml distilled water as directed in the ALA kit. 
b. 2.0 x 0.6 cm resin bed size, AG50W-X4, 100-200 mesh, H+ ionic form. 
c. Urea 0.D. determined using DB-G spectrophotometer. The O.D. of the eluted ALA (converted 
to a pyrrole) and any remaining urea washed from the column with the ALA elution was de-
termined when reacted with modified Ehrlich's reagent. 
Recovery 
% 
90 
92 
87 
87 
87 
N 
lD 
lD 
µg ALA 
1 µg 
5 µg 
10 µg 
20 µg 
30 µg 
50 µg 
Table 7 
STANDARD CALIBRATION CURVE FOR ALA, PREPARED ACCORDING TO THE DIRECTIONS 
FOR PERFORMING THE SIMPLIFIED, ONE-COLUMN TEST FOR URINARY ALA 
Trial #1 Trial #2 Trial #3 
One Test Tube Data One Test Tube Data One Test Tube Data 
0. D. O.D. 0. D. 
553 nm 553 nm 553 nm 
/ 0.031 0. 031 0.035 
0.180 0. 190 0.189 
0.405 0.400 0.400 
0.799 0.800 0.800 
1. 100 1. 100 1. 280 
1. 500 1. 500 1. 500 
Average O.D. 
For Three Trials 
0.032 
o. 186 
0.401 
0.799 
1. 160 
1. 500 
w 
0 
0 
µg ALA 
Applied To 
Column/0.50 ml Urine 
l µg 
5 µg / 
10 µg 
20 µg 
30 µg 
50 µg 
Table 8 
STANDARD CALIBRATION CURVE FOR ALA PREPARED IN NORMAL URINE* 
THROUGH THE ONE COLUMN TEST FOR URINARY ALA 
Trial #1 Trial #2 Trial #3 
One Column Data One Column Data One Co 1 umn Data 
------~--
---- -·- ~ - ---· - -···- --· ·-
O.D.** O.D.** O.D.** Averaqe O.D. 
553 nm 553 nm 553 nm For Three Trials 
0.029 0.026 0.026 0.027 
o. 163 0. 161 o. 160 o. 161 
0.343 0.346 0.340 0.343 
0.704 0.700 0.701 0. 701 
1. 249 1. 100 1. 111 1. 155 
1.505 1. 505 l. 505 1.505 
* Normal random urine adjusted to pH 5.0 before ALA added. 
** Endogenous urinary ALA subtracted from experimentally recovered ALA added to urine 
specimen. 
Note: Average 0.D. for normal urinary ALA content was 0.048. 
w 
0 
...... 
Table 9 
STANDARD CALIBRATION CURVE FOR ALA PREPARED IN WATER* 
THROUGH THE ONE COLUMN TEST FOR URINARY ALA 
Trial #1 Trial #2 Trial #3 
One Column Data One Column Data One Column Data 
µg ALA 0. D. 0. D. O.D. 
AeElied To Column 553 nm 553 nm 553 nm 
1 µg 0.025 0.025 0.025 
~ 5 µg 0.170 o. 161') 0.155 
10 µg 0.350 0.347 0.347 
20 µg 0.666 0.666 0.660 
30 µg 1. 100 1. 100 1. 100 
50 µg 1 . 50() 1. 500 1. 500 
*Distilled water pH adjusted to 5.0 before ALA added. 
Average O.D. 
For Three Trials 
0.025 
o. 161 
0.347 
0.664 
1. 100 
1. 500 
w 
0 
N 
Table 10 
EFFECT OF URINE pH ON RECOVERY OF ALA FROM COLUMNSt 
Optical Density At 553 nm* 
Urine Adjusted Urine Adjusted Urine Adjusted 
pH With HCl or NaOH With HCl or NH40H With HCl or Na2C03 
1. 0 0.250 0.271 0. 241 
2.0 0.245 0.289 0.252 
3.0 0.232 0.260 0.256 
4.0 0.249 0.273 0.230 
5.0 0.225 0.260 0.230 
6.0 0.232 0.240 0.228 
7.0 0.210 0.225 0.212 
8.0 0.188 o. 161 0.200 
9.0 o. 127 0.022 0.095 
* 0.20 ml (lOOµq) of ALA.HCl was added to each of 9 test 
tubes. 9.80 ml of normal urine, adjusted to the pH 
indicated was added and mixed well. The pH of each 
tube was checked before a 0.50 ml aliquot of udne was 
added to individual piqqyback columns. The optical 
density of the eluted ALA was determined at 553 nm. 
t Abrahams, R.H. Ph.D. Dissertation, Loyola University of 
Chicago, 1970. 
( 
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Table 11 
INTERPRETATION OF URINARY ALA LEVELS IN T~RMS 
OF THEIR RELATIONSHIP TO LEAD EXPOSURE 
Urinary ALA Range Urinary ALA Relationship To 
(mg/100 ml) Code Lead Exposure* 
0.00-0.99 Normal None 
l. 00- l. 49 l+ Moderate 
1. 50-1. 99 2+ Heavy 
2.00-2.99 3+ Severe 
3:00-5.99 4+ Critical 
6.00-10.00 5+ Overwhelming 
*Terms employed were arbitrarily selected. 
t Abrahams, R.H. Ph.D. Dissertation, Loyola University 
of Chicaqo, 1970. 
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Table 12 
EFFECT ON pH OF URINE PRESERVED WITH 
3 M OXALIC, BORIC, CITRIC, OR TARTARIC ACID 
Urine ~He 
Sample 0 Hours 12 Hoursa 24 Hoursa 
1. Oxalic Acidb 4.20 4.20 4.20 
(Very Cloudy) (Heavy Precipitate) 
2. Boric Acidb 8.30 ** ** 
3. Citric Acidb 3.00 3.70 3.80 
(Cloudy) (Heavy Precipitate) 
4. Tartaric Acidb 4.30 4.30 4.30 
** pH not further determined due to initial pH of urine sample 
being above the maximum allowable for recovery of urinary 
ALA. 
a. Urine samples stored at 4°C, in the dark. 
b. 10 ml normal urine adjusted with Na2C03 to pH 9.0 before 
being added to 15 ml screw-capped bottle containing 0.20 
ml of the indicated 3 M preservative. 
c. pH determined electronically at 23°C. 
\ 
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Urine 
Sample 
Normal Urine 
(No Preservative) 
Normal Urine 
Preserved with 0.10 
ml tartaric acid 
Normal Urine 
Preserved with 0.20 
ml tartaric acid 
Normal UrineC 
Preserved with 0.10 
ml glacial acetic acid 
Table lJ 
EFFECT OF 3 M TARTARIC ACID ON THE pH OF RANDOM 
URINE SPECIMENS STORED AT 4°C IN THE DARK 
Initi a 1 pH Urine pH After Urine pH After pH of Urine 
Of Urine Adjusting ~ith Adding To Pres- Specimend ~)pecimena 1 M Na2C03 ervative (Day O)d (Day 14) 
6.0 ** ** 6.95 
6.0 8.30 5.60 6.30 
6.0 8.30 4.11 4.15 
6.0 8.30 4.50 4. 51 
pH of Urine 
Specimend (Day 28) 
7.01 
6.40 
4. 17 
4.60 
** Urine not adjusted to pH 8.30 nor added to container with preservative, it was stored as an 
unpreserved, random urine specimen at 4°C, in the dark. 
a. Fresh voided normal urine,)TI"id-afternoon sample, pH determined electronically at 23°C. 
b. All urine specimens were adjusted with 1 M Na2C03 (except for control) and then were added 
to the bottles containing dried down 3M tartaric acid. pH determined electronically at 23°C. 
c. Glacial acetic acid used as an internal control to compare current data to that obtained from 
the preservation of urine as directed in the commercial ALA test kit. 
d. Urine pH determined electronically at 23°C. 
w 
0 
Q) 
Table 14 
EFFECT OF VARIOUS VOLUMES OF 3 M TARTARIC 
ACID ON FINAL pH OF MID-AFTERNOON URINE SPECIMENS 
pH of Urine Specimen pH of Urine Specimen 
Volume of 3 M After Adding to Bottle 
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Tartaric Acida 
After Adjugtment With 
1 M Na2C03 Containing Tartaric Acidc 
0.10 ml 9.0 5.5 
0.20 ml 9.0 4.4 
0.40 ml 9.0 3.4 
a. Appropriate volume of 3 M tartaric acid was pipetted 
into individual 15 ml glass, screw-capped bottles and 
heated for 60 minutes at 75°C. This resulted in a 
bottle containing a dry, clear film of tartaric acid 
adhering to the walls and bottom of the bottle. 
b. 12.5 ml of normal random urine was used per bottle. 
c. Average pH of three experiments per volume of tartaric 
acid. Urine pH determined electronically at 23°C. 
Table 15 
EFFECT OF STORAGE ON RECOVERY OF ALA FROM RANDOM 
URINE SPECIMENS PRESERVED WITH 3 M TARTARIC ACID 
Time Of Percent of Original 
Samplin~ µg ALA ALA Remaining 
(Days) Recoveredd (%) 
Specimenb 0 7.8 100 
#1 14 7.6 97 
8.0 µg ALA 28 7.4 95 
Specimenc 0 10.8 1 on 
#2 14 10.7 99 
11.0 µg ALA 21 1o.7 99 
28 10.6 98 
a. 12.5 ml random urine. ALA mixture stored at 4°C, in 
the dark. 
b. 200 µg ALA added per 12.50 ml random urine resulting 
in a final concentration of 8 µq ALA/0.50 ml urin~ 
applied to the dual piggyback column. 
c. 275 µg ALA added per 12.50 ml random urine resulting 
in a final concentration of 11 µg ALA/0.50 ml urine 
applied to the dual piggyback column. 
d. ALA.HCl added to normal random urine sample before 
being preserved with tartaric acid. 0.50 ml aliquot 
applied to the dual piggyback column and urinary ALA 
was eluted off. Urinary ALA recovered minus endogenous 
ALA was considered to be equal to 100% on day 0. All 
subsequent determinations were compared to this 0 day 
value (percent of original ALA remaining - %). 
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Table 16 
COMPARISON OF THE pH OF STORED RANDOM URINE SPECIMENS 
PRESERVED WITH TARTARIC ACID OR GLACIAL ACETIC ACID 
Time of Sampl in~ pH of Tartaric pH of Glacial 
of Random Urine Acid breserved Acetic Acid 
Urine Preserved Urinec 
0 Days 3.87 4.39 
7 Days 4.00 4.46 
14 Days 3.95 4.42 
21 Days 4.00 4.50 
28 Days 4.00 4.50 
a. Urine stored at 4°C, in the dark. 
b. Initial random urine specimen adjusted to pH 8.3 
with 1 M Na2C03 before being added to bottle con-
taining urine preservative. 
c. pH determined electronically at room temperature. 
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Table 17 
EXPECTED RESULTS USING THE MODIFIED METHOD 
FOR THE DETERMINATION OF URINARY PBG 
Limit of detectability of PBG in urine ........ 0.02 mg% 
Sensitivity of test ........................... 0.15 µg 
Variation between duplicate samples ........... ± 2% 
Recovery of PBG from distilled water .......... 88% 
Recovery of PBG from urine .................... 83% 
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Table 18 
INTERPRETATION OF URINARY PBG LEVELS IN TERMS 
OF THEIR RELATIONSHIP TO PORPHYRIA 
Urinary PBG Range Urinary PBG Relationship To 
(mg/l 00 ml) Code Porphyri a* 
0.00-0.03 Normal None 
0.04-0. 19 Trace Slight 
0.20-0.49 l+ Moderate 
0. 50-1. 99 2+ Heavy 
2.00-3.99 3+ Severe 
4.00-5.99 4+ Critical 
6.00-10.00 5+ Overwhelming 
* Terms employed were arbitrarily selected. 
) 
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Table 19 
STABILITY OF PBGa IN RANDOM UR~NE 
PRESERVED WITH TARTARIC ACID 
DAY DAY DAY DAY DAY DAY DAY DAY 
0 1 2 3 4 5 6 7 
µq PBG 
Recovered 14.45 13. 90 13.40 13.40 12.80 11. 6 10.7 10.4 
% Loss From 
Day Oc 0% 4% 8% 8% 12% 20% 26% 28% 
Urine pHd 3.20 3.20 3. 15 3. 19 3.20 3.20 3.25 3.23 
a. 378 µg PBG added to 10 ml random urine before urine added to 
preservative. Final concentration equals 18.94 µg PBG/0.50 ml 
urine applied to the dual piggyback column. 
b. 0.20 ml 3 M tartaric, in 15 ml glass screw-capped bottle, dried 
at 75°C for 60 minutes. 
c. Calculated from the µg PBG recovered from the elution of the 
dual piggyback column on day 0. Day 0 recovery is considered 
to be 0% loss and all subsequent determinations were compared 
to this day 0 value. · 
d. Urine pH determined e 1 ectron i ca 11 y at 23° C. 
/ 
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Table 20 
EFFECT OF URINE pH AND STORAGE TIME ON STABILITY 
OF PBG IN RANDOM URINE SPECIMENS 
DAYc 
URINE ~Hb 
pH 5.0 pH 6.0 pH 7.0 pH 8.0 pH 9.0 
0 µg PBG Recovered a 15.5 16. 4 16.2 15. 6 16.4 
1 µq PBG Recovered 14.6 15.5 15. 4 15. 5 16.3 
% Loss From Day 0 6% 5% 5% 1% 1% 
2 µg PBG Recovered 13.85 14.65 15.20 15.40 16.2 
% Loss From Day 0 11% 11% 6% 1% 1% 
3 µg PBG Recovered 13.1 14.40 14.50 14. 50 14. 7 
% Loss From Day 0 15% 12% 10% 7% 10% 
4 µg PBG Recovered 12. 9 14. 40 14.40 14.00 14. 40 
% Loss From Day 0 17% 12% 11% 10% 12% 
5 µg PBG Recovered 10.9 12.9 12.9 13.4 13.7 
% Loss From Day 0 30% 21% 20% 14% 16% 
6 µg PBG Recovered 10.0 12. 65 12.80 12.80 12.65 
% Loss From Day 0 35% 23% 21% 21% 23% 
7 µg PBG Recovered 10.0 12. 65 12. 65 12.65 12.70 
% Loss From Day 0 35% 23% 22% 19% 23% 
a. 18.94 µg PBG/0.50 ml urine anplied to dual piggyback column, µq 
recovered is the PBG eluted from the piggyback column unit and is 
considered to be 0% loss on day 0. 
b. pH adjusted with acetic acid or Na 2co3 and determined electronically 
at 23°C. 
c. Urine stored at 4°C, in the dark. 
--------
RECOMMENDED PROCEDURE FOR COLIECTION AND STORAGF. OF RANDOM 
URINE SAMPLES FOR THE DETECTION OF I.EAD POISONING (URINARY 
ALA) AND PROPHYRIA (URINARY PBG) 
FOR PBG SAMPLES TO BE ANALYZED WITHIN 24 HOURS OF URINE COLLECTION 
TIME~. ~ALA CAN BE ANALYZED FOLLOWING THESE DIRECTIONS, UP TO A 
PERIOD OF FOUR MONTHS 
1. Collect a random urine sample. Note1 It is advisable not to 
use the first voided morning specimen, late evening specimens 
after 8100 pm, or specimens obtained following excessive 
fluid intake. 
2. Add approximately 10 ml of the random urine sample to the 
bottle containing the dried layer of tartaric acid, replace 
the cap and gently mix. 
J. Place the bottle in a dark refrigerator or freezer as soon as 
possible up to 8 hours after collection. The urinary ALA 
content of samples stored in a dark refrigerator will remain 
constant up to 4 months while urinary PBG stored in the acid 
urine, in a dark refrigerator, will remain constant for a 
period of 24 hours. Frozen urinary ALA samples will remain 
constant up to a year while frozen PBG samples, in acid urine, 
will remain stable for a month. 
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FOR PEG SAMPLES TO BE ANALYZED WITHIN 72 HOURS AFI'ER URINE COLLECTION* 
1. Collect a random urine sample as directed above in direction #1. 
2. Add approximately 10 ml of the random urine sample to the amber 
15 ml screwcapped bottle. Carefully add powdered anhydrous, 
sodium carbonate (Na2C03) to raise the pH to approximately 8.o. 
One can easily acco;npllsh this pH adjustment by checking the 
changing pH with each addition of Na2C01 with pHydrion paper. 
(Micro Essential Laboratory, Inc., Brooklyn, N.Y.) 
J. Place the bottle in a dark refrigerator or freezer as soon as 
possible, after collection and pH adjustment, up to 8 hours after 
urine collection. The refrigerated urinary PEG will remain 
constant up to 72 hours while frozen urinary ?BG in alkaline 
urine will remain constant in the dark up to 8 months. 
4. When removed from storage just prior to performing the PBG analysis, 
the urine in the screwcapped bottle should be gently shaken to 
provide a homogenous sample from which to pipet the 0.50 ml aliquot 
required for the urinary PBG determination. 
* Since urinary ALA is unstable at pH 8.0, this method of sample 
collection designed for the preservation of urinary PEG for 
72 hours does not permit the measurement of urinary ALA in the 
urine specimen to which sodium carbonate has been added. 
Optical Density Mg % Mg S Optical Density Mg % Mg ~ 555 nm ALAa PBG 555 nm ALAa PBG 
0.010 0.03 0.11 0. 140 0.70 2.47 
( 0.020 0.08 0.28 0.150 0.75 2.65 
0.030 o. 13 0.46 0.160 0.80 2.82 
0.040 0.20 0. 71 0. 170 0.85 3.00 
0.050 0.25 0.88 0.180 0.90 2. 18 
0.060 0.30 1. 06 0.190 0.95 3.35 
0.070 0.35 1. 24 0.200 1. 00 3.53 
0.080 0.40 1. 41 0.220 1. 12 3.95 
0.090 0.45 1. 59 0.240 1. 22 4. 31 
0. 100 0.50 1. 77 0.260 1. 32 4.66 
o. 120 0.60 2. 12 0.280 1. 42 5.01 
0.130 0.65 2.29 0.300 1. 52 4.37 
a. Mg % ALA per 14.2 ml final reaction volume. 
b. Mg % PBG per 20.0 ml final reaction volume. 
* To convert mg % ALA to mg % PBG, multiply mg % ALA (determined from ALA standard calibration curve) by 3.53. Therefore, mg % 
PBG =mg % ALA x 3.53. 
To use this table, one determines the O.D. at 555 nm of the PBG 
sample and reads the corresponding value from the column headed 
mg % PBG. 
w 
....... 
C.11 
Table 23 
METHOD TO DETERMINE URINARY UREA 
0.50 ml 
RANDOM URINE SAMPLE 
Apply to the top column 
of a dual piggyback column 
unit. 
WASH COLUMN UNIT 
WITH 30 ml WATER 
30 ml WATER 
ELUATE 
Add 4.0 ml fresh, modified 
Ehrlich's reagent and mix 
well. 
Allow for full color 
development (15 minutes). 
LEMON-YELLOW SOLUTION 
Determine O.D. at 415 nm in 
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a standard laboratory color-
imeter against a reagent blank. 
QUANTITATE UREA 
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METHOD FOR DETERMINATION OF TISSUE LEVELS OF DELTA-AMINOLEVULINIC ACID (ALA) 
PRECIPITATE 
I om tissue 
! homogenize in 9 ml of cold 0.001 N HAc 
HOMOGENATE 
add 0.1 ml of 5 % TCA, miK and let stand for 10 min, and 
centrifuge at 600 K o for 20 min at roam temperature 
SUPERNATANT 
/' adjust to pH 5.0 with solid Na 2 C03 
0. 001 N HAc and centrifuge / 
1 
wash twice with 2 ml of l and freeze overnight in the dark 
at 600KO for 10 min / 
· combine / / 
FROZEN SUPERNATANT 
* defrost in a 45 C water bath and mix 
DEFROSTED SUPERNATANT WASH-
heat in a 45 C water bath for 5 min, cool 
to room temperature and then centrifuge 
at 600 x o for 20 min 
PRECIPITATE SUPERNATANT 
2 ml distilled H2 o / + dual column chromatography unit l 
wash twice with 1 I add to lop column of tandem 
and centrifuge I analyze for ALA 
WASH- _ c~mbine _J (DAVIS, J.R. !! al., Arch Environ Health, 
17: 164, 1968) 
co 
r-1 
CV) 
Table 25 
METHOD FOR DETERMINATION OF TISSUE BLANK IN THE DELTA-AMINOLEVULINIC ACID (ALA) ANALYSIS 
ELUTED SAMPLE FROM THE CATION COLUMN 
~ (From the addition of combined supernatants to the tandem dual column chromatography unit) 
7.0 ml of ELUATE 
I Divide into two 3,0 ml 
+ • 
fractions 
TISSUE BLANK ALA DETERMINATION 
Add 3.0 ml of fresh Ehrlich's 
reagent. 
Determine optical density at 553 mµ 
after 15 minutes, reading the sample 
against a distilled water blank. 
Add 0.10 ml acetylacetone. 
Boil in a water bath for 10 
minutes, cool to room temp-
erature. 
Add 3.0 ml of fresh Ehrlich's 
reagent. 
Determine optical density at 
553 mp after 15 minutes, 
reading the sample against a 
distilled water blank. 
O'> 
r-1 
M 
Sample 
1.0 gm liver 
plus 2.50 µg ALA 
1.0 gm liver 
plus 5.00 µg ALA 
1.0 gm liver 
plus 10.00 pg ALA 
1.0 gm liver 
plus 20.00 pg ALA 
Table 26 
RECOVERY OF DELTA-AMINOLEVULINIC ACID (ALA) FROM RAT LIVER 
pg Endogenous Total µg Total µg % 
ALA ALA Expected ALA Recovered Recovery 
0.07 2.57 2.34 91 
0.07 5.07 4.66 92 
0.07 10.07 9.26 92 
0.07 20.07 18.46 92 
-----
Table 27 
THE EFFECT OF A SUBCUTANEOUS INJECTION OF LEAD 
ACETATE ON THE ACCUMULATION OF ALA IN THE BONE 
MARROW AND KIDNEY OF THE ADULT MALE RABBIT 
CONTROL 20 DAYS 58 DAYS 
µg ALA/gm µg ALA/gm µg ALA/gm 
BONE MARROW 0.25 4.50 24. 63 --
FOLD INCREASE 18 98.52 
KIDNEY 0.40 3.49 10.92 
FOLD INCREASE 8.73 27.30 
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Table 28 
THE EFFECT OF A SUBCUTANEOUS INJECTION OF LEAD 
ACETATE ON THE ACCUMULATION OF PBG IN THE BONE 
MARROW AND KIDNEY OF THE ADULT MALE RABBIT 
CONTROL 20 DAYS 58 DAYS 
µg PBG/gm µg PBG/gm µg PBG/gm 
BONE MARROW 0.20 10.00 8.00 
FOLD INCREASE 50.00 40.00 
KIDNEY 0.25 13. 75 21. 13 
FOLD INCREASE 55.00 84.52 
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Table 29 
METHOD* TO SEPARATE AMINOACETONE (AA) FROM 
DELTA-AMINOLEVULINIC ACID (ALA) 322 
SUPERNATANT FROM TISSUE HOMOGENIZATION 
Add to dual piggyback column unit 
and wash with 30 ml water. 
From the cation AG50W-X4 column, 
elute the ALA and AA with 1 M Na 
acetate. 
Convert to pyrroles by Knorr-type 
condensation with acetylacetone 
and heat. 
ALA AND AA PYRROLES 
AMINOACETONE PYRROLE 
I Add equal volume of fresh f modified Ehrlich's reagent. 
AA-PYRROLE EHRLICH'S REACTION 
Allow to stand for 10 minutes 
at room temperature. 
Determine optical density at 
555 nm in a standard laboratory 
·colorimeter. 
QUANTITATE FOR AA 
* Marver, et al. Anal. Biochem. l.1_:53-60, 1966. 
Apply the pyrroles to an anionic 
AG-l-X8 column, 100-200 mesh, 
acetate form. 
Elute the AA pyrrole with 10 ml of 
n-butanol containing 0.01 M NH40H. 
DELTA-AMINOLEVULINIC ACID PYRROLE 
(Remaining on the column) 
Wash column with 10 ml of 1 M 
acetic acid. 
Elute ALA pyrrole with 10 ml of 
a mixture of glacial acetic acid 
and methanol (1 :2). 
ALA PYRROLE 
I Add equal volume of fresh t modified Ehrlich's reagent. 
ALA-PYRROLE EHRLICH'S REACTION 
Allow to stand for 15 minutes at 
room temperature. 
Determine optical density at 553 nm 
in a standard laboratory colorimeter 
QUANTITATE FOR ALA 
Table JO 
TOTAL PERCENT OF FINAL COLOR DUE TO AMINOACETONE 
IN A URINE SPECIMEN FROM A LEAD POISONED RABBITd 
Method 
Urinary ALA (Davis)a 
Urinary ALA (Marver)b 
ALA 
{Mg %) 
3.50 
3.42 
AA {Mg %)C 
0.07 
0.07 
Total % Of Color 
Due To Aminoacetone 
2.00 % 
2.01 % 
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a. ALA eluted from cation ionic column with 1 M Na-acetate, the ALA converted 
to a pyrrole by a Knorr-type condensation with acetylacetone and heat. ALA 
pyrrole reacted with modified Ehrl,ch 1 s and determined at 553 nm. ALA quan-
titated by referring to a standard calibration curve. 
b. ALA converted to a pyrrole by a Knorr-type condensation with acetylacetone 
and heat. The ALA pyrrole is added to an anionic AG-l-X8 column and ALA 
pyrrole is eluted (after AA pyrrole) with a mixture of glacial acetic acid 
and methanol (1 :2). The eluted ALA pyrrole is reacted with modified Ehrlich's 
and determined at 556 nm. ALA quantitated by referring to a standard calibra-
tion curve. 
c. AA pyrrole eluted from anionic AG-l-X8 column with 10 ml n-butanol containing 
0.01 M ammonium hydroxide. The AA pyrrole is mixed with an equal volume of 
modified Ehrlich's reagent. The AA pyrrole is determined at 555 nm at exactly 
10 minutes. (Marver, et al. Anal. Biochem. 14:53-60, 1966). 
d. Rabbit given single subcutaneous dose of 200 mg/kg body weight of lead acetate. 
I 
Tissue 
Kidney 
Table Jl 
TOTAL PERCENT OF FINAL COLOR DUE TO AMINOACETONE 
IN TISSUE SAMPLES FROM A LEAD POISONED RABBIT* 
Total % of Color 
µg ALA/gm Tissue µg AA/gm Tissue Due to Aminoacetone 
1. 75 0.025 0.01 % 
Bone Marrow 12.84 0.140 0. 01 % 
Spleen 2.50 o. 157 0.06 % 
Liver 0.67 0.010 1.49 % 
* Rabbit given single subcutaneous dose of 200 mg/kg body weight 
of lead acetate. 
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PELLET 
METHOD FOR TRANSPLANTING THE 
WALKER 256 CARCINOSARCOMA 
60 DAY OLD SPRAGUE-DAWLEY RAT BEARING 
A 7 DAY OLD SUBCUTANEOUS TUMOR 
Sacrifice by decapitation. 
Surgically remove the subcutaneous tumor. 
Place in a sterile petri dish and wash with 
sterile saline. 
Transfer the cleaned tumor to a second sterile 
petri dish and finely mince 2 gm of tumor by 
repeated cutting with sterile scissors. 
MINCED WALKER 'fUMOR 
Add minced tumor to a sterile tissue press 
fitted with a fine sieve covered with a 90-mesh 
stainless steel screen. 
Under pressure force the tumor cells through 
the sieve into 5 ml sterile saline. 
WALKER TUMOR CELL SUSPENSION 
(Connective tissue and cell 
debris - DISCARD) 
Inject 0. 5 ml subcutaneously 
in the region of the lower 
abdomen la tera.l to the Linea 
Alba. ~~ 
INJECTED RAT BEARING THE WALKER TUMOR 
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PELLET 
(Discard) 
Table JJ 
DETERMINATION OF ALAD ACTIVITY IN 
RAT WHOLE BLOOD 
0. 15 ml WHOLE BLOOD 
l Add I .45 ml distilled water. 
HEMOLYSATE 
Add 1 • 0 ml fresh 0. 01 M ALA, pH 7 . 0-7. 4 
Incubate at 37 C for 60 minutes 
INCUBATION MIXTURE 
Stop reaction by adding 1 ml of 10% 
trichloroacetic acid and 0. 05 ml of 
saturated copper sulfate solution. 
Centrifuge at room temperature at 
600 x g for 10 min. 
UPERNATANT 
2 ml supernatant added to 2 ml 
modified Ehrlich's reagent. 
Allow 2 min. for full development 
of color after mixing. 
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Measure absorbance in a standard 
laboratory colorimeter at 555 mµ 
against a reagent blank. 
CALCULATE ALAD UNITS 
44.61 
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Table )4 
FORMULA FOR DETERMINING ALAD ACTIVITY 
100 0060 - ODo x Hct x 44.61 = Units of ALAD* 
Where 0060 = Optical density after 1 hour at 37°C. 
= Optical density at 0 time (it was measured 
in samples to which trichloroacetic acid 
and copper sulfate were added to the incu-
bation mixture before the addition of blood; 
it was consistently found to be 0). 
Incubation Volume (3.65 ml) 1 X 2b = Blood Volume (0. 15 ml) X 60 (time) X 2a X 0.036 (PBG ext. coeff) 
a. The first calculation is multiplied by 2 because one ml aliquot of this 
incubation mixture is mixed with an equal part of Ehrlich's reagent. 
b. The final answer is multiplied by 2 to represent the fact that the enzyme 
activity is defined as the amount of enzyme necessary to convert 1 µ mole 
of ALA to PBG. It is necessary that 2µmoles of ALA are utilized to syn-
thesize one µmoles of PBG. 
* A unit of ALAD activity is defined as the amount of enzyme necessary to 
convert 1 µmole per milliliter per minute of ALA to PBG per milliliter 
of red blood cells. 
Table 35 
DETERMINATION OF ALAD ACTIVITY IN 
WHOLE BLOOD* VERSUS PLASMA 
Sample ALAD Units Sample 
50 µL whole blood 13.97 50 µL plasma 
100 µL whole blood 18. 18 100 µL plasma 
200 µL whole blood 24.11 200 µL plasma 
ALAD Units 
0 
0 
0 
* Blood and plasma taken from same patient and from the same 10 
ml blood sample. 
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Table 36 
STABILITY OF THE COLOR REACTION DEVELOPED 
IN THE ANALYSIS OF ALA DEHYDRASE (ALAD) 
Time Color Reaction 
Exposed To Light Opt i ca 1 Density Percent Percent 
(Minutes) 555 nm Color Remaining Color Loss 
2 0. 129 100 0 
5 0.127 98.45 1. 55 
10 0. 122 94.57 5.43 
15 0. 121 93.79 6.21 
20 0. 119 92.25 7.75 
25 0.118 91. 47 8.53 
30 o. 117 90.69 9.31 
35 o. 116 89.92 10.08 
40 o. 114 88.37 11. 63 
45 o. 110 85.27 14.73 
50 0. 108 83.27 16.28 
55 0. 106 82.17 17.83 
60 0.106 82.17 17. 83 
400 µl whole blood from tail vein of control 60 day old rat. 
Ehrlich's reagent= 1 gm DMAB dissolved in 34 ml glacial acetic acid 
to which is added 16 ml of 70% perchloric acid. 
Reaction conditions = 2.0 ml of supernatant from the incubation 
reaction plus 2.0 ml of fresh Ehrlich's reagent. 
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PELLET 
(Discard) 
Table 37 330 
METHOD FOR PREPARING A WATER EXTRACT 
OF THE WALKER CARCINOSARCOMA 
3 0 gm TUMOR (7 days after transplantation) 
l Homogenize in 1 SO ml cold dis tilled water 
1: S (W:V) HOMOGENATE 
PELLET 
(Discard) 
Swirl for 30 min. at 4 C and 
centrifuge at 10, 000 x g for 
3 0 min • a t 4 C . 
SUPERNATANT 
Centrifuge at 600 x g for 10 min. 
at room temp. 
SUPERNATANT 
Centrifuge at 1 OS, 000 x g 
for 60 min. at 4 C. +---------. 
PELLET SUPERNATANT 
(Discard) 
1 
Lyophilize for 
24 hours 
LYOPHILIZED TUMOR EXTRACT 
Table J8 
METHOD FOR PREPARING A WATER EXTRACT 
OF NORMAL RAT LIVER 
PELLET 
(Discard) 
8. 0 gm NORMAL LIVER 
1 
Homogenize in 40 ml cold 
distilled water. 
1 :5 0N:V) HOMOGENATE 
PELLET 
(Discard) 
Swirl for 30 min. at 4 C and 
centrifuge at 10, 000 x g for 30 min. 
at 4 C. 
SUPERNATANT 
' 
Centrifuge at 105, 000 x g 
for 60 min. at 4 C 
SUPERNATANT 
Lyophilize for 
24 hours 
LYOPHILIZED LIVER EXTRACT 
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CHARACTERISTIC FEATURES OF LEAD POISONING COMPARED WITH SEVERAL TYPES OF PORPHYRIAS 
ERYTHROPOI ETI C HEPATIC 
Lead Acute Porphyri a Cutanea 
Characteristics Poisoning Uroporphyria Protoporphyrin Intermittent Variegata Tarda 
Inheritance None Recessive Dominant Dominant Dominant Dominant 
Sex Both Both Both Both Both Both 
Age of onset Any age 0 - 5 0 - 5 12 - 40 20 - 30 10 - 30 
Phases of the 
disease --- --- Latent Acute Latent Acute Latent Acute 
Photos ens iti vity 
cutaneous lesions N ++++ ++ 0 0 ++ ++++ 0 0 or + 
Abdominal, phychic 
and/or neurologic 
symptoms ++ 0 0 0 +++ + ++++ 0 + 
URINE: 
Color N Red N N Red N N N N or Red 
ALA ++++ N N + +++ + ++ N ++ 
PBG N N N + or ++ ++++ + or ++ ++++ N + 
Uroporphyrin + ++++ N ++ +++ N to + +++ N ++++ 
Coproporphyrin ++ ++ N ++ ++ N to + ++ N +++ 
w 
N .... Norma 1 0 .... Absent w N 
+ .... Increased ALA .. Delta-Aminolevulinic Acid 
++++ Greatly Increased PBG .. Porphobilinogen 
Table 40 
CHEMICALS THAT INDUCE PORPHYRIN FORMATION IN PRIMARY 
CULTURES OF CHICK EMBRYO LIVER CELLS* 
Chemical 
Allylisopropylacetamide 
Ami nopyri ne 
Bemegride 
Theophylline 
Orinase 
Meprobamate 
Sul fona l 
Glutethimide 
Mesantoin 
Dilantin 
Trimethadione 
Chloramphenicol 
Chemical 
Phenobarbital-Na 
Grislofulvin 
Progesterone 
05 -Pregnenolone 
Testosterone 
Ethinyl Estradiol 
Estradiol 
Norethandrolene 
Estrone 
Menthol 
Diallybarbituric Acid 
* Granick, S. J. Biol. Chem. 241 :1359-1375, 1966. 
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